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Abstract 
 
Motility is a key feature of the complex life cycle of Plasmodium falciparum, the 
apicomplexan parasite that causes human malaria. In particular, the invasion of erythrocytes 
by blood stages known as merozoites represents the gateway to symptomatic disease. The 
motive force required for this process is thought to be provided by a conserved actomyosin 
motor consisting of an unusual myosin (myoA) that is part of a multi-protein assembly 
making up the biomolecular invasion machinery. One of these proteins is Myosin A Tail 
Domain Interacting Protein (MTIP), which acts as an anchor for the myoA motor at the inner 
membrane of the merozoite. The MTIP-myoA complex can be reconstituted in vitro using 
peptides mimicking the C-terminal tail of myoA, and since inhibition of the interaction in vivo 
should stall invasion and disrupt the parasitic life cycle, it has been identified as a target for 
the development of novel antimalarials and chemical genetic tools. 
This thesis describes a detailed analysis of the structure and dynamics of the MTIP-myoA 
tail complex, and the subsequent development of molecules intended to disrupt this 
interaction. Initially, the crystal structure of the complex from P. falciparum is solved and 
validated as a reasonable model for the solution-state structure using a range of NMR 
spectroscopic techniques. MTIP forms a rigid clamp around the myoA tail, which adopts a 
helical conformation and is completely buried by the protein. NMR spectroscopy is also used 
as a primary tool to investigate MTIP in the absence of a ligand, a crystal structure of which 
is lacking. The backbone motions of this ‘unliganded’ protein on a range of timescales are 
examined, and these data are complemented by other biophysical analyses. 
Structure-function relationships are extracted and the specificity of MTIP as a binding partner 
for myoA is investigated. By comparison to ‘wild-type’ data, the effect of a recently-reported 
MTIP phosphorylation event is explored, via phospho-mimetic mutation of the site. This 
analysis provides a structural basis for a possible mode of post-translational regulation of 
myoA-based motility, since modification appears to break the rigid MTIP-myoA clamp. 
The structural data are also used to design constrained myoA tail helices, with the aim of 
improving the cell permeability and stability of wild-type sequences. Three distinct helix 
constraint technologies are compared using a suite of biophysical experiments, and co-
crystal structures with MTIP are solved to validate the design strategy. Further, these 
structures provide novel insights into the targeting of buried protein-helix interactions. 
Finally, fragment-based approaches to MTIP-myoA inhibition are investigated. A screen of a 
500-member library is conducted, with the aim of identifying small molecules that target 
hotspots of the interaction and/or stabilise non-productive conformations of MTIP. 
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Chapter 1 Introduction 
This thesis advances the understanding of molecular (structural, thermodynamic and 
dynamic) features of the complex between the myosin A (myoA) motor protein and its light 
chain myoA tail domain interacting protein (MTIP), thought to be central to the machinery 
used by malaria (Plasmodium) parasites to move and invade host cells. This understanding 
is used to inform on possible modes of modulation of the complex in two senses; i.e. (i) does 
the parasite have mechanisms to regulate the function of these proteins and if so, what are 
they? and (ii) might it be possible to develop exogenous, specific molecules that inhibit this 
interaction, either as starting points for novel antimalarials or chemical genetic tools to 
unpick biological function? In this chapter, the biological context of the study will be 
introduced via a description of the Plasmodium falciparum life cycle, with a particular focus 
on so-called ‘gliding motility’ and invasion of human erythrocytes. Existing data in the 
literature on the molecular bases of these processes will be described, including where 
necessary findings from homologous systems in other apicomplexan parasites (e.g. 
Toxoplasma gondii).  
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1.1 The life cycle of the malaria parasite, Plasmodium 
Malaria is one of the leading causes of mortality and morbidity among more than three billion 
people living at risk of infection, and its incidence correlates with poverty.1 Five species of 
the protozoan parasite genus Plasmodium, which belong to the phylum Apicomplexa, have 
been shown to cause malaria in humans.2,3* The genome of the most lethal, P. falciparum, 
was sequenced in 2002 and contains more than five thousand genes,4,5 providing the 
parasite with a fascinating and extensive toolkit with which to survive and undergo a complex 
life cycle in both the mosquito vector and mammalian host. The following review will provide 
a brief overview of the cellular events that comprise the life cycle, and then will describe 
some of the molecular details of parasite motility, with a focus on invasion of erythrocytes in 
the blood stage of the cycle.   
1.1.1 Key cellular events in the Plasmodium life cycle 
The life cycle (shown in figure 1.1) begins when an infected mosquito takes a blood meal, at 
which point motile, elongated stages called sporozoites developed in the salivary gland of 
the mosquito are delivered to the host, mostly via injection into the dermis. The sporozoites 
appear to enter the host bloodstream via a ‘slow trickle’6 in which there is random motion of 
sporozoites in the skin until contact is made with the endothelium of the blood or lymph 
circulatory systems.7 The parasites are carried to the liver where they contact and invade 
hepatocytes.8-10 Movement to and invasion of hepatocytes is thought to rely upon a 
substrate-dependent mode of locomotion known as ‘gliding motility’,11,12 the molecular basis 
of which will be discussed in the next section. The parasites remain in the liver for several 
days, during which time they develop and then asexually reproduce to form thousands of 
merozoites.13 This development and schizogony is immediately initiated by sporozoites of 
P. falciparum, although other species such as P. vivax and P. ovale can persist as dormant 
liver stages known as hypnozoites.2,14 As the dying host cell ruptures, the merozoites are 
delivered into the bloodstream by specialised vesicles, termed ‘merosomes’, which protect 
the parasites from cellular apoptotic pathways and the host immune system.15 Each 
merozoite has the ability to invade an erythrocyte, in which it can multiply asexually to form a 
schizont. This ‘blood stage’ gives rise to the symptoms of malaria.13 
The P. falciparum merozoite cell is the smallest extracellular parasite stage16 (1-2 µm 
across) and is well adapted for the task of invading erythrocytes: it has an apical prominence 
with which to contact its target, and organelles nearby called rhoptries and micronemes that 
secrete proteins thought to be important for invasion.17 The morphological details of this 
                                                     
*
 P. falciparum, P. vivax, P. ovale, P. malariae are specific to humans; incidences of primate 
P. knowlesi infection of humans have also been identified (Singh et al. 2004). 
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process were observed in the 1970s by microscopy experiments on simian and avian 
Plasmodium species.18,19 Primary contact of the merozoite with the target red blood cell is 
accompanied by a deformation of its plasma membrane.18,20 The interaction at this point is 
thought to be weak and reversible;21 during the period of membrane perturbation, 
reorientation of the merozoite occurs such that its apical end is bound to the erythrocyte via 
a stronger interaction.21,22 Once this phase has occurred, the erythrocyte is restored to its 
original morphology, with the merozoite irreversibly attached via a ‘tight junction’.18,19 The 
invasive process, in which the junction moves to the other end of the merozoite,* takes an 
average of 17 seconds for P. falciparum.20 This timescale correlates closely with the invasion 
by the ‘evolutionarily-distant’ P. knowlesi species.18,19 A ‘parasitophorous vacuole’, which 
forms during invasion and contains the parasite, is sealed off from the plasma membrane 
and the tight junction removed.22 
 
Figure 1.1 Simplified scheme of the Plasmodium life cycle inside the human host. (a) Injection of sporozoites by 
the mosquito vector into the dermis. (b) The sporozoites are carried to the liver where they infect hepatocytes and 
develop into merozoites. (c) The merozoites invade erythrocytes, developing through the trophozoite stage and 
dividing asexually (schizogony). As the host erythrocyte ruptures, daughter merozoites egress and reinvade a 
new host red blood cell. (d) Some parasites develop into sexual stages (gametocytes) that are responsible for 
transmission to the mosquito vector. Figure reproduced with permission from Michalakis and Renaud.
23
 
 
 
Inside the red blood cell, remodelling of the host cell begins as the merozoite enlarges and 
develops into a feeding stage known as an early trophozoite (or ‘ring’ stage owing to its 
characteristic morphology).17 Protected by the parasitophorous vacuole and using nutrients 
                                                     
*
 The tight junction is therefore alternatively known as the ‘moving junction’; the former term will be 
used in this thesis. 
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from the host cytoplasm, the ring develops into a mature trophozoite. Several nuclear 
divisions characterise the subsequent schizont stage, and rearrangement of the cytoplasm in 
the mature ‘segmenter’ form allows formation of around 20-30 daughter merozoites. After 
erythrocytic schizogony, merozoites egress from the host cell following lysis of the 
schizont,24 and reenter the bloodstream where each can infect a new red blood cell. The 
rupture of the erythrocyte’s plasma membrane triggers a sudden host immune response 
leading to feverish symptoms that repeat periodically according to the timescale of the 
asexual blood stage. In P. falciparum, the blood stage cycle takes around 48 hours.13 
Some intracellular parasites differentiate into male and female gametocytes that are 
ingested by a mosquito upon taking a blood meal. Within the mosquito gut, gametogenesis 
leads to the formation and release of male and female gametes. Fertilisation then results in a 
zygote that develops into a motile ookinete, which moves and crosses the mosquito midgut 
wall and transforms into an oocyst on the outer wall. Over several days, this oocyst grows in 
size, and within it differentiation and mitosis lead to formation of sporozoites. Rupture of the 
oocyst releases the sporozoites into the hemocoel, and these move to and infect the 
mosquito salivary glands ready for transfer to the next vertebrate host.25 
1.1.2 Molecular basis of Plasmodium erythrocyte invasion and gliding motility 
Gliding motility 
Apicomplexan parasites spend much of their life cycles inside host cells, as exemplified 
above. The active movement to, invasion of, and egress from these cells is therefore vital to 
their success, but the parasites are not armed with any specialised appendages with which 
to move.* Instead, it is thought they employ a form of substrate-dependent locomotion known 
as ‘gliding motility’, first characterised in work by King.11 Gliding motility is thought to be 
powered by an actomyosin motor,26,27 which is conserved across the phylum and located 
between its plasma membrane (PM) and a ‘membranous network of flattened vesicles’28 
termed the inner membrane complex (IMC). It has been assumed that the same molecular 
motor that enables gliding motility and egress is also employed in generating force for 
invasion of host cells such as erythrocytes.29 However, recent studies have suggested that 
this assumption may need reviewing; the contemporary data that question the association of 
these processes (and the molecular details thereof) will be discussed later in this section.  
Erythrocyte-parasite interactions and the tight junction 
Figure 1.2 shows the stages of erythrocyte (re-)invasion following schizogony, red blood cell 
rupture and egress. The initial weak attachment of the merozoite on the surface of the 
                                                     
*
 Apart from male gametes, which are flagellated. 
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erythrocyte is thought to be mediated by a coat of Merozoite Surface Proteins (MSPs) such 
as MSP1,22,30-32 a protein that has been characterised thoroughly and gained particular 
attention as an antimalarial vaccine candidate.33  
 
Figure 1.2 2D schematic overview of the four stages of erythrocyte invasion by Plasmodium merozoites 
(simplified diagram inset, showing important organelles), with annotations reflecting putatively key molecular 
determinants.  
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Interactions of parasitic Reticulocyte-binding protein Homologues (RHs) and Erythrocyte-
Binding-Like (EBL) proteins with erythrocyte receptors have been implicated in governing the 
subsequent reorientation of the merozoite and attachment via its apical end.22,28,34 This 
attachment appears to commit the parasite to invasion, described as the ‘master switch that 
triggers all downstream events’.35 
The apical reorientation is characterised by release of molecules* from the apical parasite 
rhoptries and micronemes to form a robust attachment with the erythrocyte, known as a tight 
junction. Microneme-derived Thrombospondin-Related Anonymous Protein adhesins 
(TRAPs, known as MTRAP in merozoites) have been implicated in this junction and its 
attachment to the parasite actomyosin motor (see below).29,36,37 Various RhOptry Neck 
proteins (RONs) are thought to be injected into the host cell; RON2 is inserted into the host 
plasma membrane and other RONs, including RON4, are thought to localise to the host 
cytoplasm – the resulting ‘RON complex’ may serve to bridge the parasite to the host 
cytoskeleton.38-41 Recently, recombinant TgRON4 constructs were shown to bind to 
mammalian β-tubulin in co-immunoprecipitation experiments, although the authors did not 
detect an interaction for PfRON4.42 However, PfRON4 has been shown at the apex of the 
merozoite upon attachment and as a ring around the merozoite mid-way through invasion, 
validating this protein as a ‘marker’ for intact tight junctions.35 One interaction that has 
gained a great deal of attention recently is that between RON2 (spanning the host plasma 
membrane) and micronemal protein Apical Membrane Antigen 1 (AMA1) that sits in the 
merozoite membrane.40,43-45 This interaction has been proposed as the central scaffold of the 
tight junction, ‘defining a molecular seal through which the rhoptry contents pass’,35 thus 
orchestrating invasion, although data from other zoites (namely T. gondii invasive stages 
called tachyzoites, and Plasmodium sporozoites) have questioned the role of AMA1 in the 
junction.46,47 A peptide (known as ‘R1’), identified from a phage display library, has been 
shown to disrupt the interaction between the RON2 and AMA1;48 the interaction has now 
been structurally characterised.43,49 Such peptidic and, more recently, small molecule 
inhibitors of the interaction can be used to block invasion.48,50 However, R1-treated 
merozoites still released rhoptry components (albeit aberrantly) and still showed evidence of 
actomyosin motor activation.35 Taken together, these observations support the notion that 
upon apical attachment, the parasite is committed to invasion, but that disruption of 
                                                     
*
 It should be noted that the list of putative host-parasite interactions contributing to invasion is long 
and ever-growing; many of the parasite proteins (and their interactions) thought to be involved (by 
bioinformatics predictions based on homology, proteomics or knock down studies) have not been 
characterised thoroughly and therefore all the models of molecular architecture pertaining to invasion 
must be treated as such. As the repertoire of genetic and microscopy methods continues to expand 
and improve, more molecular details are continuously added that may serve to subtly alter the models 
or force a more major overhaul. 
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important molecular events (e.g. RON complex assembly) can cause the process to 
malfunction. Activation of the parasite actomyosin motor is a thought to be an important 
event in invasion; the molecular details of the motor are described below. 
Working model of the actomyosin motor 
At the outset of the research reported in this thesis in 2010, an overall molecular architecture 
explaining how the parasite actomyosin motor works had been put forward and largely 
agreed upon in the literature. The motor complex is made up of a complex assembly of 
proteins, the central components of which has been termed the ‘glideosome’ due to its 
putative role in gliding motility.51,52 One model, illustrating this assembly in the context for 
erythrocyte invasion and combining recent data, is shown in figure 1.3. 
 
Figure 1.3 Schematic diagram of the Plasmodium motor complex and tight junction in the context of its putative 
role in erythrocyte invasion by blood stage parasites (merozoites). A number of the key proteins and protein-
protein interactions in this system are shown. MTRAP = Merozoite-specific Thrombospondin-Related Anonymous 
Protein; AMA1 = Apical Membrane Antigen 1; GAP(M) = Gliding-Associated Protein (with Multiple membrane 
spans); RON = RhOptry Neck protein; MTIP = Myosin A Tail domain Interacting Protein; IMC = inner membrane 
complex; PM = plasma membrane. Co/post-translational lipid attachments are indicated on MTIP and GAP45 
with black lines. 
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It should be noted that the roles of several of these proteins were annotated via observations 
of their homologues in another apicomplexan parasite, T. gondii; these may have different 
names in Plasmodium e.g. the homologue of Myosin A Tail domain Interacting Protein 
(MTIP, see below) is known as the Myosin Light Chain 1 (MLC1) in T. gondii and 
Plasmodium TRAPs are called MICronemal protein adhesins (MICs). 
In the prevailing Plasmodium model,*53 a class XIV myosin, myosin A (myoA), is anchored to 
the IMC via interaction with a light chain called myosin A tail domain interacting protein 
(MTIP)54-57 which itself is thought to interact with two ‘gliding-associated proteins’ (GAP45 
and GAP50).29,58 Immunoprecipitation experiments on the motor complex from blood-stage 
parasites reliably pull down these components together,29,59,60 although the interactions of 
GAP45 and GAP50 with MTIP have never been shown in vitro with purified proteins. GAP50 
embeds in the IMC,61 and GAP45 was shown to be myristoylated and palmitoylated to 
enable IMC attachment.62 The so-called Gliding-Associated Proteins with Multiple membrane 
spans (GAPMs) are also IMC membrane proteins and their role has been annotated as 
providing an anchor between the IMC and the parasite cytoskeleton.63 In 2010, a model in 
which GAP45 was attached to the IMC only was overhauled; work from Frenal et al. 
suggested that TgGAP45 is also palmitoylated at its C-terminus and fulfils a role of 
maintaining pellicle cohesion by anchoring to the PM and IMC simultaneously via its N- and 
C-terminal lipidations respectively64 – a model since recognised to be reasonable in 
Plasmodium.65  Although the paper sought to add detail to the TgMLC1-GAP45 interaction 
via mutational analysis – localising the interaction site on TgMLC1 to conserved residues in 
its disordered N-terminal extension and on GAP45 to its C-terminal coiled coil domain – it 
was also suggested that MLC1 may itself attach to the IMC via N-terminal palmitoylation. 
This has since been supported by the work of Jones and co-workers, who used a chemical 
proteomics workflow to identify palmitoylated PfMTIP in blood stage parasites.65 
Interestingly, a recent study by Wright and co-workers showed that effective knockout of N-
myristoylation in P. falciparum using a potent small-molecule N-myristoyl transferase 
inhibitor caused an irreversible failure to assemble the IMC, supporting a more general 
notion that protein lipidation is an essential feature in the integrity of the motor complex.66 
Other members of the complex have been recently identified in T. gondii: a second small 
myoA light chain dubbed the ‘Essential Light Chain 1’ (ELC1)67 that may bind the myoA tail 
further towards the N-terminus (than MLC1) and GAP40, a membrane protein that localises 
to the IMC;64 homologues exist in Plasmodium but the proteins have not yet been 
characterised in detail.  
                                                     
*
 For a contemporary and comprehensive review of the prevailing model of P. falciparum actomyosin 
motility in the context of erythrocyte invasion, see Farrow et al. (2011)
53 
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The action of the myoA motor is coupled to ATP hydrolysis; the motive force produced 
enables the myosin head domain to tread along short actin filaments towards the barbed (+) 
end, monomers of which are thought to be recruited by profilins and polymerised in situ by 
formin with actin depolymerising factor also proposed to have an important role.68-71 The 
dynamic process of actin filament formation72 in both a spatial and temporal sense appears 
to be tightly regulated and highly specialised; its putative mechanism is supported by 
evidence of Pfformin localisation at the moving tight junction,68 but, as with other details, 
there has been debate due to discrepancies with data from Toxoplasma73 and studying this 
small, dynamic system in vivo is technically challenging. Promisingly, Riglar et al. have used 
super-resolution imaging to examine P. falciparum red blood cell invasion and amongst other 
observations, were able to use a parasite-specific actin antibody to show that a ring of actin 
is present at the tight junction midway through invasion.35  
The force applied to actin filaments is thought to translate into overall movement of the zoite 
via another set of protein-protein interactions (PPIs). Tetrameric aldolase has been 
implicated in joining the filament to the tight junction, via the cytoplasmic tails of TRAP 
adhesins.74,75 Furthermore, the cytoplasmic tail of AMA1 (which is thought to link the 
merozoite plasma membrane to the host-localised RON complex, see above) can bind to 
rabbit muscle aldolase in vitro,45 suggesting that this may provide a further link between the 
junction and the motor. These interactions are illustrated in the model shown in figure 1.3. 
However, the macromolecular assembly of these putative interactions in the parasite 
remains ambiguous; it is not absolutely clear whether the link between the tight junction and 
the motor is direct or indirect and how a dynamic yet mechanically-rigid link is maintained; 
furthermore, recently-reported knockouts of various molecules in the above system have 
suggested that the model may require reevaluation (see below).76 Nonetheless, within this 
model, the force* generated by the actomyosin motor pulls on the tight junction moving it 
rearwards and thus propelling the parasite forward. Under the assumption that gliding 
motility and invasion use the same actomyosin motor, it may be considered that the action of 
the motor is conserved but that the interactions of surface proteins with extracellular 
substrates vary. Activity of the actomyosin motor is thought to be controlled by a tight and 
complex regulatory network; the spatiotemporal dynamics of actin polymerisation (see 
above) are clearly an essential part of this, but calcium signalling and phosphorylation also 
appear to play key roles.† 77-79 In 2011, Solyakov et al. used a kinome-wide reverse genetics 
approach in tandem with a phospho-proteomics analysis to identify 36 kinases that were 
                                                     
*
 Contemporary data have suggested that other (e.g. hydrodynamic) forces may be important in 
enabling invasion (see below and Meissner et al., 2013).
76 
†
 For a broader discussion of this complex network, see the conclusion to the paper by Jones, 
Cottingham and Rayner (2009)
77
 and the recent review by Jacot and Soldati-Favre (2012).
78 
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suggested to be essential for erythrocytic schizogony.80 Several of these, for example 
Calcium-Dependent Protein Kinase 1 (CDPK1),81-83 cAMP-dependent Protein Kinase 
(PKA)84 and cGMP-dependent Protein Kinase (PKG)85,86 have all been suggested 
independently as important in regulating Plasmodium motility. The glideosome (in particular, 
GAP45) has been shown to be extensively phosphorylated in both Toxoplasma and 
Plasmodium in vitro and in vivo;60,82,87,88 broad spectrum and specific kinase inhibitors have 
been applied to parasites and have been shown to cause developmental arrest and/or 
invasion defects.77,81,89,90 Calcium signalling has long been thought to influence microneme 
discharge at the start of the invasion cascade and it has been observed that free merozoites 
show a high intracellular calcium level that is reduced upon erythrocyte attachment.79,91 
Treatment of merozoites with calcium chelator BAPTA-AM caused a dose-dependent 
impairment of invasion, while membrane-impermeable analogue BAPTA had no effect.77 
The role of GAP45 phosphorylation in relation to glideosome assembly has come under 
particular scrutiny and it seems that more than one kinase (likely including both calcium-
dependent and calcium-independent enzymes) is responsible for the wide range of 
modification sites.60,77 Gilk et al. formed a hypothesis that in T. gondii, the final association of 
the myoA-MLC1-GAP45 complex (believed to be formed co-translationally on cytoplasmic 
ribosomes) with GAP50 was dependent on the dephosphorylation of Ser163 and Ser167 of 
GAP45: when these residues were mutated to glutamic acid (to mimic phosphorylated 
serines), association was not observed.87 The authors therefore propose that the 
phosphorylation state of these serines controls the timing of the assembly, until GAP50 is 
localised in the IMC. It has been debated whether phospho-sites on GAP45 might regulate 
its assembly with the MTIP-myoA complex.78 However, testing hypotheses regarding 
interactions at the phospho-site-specific level is fraught with experimental challenges. On the 
one hand, it is reasonable to argue that the ideal experiment should be conducted in living 
parasites since in vitro studies on recombinant protein complexes may not accurately 
reconstitute the system’s complexity (e.g. foldedness, stoichiometry, membrane attachment, 
the presence of accessory proteins or other post-translational modifications) or be 
impossible to conduct (e.g. due to low expression levels or stability). On the other hand, 
classical experiments in vivo tend to rely either on inhibition (specific or non-specific) of 
kinase(s) or expression of phospho-mimetic (e.g. Ser to Glu, as above) or phospho-null (e.g. 
Ser to Ala) mutants, and then observation of phenotype and/or approximate protein 
localisation(s). In the context of living systems, these experiments are both problematic since 
a given kinase may have multiple targets at different time points and (irreversible) mutation 
does not capture the dynamic and reversible nature of phosphorylation. In general, structural 
studies on parasite proteins to predict the effects of phosphorylation have not been 
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conducted, but if the above concerns are acknowledged, this sort of experiment would be 
valuable. In the case of GAP45, the protein has been expressed in recombinant systems 
and tested as a substrate for kinases like CDPK1, but structural characterisation and 
biophysical evidence of interactions (and stoichiometries thereof) with putative glideosome 
partners remains elusive. Taking the various pieces of evidence together, it appears 
plausible that rather than by a direct interaction, that GAP45 may assemble with other 
glideosome components at the IMC via an as-yet-undefined aggregation of lipid attachments 
with the membrane, and/or that phosphorylation may in itself regulate the activity of the lipid 
transferase enzymes. The latter notion has been suggested as plausible in Plasmodium65,77 
and interplay between palmitoylation and phosphorylation has been observed in the 
regulation of voltage-gated potassium channels in mammalian cells.92 
MTIP and myoA have also been shown to be phospho-proteins in living P. falciparum 
parasites;82,93 phosphorylation of the myosin at Ser19, in the N-terminal part of the protein 
outside the head domain, has not been the subject of functional investigations but the site is 
conserved in TgmyoA. Discussion on previous work addressing the presence and 
implications of phospho-sites on PfMTIP (and TgMLC1) is presented in detail in chapter 4. 
Evidence for actomyosin motor activity in erythrocyte invasion and contemporary debate 
The role of actomyosin motility in gliding motility and host cell invasion by Apicomplexa has 
been suggested by numerous pieces of work. The 1979 study by Miller et al. showed that 
invasion of erythrocytes was prevented when blood stage malaria parasite were treated with 
F-actin-destabilising cytochalasin B;94 variations on this drug treatment regime have since 
been used widely as a tool to study motility. In 1998, Pinder et al. showed that a myosin 
ATPase inhibitor blocked invasion and motility in Plasmodium;95 this had the same effect on 
T. gondii invasive stages.27 Moreover, disruption of the TgmyoA gene expression was shown 
to cause ‘severe impairment’ of host cell invasion,96 a phenotype also observed when the C-
terminus of myoA (i.e. lacking the head domain) was overexpressed in extracellular T. gondii 
parasites.97 The latter experiment should lead to displacement of full-length myoA from its 
complex with MLC1 and thus disassembly of the motor from its cargo, which would explain 
this result. Notably, when this was repeated in intracellular parasites, cytokinesis was 
blocked suggesting another role for myoA-based motility in cell division. 
In 2013, Andenmatten et al. from the Meissner group published a method to conditionally 
knock out (KO), rather than induce a knockdown (KD) of, parasite genes in T. gondii, 
exemplifying the new system with three putative ‘invasion factors’: MIC2 (the homologue of 
Plasmodium MTRAP), myoA and actin.98 Remarkably, it was found that clonal myoA-KO and 
MIC2-KO parasite lines could be maintained in culture and invade host cells, albeit with 
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much lower efficiency and impaired gliding motility. The myoA-KO invasion phenotype was 
actually comparable to that observed for the tetracycline-induced myoA-KD published in 
2002;96 the residual ability to invade had at that time been attributed to residual expression 
of the myosin. Unsurprisingly, this has sparked a great deal of interest and debate in the 
possibility of alternative apicomplexan host cell invasion mechanism(s). The method has 
since been extended to P. falciparum99 although the corresponding myoA, MIC2, actin KOs 
have not yet been reported. In P. berghei (and T. gondii) AMA1 knockout has been 
achieved;47 parasites lacking this molecule showed impaired adhesion to host cells but 
remained invasive, calling into question the role of the highly conserved AMA1-RON2 
complex, inhibitors of which block invasion (see above). The conclusion of this study is that 
‘AMA1 acts in a host cell-binding step that impacts the frequency but not quality of RON-
dependent tight junction formation, and the AMA1-RON2 interaction is not involved in the 
transduction of the force generated by the zoite motor during invasion.’47 
The most recent data to emerge from the Meissner group refocuses attention on glideosome 
components in T. gondii. In addition to the myoA gene KO, which is given more thorough 
attention, MLC1 (the homologue of Plasmodium MTIP) and GAP45 KOs were also 
generated, with further remarkable results.100 Intriguingly, the invasion phenotypes of 
individual myoA KO parasites were varied, with the majority invading in a ‘spasmodic, stop-
and-go’ fashion that took up to ten minutes (cf. ~20-30 seconds normally). However, the 
fastest recorded entry was 25 seconds, suggesting that the force required could be 
generated in the absence of the myoA motor. The study leaves open the possibility of 
compensation by other myosins, since attempts to knock out myoB/C in addition to myoA 
resulted in a more severe invasion phenotype. The MLC1 KO parasites showed comparable 
features to the myoA KO parasites i.e. impaired gliding motility in circular motions and 
significantly less efficient invasion on average. Notably, egress was almost totally blocked 
such that the MLC1 KO parasites could not be maintained in culture. MLC1 depletion caused 
mislocalisation of myoA, which implies that other myosin light chains could not compensate. 
Perhaps the most intriguing results were for the GAP45 KO parasites. GAP45 is thought to 
span the space between the parasite’s IMC and PM and thus maintain pellicle integrity 
(figure 1.3). As may therefore have been expected, GAP45 KO parasites were 
morphologically different and the removal of this protein caused other components (e.g. 
myoA and MLC1) to be cytosolic due to altered membrane/IMC organisation. Despite this, all 
observed parasites were able to glide (albeit slower than WT parasites) and furthermore, this 
was more efficient than in myoA or MLC1 KO parasites. Invasion and egress were severely 
compromised, but, as with KOs of the myoA and MLC1, the former occurred ‘through’ the 
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tight junction, as usually observed in wild-type parasites. The KO data from T. gondii are 
summarised in table 1.1. 
 
Table 1.1 Phenotypic analyses of T. gondii parasites with glideosome component knock outs (KO). Adapted from 
recent papers by Meissner and co-workers.
76,98,100
 Viability refers to whether or not the KO parasites could be 
permanently maintained in culture. Percentage values for egress, invasion and gliding refer to the number of 
parasites observed to have successfully achieved these motile processes, normalised to WT cultures, but do not 
refer to the efficiency or speed of the processes in each case. 
 
Taken together, the genetic data presented above have profound implications on the 
understanding of apicomplexan parasite gliding motility and invasion; processes which, until 
2013, had largely been ascribed molecular determinants. It is, of course, possible that the 
data that have been gathered on T. gondii (mostly tachyzoites) do not hold for Plasmodium 
species, or are dependent on the particular combination of zoite stage/shape and/or host 
cell/substrate. However, if the notion that apicomplexan parasites use homologous systems 
for motility (including invasion) is to be believed – which is plausible, given the conservation 
of so many of the molecules listed above across the phylum – then it appears that there 
must be some as yet undetermined myoA- or glideosome-independent invasion mechanism. 
While the actomyosin motor seems to play a vital role in egress and in smooth/efficient 
gliding and invasion, parasites seem capable of moving and invading in its absence and the 
Meissner group has made a preliminary suggestion that an alternative mechanism might be 
driven by hydrodynamic forces (as implicated, for example, in the movement of 
keratinocytes101). However, experimental data demonstrating this are currently lacking. The 
KO data also call into question the association of motile processes like parasite egress and 
gliding motility with invasion given the phenotypes observed; in this regard, a recent review 
by Meissner et al. points out that in parasites other than Toxoplasma and Plasmodium (e.g. 
other apicomplexans, or organisms from outside the phylum), this association is not always 
evident.76 The role of the host cell has also gone largely unstudied; it may play an important 
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role and seems unlikely to be entirely passive, particularly given the growing evidence that 
the host cytoskeleton is modulated during invasion.102,103 
In summary, the ‘paradigm’ of Plasmodium parasite motility may be at a turning point – or, 
as Thomas Kuhn might suggest, ‘in crisis’: 
‘The transition from a paradigm in crisis to a new one […] is far from a cumulative 
process, one achieved by an articulation or extension of the old paradigm. Rather it is 
a reconstruction of the field from new fundamentals.’ 104 
Whether the linear model for generation of force by the actomyosin motor complex (shown in 
figure 1.3) will require such a complete reconstruction is not clear. It is also possible that the 
components of the machinery exhibit multiple redundancies, or that a separate, 
compensatory mechanism exists. The T. gondii genetic data suggest that the myoA motor is 
vital in parasite egress from host cells, and is also important in providing directionality and 
efficiency to gliding and invasion; how this is achieved at the molecular level is not clear.  
Clearly, ‘traditional’ genetics (e.g. knock downs, knock outs or mutations) coupled with 
imaging/phenotypic analysis, the resolution of which is ever-improving, will continue to arm 
parasitologists with tools to investigate mechanisms at the protein level. However, there is 
also considerable need for detailed biophysical and structural investigations into such 
systems as the actomyosin motor, in order to inform the development of selective chemical 
tools to unpick complex biological functions without such drastic perturbation of the 
organism. As has been exemplified already in Plasmodium by work from the Tate66 and 
Bogyo105 laboratories, the combination of chemistry, structural biology and parasite biology 
may be powerful in this regard and can also enable validation of novel (and urgently-needed) 
antimalarial drug targets. The work in this thesis comprises such an investigation (and 
subsequent tool development) into the complex between myoA and MTIP from 
P. falciparum; this complex is the focus of the next section. 
1.2 The MTIP-myoA complex from P. falciparum 
1.2.1 Myosin A (myoA) and other Plasmodium myosins 
By association with actin and hydrolysis of ATP to provide the energy source, myosins 
function to provide dynamic motility to a cell or group of cells e.g. muscle contraction, 
vesicular trafficking and cell division. There are several classes, divided broadly according to 
their global structure. Typically, a myosin protein will consist of three domains: the N-terminal 
head (or motor) domain, whose role is to bind F-actin upon hydrolysis of ATP; a ‘neck’ (or 
regulatory) domain, which may serve to regulate the action of the myosin via interaction with 
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signalling molecules and/or myosin light chains; and a C-terminal ‘tail’ domain, whose role 
and structure varies but appears to be in directing interaction with the motor’s cargo.106 
Briefly, actomyosin motility is generated via a catalytic cycle as follows: (i) the myosin head 
domain binds to actin and ADP and phosphate (Pi) are bound in the active site of the 
domain; (ii) Pi then ADP are released sequentially causing a conformational change that 
produces the ‘working stroke’ via a sliding force on the actin filament, with the myosin 
remaining bound to actin throughout; (iii) the myosin detaches from actin upon binding ATP 
and hydrolysis of the nucleotide resets the conformation in step (i) (the ‘recovery stroke’).53 
Due to the common role of myosin head domains, this region tends to be highly-conserved, 
with the ‘neck’ and ‘tail’ domains more divergent and capable of binding a range of light 
chains and calmodulin family proteins.  
The P. falciparum genome encodes six myosins, named (myo)A-F (table 1.2).  
 
Table 1.2 Details of the six Plasmodium falciparum myosins, named A-F (alternative names based on clustering 
with T. gondii myosins are given in italicised brackets). The transcription profiles and pairwise sequence 
alignments are taken from Chaparro-Olaya et al.
107
 
 
A, B and F are transcribed throughout blood stage development (rings, trophozoites and 
schizonts) while C and E are specific to trophozoites and schizonts respectively, and mRNA 
of D is present in both the latter stages.107 
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MyoA is a class XIV myosin found in apicomplexan parasites such as T. gondii (the species 
in which this class was first identified)108 and P. falciparum.95 Originally confined to this 
phylum, reorganisation of the myosin super-family was recently proposed in which class XIV 
was subdivided and included 12 myosin sequences from the ciliate species Tetrahymena 
thermophila.109 Like other myosins in the class, P. falciparum myoA contains 818 residues 
and is simple in structure consisting of a head domain directly linked to a short (56-residue) 
tail domain that binds to light chain MTIP, with no apparent neck region (or vice versa, 
depending on how strictly the tail and neck are named, see figure 1.4); these are the 
smallest myosins to have been characterised.53 
 
 
Figure 1.4 The simplified domain structure of P. falciparum myosin A (PfmyoA). 
 
Its blood stage expression pattern shows a peak in late schizogony which fades after 
invasion.29,57 MyoB also belongs to class XIV and bears close homology to myoA (35% 
identity and 59% similarity) but its function is unknown, and it does not cluster with other 
apicomplexan myosins. Although PfmyoB tail peptides can also bind to MTIP in vitro 
according to fluorescence-based assays,110 it appears that in vivo the protein is targeted to a 
different light chain (Green, Holder et al. and Chatterjee, Bergman et al., unpublished 
results). Preliminary data suggest a distinct apical localisation in merozoites, with an 
expression profile in the blood stage similar to that observed for myoA.111 Little is known 
about the more conventional Pf myosins C-F; Foth et al. renamed these myosins to illustrate 
homology with the (larger) T. gondii myosin repertoire, more of which has been annotated 
functionally.109 Within the latter repertoire, alternatively-spliced gene products TgmyoB and 
TgmyoC have been implicated in having roles in cytokinesis,112 but do not have homologues 
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in Plasmodium. The possibility that other apicomplexan myosins other than myoA play a role 
in motility has not been discounted. 
Despite the recent data that suggest the presence of an alternative cell invasion mechanism 
in homologue T. gondii, myoA in Plasmodium has been implicated strongly in providing 
directional force in egress, gliding motility and invasion. Interaction of PfmyoA with PfMTIP, 
via its C-terminal 20 amino acids, is discussed in subsequent sections (and is the subject of 
extensive investigation in this thesis); it has been suggested recently that another light chain 
may also bind to the myoA tail domain, upstream of the MTIP binding site. This other light 
chain has been called the ‘essential light chain (ELC) 1’ in T. gondii; the homologous protein 
has not been characterised in P. falciparum but has been identified (Yusuf, Green, Holder et 
al., unpublished results). ELC1 may serve to rigidify the myoA tail/neck (i.e. the lever arm) to 
improve efficiency of the power stroke. In T. gondii ELC1 is predicted to be calcium-binding; 
taken together, this might suggest a molecular basis for motor activity regulation via calcium 
stimulation.67 A sequence alignment of the conserved C-termini of Plasmodium and T. gondii 
myoA proteins is shown in figure 1.5. 
 
Figure 1.5 Sequence alignments of P. falciparum, P. vivax, P. yoelii, P. knowlesi, P. berghei and T. gondii myoA 
tails, extracted from plasmodb.org
113
 and toxodb.org.
114
 The alignments were performed in Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). Numbering above the sequence refers to PfmyoA (818 residues). 
 
 
1.2.2 Myosin A tail domain interacting protein (MTIP) 
Myosin A Tail domain Interacting Protein (MTIP) of P. falciparum is a small (~25 kDa), 
soluble protein which acts as a light chain of myoA.54-57,59 Like myoA, the expression of MTIP 
in blood stage parasites peaks during late schizogony i.e. at the point of merozoite egress 
and (re)invasion of erythrocytes, and it is localised at the periphery of the parasites (figure 
1.6).57 Although MTIP is highly acidic (e.g. PfMTIP has a theoretical pI of 4.2*) and is 
predicted based on primary sequence to contain several EF hands (secondary structural 
elements that are usually indicative calcium binding), calcium binds only weakly to MTIP: the 
K(Ca2+) of MTIP was two orders of magnitude weaker than calmodulin.57 
                                                     
*
 Calculated from the primary sequence at web.expasy.org protparam  
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Figure 1.6 Expression and localisation of MTIP during P. falciparum blood stages. Left: expression peaks at the 
end of the ~48-hour cycle i.e. during schizogony and subsequent erythrocyte rupture, at which point parasites 
egress and reinvade. Right: immunofluorescence shows that MTIP accumulates at the anterior end of a free 
merozoite (parasite nucleus shown by DAPI staining). Figure adapted with permission from Green et al. 
57
 
 
A far-UV circular dichroism spectrum of PfMTIP suggests a protein with high (~40%) α-
helical content,57,110 which is corroborated by the X-ray crystal structures of truncated 
versions (see next section).55,56,115 The domain corresponding to residues ~1-60 (also known 
as the ‘N-terminal extension’ of MTIP) is apparently disordered and does not influence the 
binding to myoA,110,116 but appears to contribute to localisation of the complex via post-
translational palmitoylation64,65 on one or more conserved cysteine residues (Cys5 and 
Cys8). Residues 61-204 (PfMTIPΔ60) form two domains called the N- and C-terminal 
domains connected by a linker; the domain structure of the protein is shown schematically in 
figure 1.7. 
 
Figure 1.7 The simplified domain structure of P. falciparum myoA tail domain interacting protein (PfMTIP). 
 
MTIPs from Plasmodium species are highly conserved throughout the sequence as 
illustrated by figure 1.8. This suggests strongly that the secondary and tertiary structure of 
the protein is also conserved. It is less clear that T. gondii MLC1 forms the same fold as 
MTIP based on residue identity (and there is no structure of TgMLC1 with or without 
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TgmyoA bound), but there is high similarity in residues that are not conserved in this protein 
and it is predicted via homology modelling to adopt a comparable, largely helical fold when 
bound to the TgmyoA tail domain.67 
 
Figure 1.8 Sequence alignments of P. falciparum MTIP with P. vivax, P. yoelii, P. knowlesi, P. berghei MTIP and 
MLC1 from T. gondii, extracted from plasmodb.org and toxodb.org. Highlighted in the top line is sequence of 
PfMTIP coloured by its domain structure of MTIP (as shown in figure 1.7). The alignments were performed in 
Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/). 
 
The region that displays the lowest primary sequence conservation in Plasmodium MTIPs 
spans residues ~40-77 (using PfMTIP numbering); this overlaps in part with one region of 
the protein predicted to exhibit the greatest disorder (residues 38-69).* Indeed although 
                                                     
*
 Predicted using the DISOPRED2 server found at http://bioinf.cs.ucl.ac.uk/psipred/ 
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residues 61-77 are observed in crystal structures of PfMTIPΔ60, atoms from these residues 
display strikingly higher B-factors than the remainder of the protein.56,115 
While it is thought that the N-terminal extension does not contribute to myoA tail binding, the 
high sequence identity of residues 1-40 may point to a conserved function. As well as the 
conserved cysteines mentioned above, several portions of this apparently unstructured 
region are totally conserved. One interaction demonstrated in vitro is that between PfMTIP 
and PfRab11A, a GTPase implicated in mediating delivery of new plasma membrane to 
daughter merozoites during erythrocytic schizogony. A model is presented in which a myosin 
motor drives vesicular trafficking in this process, with MTIP simultaneously acting as the 
myosin light chain and interacting with mediator Rab11A.97 It has not yet been established 
which MTIP residues are responsible for this interaction, but it could be that they include 
these conserved N-terminal residues. It may also be that the conserved residues make 
contacts with other proteins such as GAP45 in the glideosome; mutation of Asp23/Asp25 to 
alanines, and (in a separate construct) of Pro33/Gly34/Phe35* to Ala-Ile-Ala, prevented pull 
down of TgMLC1 with TgGAP45 and TgGAP50.64 The same was also observed when both 
palmitoylatable cysteines were mutated to alanine, suggesting a link between lipidation and 
correct assembly. These putative PPI sites have not been demonstrated in vitro, as noted in 
the previous section.  
1.2.3 The interaction between MTIP and the myoA tail 
Initial observations 
The nature of the interaction between the tail of myoA and MTIP has been the subject of 
several studies since MTIP was first observed in sporozoites of P. yoelii, via a yeast two-
hybrid screen (see below for further discussion of yeast two-hybrid results).54 In this article, 
Bergman et al. concluded that it is the conserved C-terminal 15 amino acid residues of the 
PymyoA tail which bind to MTIP and show that mutation of a dibasic motif to alanines 
(R812A/K813A, see figure 1.5) abolishes interaction; this agreed with the results of a 
previous experiment that demonstrated the importance of an analogous motif in the TgmyoA 
tail.117 Green et al. further characterised the interaction in blood stage P. falciparum 
parasites, and demonstrated using a fluorescence-based assay that the in vitro interaction 
between PfMTIP and a C-terminal PfmyoA tail peptide was tight (KD = 265 nM), calcium 
independent and showed 1:1 stoichiometry. This peptide could effectively displace full-length 
myoA from parasite lysates. An in vitro motility assay was also conducted in which MTIP-
myoA was immobilised on glass slides (via an MTIP antibody) and incubated with actin and 
ATP; the motility was also calcium-independent, which suggests (along with other 
                                                     
*
 Using PfMTIP numbering of the residues, which are totally conserved in TgMLC1 (see figure 1.8). 
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biophysical evidence) that unlike many myosin light chains, the MTIP-myoA interaction and 
the dynamics of the complex are not directly regulated via calcium binding.57 
Crystal structures 
At the outset of the research reported in this thesis in 2010, two crystal structures of 
Plasmodium MTIPs had been published by researchers from the Hol group. The first used a 
truncated P. knowlesi MTIP (PkMTIPΔ78) with a 15-mer P. yoelii tail peptide, with diffraction 
data from crystals grown in a solution at pH 5.3.55 The second used a truncated 
P. falciparum MTIP (PfMTIPΔ60) with the same P. yoelii tail peptide, with diffraction data 
from crystals grown in a solution at pH 7.5.56 The two structures are shown in figure 1.9 and 
are also discussed in chapter 3. The pH of the solution (and difference in MTIP construct 
lengths) changes the MTIP conformation and interaction with the myoA tail drastically; in the 
first structure the peptide is only bound to one of three MTIP subunits observed in the 
asymmetric unit with the remaining two subunits ‘unliganded’. Common to all subunits was a 
long, central helix spanning residues 125-152, which connected the N-terminal domain 
(NTD) to the C-terminal domain (CTD). In the uncomplexed structures, there was some 
deviation of MTIP structure suggesting that the protein may adopt several conformations in 
solution. In the ‘liganded’ subunit it was shown that the CTD of MTIP bound the helical 
PymyoA tail, in doing so burying 1389 Å2 of exposed protein surface. Side-chains of Gln808 
and His810 were involved in ‘numerous’ hydrogen bonds with MTIP, while Arg812 and 
Arg814 (Lys814 in PfmyoA) made electrostatic interactions with Glu179 and Asp201, 
respectively.* Leu804, Val807 and Ile811 on one face of the myoA tail helix appeared to be 
sequestered in hydrophobic pockets created by a number of MTIP CTD residues, for which 
Phe148, Leu168, Leu175 and Phe198 were deemed particularly important in light of their 
total conservation among Plasmodium MTIPs.  
Attention was paid in particular to the role of myoA residue Lys813, which although totally 
conserved breaks the ‘IQ motif’ commonly observed in myosin light chain or calmodulin (EF-
hand) binding domains; this position of the IQ motif is (strictly) occupied by glycine. In the 
first structure, Lys813 is solvent exposed and it was supposed that its presence prevents (on 
steric grounds) a clamped structure seen for homologous scallop muscle myosin essential 
light chain (ELC) in complex with the IQ motif of myosin heavy chain118 (containing Gly in 
that position).  
                                                     
*
 Although this structure was of PkMTIP, residue numbering given here refers to PfMTIP for clarity and 
consistency. 
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Figure 1.9 The first two crystal structures of MTIP-myoA solved by the Hol group (pdb codes: 2AUC (top) and 
2QAC (bottom)); features of each structure are annotated. 
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However, this was a false interpretation: Lys813 is actually an important determinant of tight 
binding, as demonstrated by the crystal structure solved at neutral pH and as suggested by 
yeast two-hybrid analysis.56 In the latter structure, which contains one MTIP-myoA complex 
per asymmetric unit, the hydrophobic face of the myoA tail occupies the same hydrophobic 
groove in the MTIP CTD. However, rather than by a rigid central helix, the NTD is connected 
to the CTD via a coiled, kinked linker (consisting of residues 136-140), allowing the domains 
to ‘clamp’ around the myosin tail, burying 2017 Å2 of solvent-exposed surface area and 
enabling the array of myoA tail side-chains to interact extensively with both MTIP domains 
(figure 1.10). Lys813 is in this case completely buried from solvent, and its entire side-chain 
is in contact with MTIP. The primary side-chain amine functionality interacts with the 
backbone carbonyl of Ile202 and the MTIP C-terminus (Glu204), while its side-chain carbon 
atoms engage in hydrophobic contacts with Leu104 and Gly103. Arg806, also totally 
conserved in apicomplexan myoA tail domains, makes interactions with a number of MTIP 
residues, including the side-chain of Asp139 in the linker, and the backbone of Ala105 and 
side-chain of Ser107 in the NTD. 
 
 
Figure 1.10 Array of side-chains presented by the helical PymyoA tail when bound to PfMTIPΔ60 at pH 7.5. 
 
Overall, the second crystal structure shows that PfMTIPΔ60 adopts a largely helical fold that 
is composed of four non-calcium-binding EF-hands, with two in each domain (figure 1.9). 
These pairs of EF-hands are held together by short β-strands to form a stable tertiary 
structure in the presence of the myoA tail. This compact, clamped conformation is stabilised 
by a number of ‘intra-MTIP’ interactions, including a hydrogen bond between Ser108 and 
Asp173 in the NTD and CTD respectively. Furthermore, an intra-myoA tail hydrogen bond is 
formed between (unprotonated) His810 and Lys813. His810 also interacts with Asp139; its 
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ability to make these interactions simultaneously at pH 7.5 is deemed to be one of the 
causes for such a different conformation compared with the first structure, since pH 5.3 
favours the protonated form which would prevent interaction with the positively charged 
Lys813 side-chain (figure 1.11).  
 
 
 
Figure 1.11 Conformational differences between MTIP-myoA structures at pH 5.3 (grey) and pH 7.5 (coloured as 
in figures 1.9 and 1.10): binding of the hydrophobic side (Leu804, Val807 and Ile811) of the PymyoA tail is 
conserved in both structures, but at neutral pH the N-terminal MTIP domain can form a clamp via interactions 
between Ser108 and Asp173. Thought to be crucial in this pH dependence is the protonation state of His810 
(inset; equilibrium populations of histidine side-chain protonation states were calculated with ChemAxon 
MarvinView version 6.1.6); an uncharged histidine side-chain allows simultaneous interaction between it and both 
myoA Lys813 and MTIP Asp139. The structures were aligned by MTIP CTD residues 150-200 in PyMOL.  
 
Another crystal structure of PfMTIPΔ60, this time in complex with PfmyoA(799-818), was 
solved* by molecular replacement using the 2007 PfMTIPΔ60-PymyoA structure as a search 
model.115,119 This structure, with components solely from P. falciparum, is supportive of the 
                                                     
*
 The initial, incompletely-refined model for the structure was reported in C. H. Douse, MRes thesis 
(Imperial College London).
119 
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second published structure from the Hol group. There is a consensus that the compact 
conformation is of physiological relevance; this is further discussed in chapter 3. 
Solution state structural studies 
Circular dichroism spectra of full-length and truncated PfMTIP constructs in solution are also 
suggestive of the highly helical fold observed for residues 61-204 in crystal structures, with a 
largely unstructured N-terminal extension.110 Preliminary, two-dimensional NMR spectra with 
uniformly 15N-labelled samples of PfMTIP constructs acquired by Thomas et al. in this 
laboratory further supported the notion that residues 1-60 are unstructured in vitro and do 
not contribute to the folding of the rest of the protein;116 it was observed that ‘deletion of 
[residues] 1-60 improves dispersion of [amide] resonances and decreases signal overlap at 
the centre of the spectrum.’ * This is further investigated in chapter 3. Addition of unlabelled 
PfmyoA tail peptides spanning residues 803-818 or 799-818 to 15N-labelled PfMTIPΔ60 and 
monitoring of the labelled protein signals improved the dispersion of resonances further, 
consistent with the formation of a stable complex. Differences between the spectra for 
complexes of the protein with the two peptides were interpreted in terms of additional 
interactions made by myoA residues 799-802, which supported data from fluorescence-
based inhibition assays (see below). However, the spectra were not assigned due to 
instability of MTIP samples; it was observed that the protein had a tendency to form 
insoluble aggregates over the long timescale of the triple resonance experiments required to 
make assignments (i.e. several days at concentrations greater than 300 µM). 
Conditions for triple resonance NMR experiments on the complex between (13C, 15N-labelled) 
PfMTIPΔ60 and PfmyoA(799-818) were subsequently established (C. H. Douse, MRes 
thesis; details of the assignment methods are discussed in chapter 3). Addition of a further, 
size exclusion chromatography purification step in the protein preparation protocol, together 
with optimisation of the buffer conditions, were sufficient to ensure the protein remained 
homogenous for several days at 303 K. Data necessary for the assignment of backbone 
chemical shifts were acquired.119 The final assignment of the spectra and use of these data 
in studying the MTIP-myoA complex are discussed in chapter 3. 
Summary of structural data 
Table 1.3 shows the primary sequence of PfMTIP and how this relates to existing structural 
data. Also shown for reference are the positions of putative post-translational modifications, 
and those residues that have been annotated for interaction with GAP45. 
                                                     
*
 Backbone amide NMR signals tend be better dispersed in structured parts of proteins, whereas 
disordered regions that rapidly sample several conformations tend to give rise to a narrow range of 
chemical shifts in the centre of an amide-detected experiment (8.0-8.5 ppm). 
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Table 1.3 Primary and secondary structure of PfMTIP coloured according to domain boundaries suggested by 
existing structural data (light grey = disordered N-terminal extension; dark green = N-terminal domain; 
dark grey = interdomain linker; light green = C-terminal domain). Positions of putative post-translational 
modifications are shown (Palm = palmitoylation site; Phos = phosphorylation site) along with residues thought to 
be involved in interaction with GAP45. 
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Yeast two-hybrid screens 
A number of yeast two-hybrid (Y2H) assays have been carried out to seek an understanding 
of the interaction between myoA and its light chain MTIP. Briefly, such assays involve fusing 
putative interacting partners (or mutants thereof) to separate DNA-binding and 
transcriptional activating domains of a yeast transcription factor. If there is an interaction 
between the partners, transcriptional activity is reconstituted and a reporter gene is 
expressed. Expression of this reporter may either be essential for the yeast to grow on 
plates, or may be an enzyme (e.g. β-galactosidase) for which there is a simple histochemical 
method to detect activity.  
The initial experiment using P. yoelii constructs identified these binding partners and showed 
that R812 and K813 are particular determinants of interaction on the myoA ‘side’. While 
residues 80-204 of PyMTIP were sufficient for interaction, further truncation (95-204) 
abrogated interaction, as did truncation of the PyMTIP C-terminus (1-189).54 Accompanying 
the two crystal structures from the Hol group were further Y2H studies; these showed that 
PymyoA mutations L804A, R806A, V807A, H810A, H810E, I811A, R812A, K813A and 
R814A all prevented interaction with PyMTIP. On the MTIP side, the role of a number of key 
residues was also ‘confirmed’ to back up the structural data.55,56 In 2006, the Rayner group 
conducted analogous experiments using PfMTIP-myoA constructs.59 The importance of 
residue Arg812 was confirmed since R812A abolished interaction, while mutations K813A 
and K814A were tolerated but reduced the activity of a β-galactosidase reporter (with 
Lys813 deemed more important to the interaction than Lys814). The importance of totally 
conserved myoA residue Gln808 was also established for the first time; Q808A mutation 
abolished interaction. A PfMTIP construct lacking the C-terminal 5 amino acids 
(residues 1-199) was able to interact at near wild-type level with PfmyoA, but further 
truncation (residues 1-189) prevented interaction, as observed in the initial work by Bergman 
et al. Taken together, the two studies suggest that MTIP residues 80-199 are necessary and 
sufficient for interaction with myoA. Attention was also paid in the latter study to the 
conserved Trp171/Gly172/Asp173 motif in PfMTIP since analysis of data for homologous 
proteins from outside the Apicomplexa phylum shows that this so-called ‘Q-loop’ is important 
for interaction with the Gln residue in the binding partner (Gln808 in myoA). Triple mutation 
of these residues to Ala abolished interaction with myoA, with Asp173 shown in other 
mutants to be particularly essential. The latter observation is understandable in the context 
of the second crystal structure, published the following year, in which it is this Asp residue 
that makes the important intramolecular interaction with Ser108 to hold the MTIP clamp 
around the myoA tail. The Y2H observations are summarised in tables 1.4 (focusing on 
MTIP residues) and 1.5 (focusing on myoA tail residues). 
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Table 1.4 Sequence of PfMTIP (as shown in table 1.3) coloured and annotated according to importance in the 
interaction with the myoA tail (informed by structural and Y2H studies). Highlighted in green are residues 80-199 
i.e. the region necessary and sufficient for interaction. Marked with * are residues observed in the 2007 MTIP-
myoA crystal structure to be in direct contact with the myoA tail. Marked with ^ are residues shown to be 
particularly important via Y2H mutants. Data taken from Bergman et al.,
54
 Jones et al.
59
 and Bosch et al.
55,56
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Fluorescence-based assays 
Work by Thomas and co-workers in this laboratory further characterised the key MTIP-myoA 
interactions. In place of the yeast two-hybrid system, Thomas adapted the fluorescence-
based binding assay used by Green et al. to a 96-well plate format to determine binding 
parameters for a number of peptide-protein combinations.57,116 An environmentally-sensitive 
fluorescent reporter was attached to the N-terminus of the myoA peptides, allowing either 
direct measurement of the interaction (between MTIP and fluorescent myoA peptides) or the 
‘inhibitory’ potential of unlabelled peptides (via displacement of a preformed complex of 
MTIP with a fluorescent myoA peptide ‘probe’ of known affinity). 
In light of the crystal structures described above, the individual roles of the MTIP domains 
were analysed in comparison to the full-length protein. It was found that whereas full-length 
MTIP bound all (dansylated*) peptides containing the final 15 residues (803-818) in a 1:1 
ratio with a KD of less than 100 nM, the CTD and NTD showed much weaker binding 
separately, consistent with a model in which both lobes clamp around the myosin tail. Tighter 
binding was observed with the CTD for all peptides tested. 
Thomas also measured half-maximal inhibitory concentrations (IC50s) for a number of 
unlabelled PfmyoA tail peptides of different lengths and with different residues mutated to 
alanine, in order to identify the key residues for binding. It was first established that 
PfmyoA(799-818) (i.e. the C-terminal 20 amino acids) contained the residues required for 
optimum binding to MTIP; this peptide was the basis of the series of truncations/mutations. 
Deletion of Ala817 and Glu818 residues at the C-terminus did not have a significant effect on 
binding. However, when Val816 and Met815 were sequentially removed, the IC50 value 
sequentially increased (i.e. poorer inhibition) and inhibition was not observed when the 
peptide was truncated past Lys814. In comparison to PfmyoA(799-818), the IC50 of 
PfmyoA(803-818) was an order of magnitude larger, implicating residues 799-802 with 
binding and/or structural roles; this was of interest since these residues were not included in 
the (PymyoA) peptide used for the first crystal structures. In the alanine scanning 
experiments, mutation of Ile801, Leu804, Arg806, Val807, Gln808, His810, Ile811, Arg812, 
Lys813 and Lys814 all drastically reduced potency. The importance of electrostatic 
interactions and pH in complex formation was highlighted by measurement of affinities in 
different buffers; lowering the ionic strength of the buffer increased affinity, and neutral pH 
was optimal for tight binding.110 Data from these fluorescence assays are summarised along 
with yeast two-hybrid data in table 1.5. 
                                                     
*
 Fluorescent, dansylated peptides showed higher affinities than apparent Ki values calculated for 
unlabelled analogues, presumably due to discrepancies between the direct binding and displacement 
(inhibition) assays, and/or interactions with the dansyl fluorophore. 
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Table 1.5 Sequence of the C-terminal 20 amino acids of PfmyoA coloured and annotated according to 
importance in the interaction with MTIP (informed by Y2H and fluorescence-based binding studies). Highlighted 
in blue are those included in the 2007 crystal structure of PfMTIPΔ60-PymyoA(803-817) (PymyoA residues given 
in brackets). n.d. = no relevant data have been recorded. Data taken from Bergman et al.,
54
 Jones et al.,
59
 
Bosch et al.
55,56
 and Thomas et al.
110,116
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1.2.4 Inhibition of Plasmodium MTIP-myoA  
Attempts have been made to target the MTIP-myoA interaction with inhibitors. As noted 
above, given the putative roles of myoA-based motility in apicomplexan gliding, invasion, 
cytokinesis and egress, disruption of the complex between the myoA tail and its anchoring 
light chain should impair parasite growth and development at various points in the 
Plasmodium life cycle. Indeed, overexpression of the TgmyoA tail domain in extracellular 
T. gondii parasites resulted in a significant block of invasion;97 such a phenotype is likely due 
to the displacement of the full-length myosin from its complex with TgMLC1 (the homologue 
of Plasmodium MTIP) i.e. the aim of an exogenous inhibitor. 
Accordingly, there has been suggestion that targeting the MTIP-myoA complex might be a 
novel antimalarial drug strategy;55,116,120 the recent work on disrupting the RON2-AMA1 
interaction has set a precedent for PPI inhibitors being developed in this way.43,50 
Furthermore, the highly distinctive structure and sequence of Plasmodium myoA as 
compared to human myosins, and the uniqueness of the ‘glideosome’ complex in general, 
suggest that specific disruption of myoA function may be achievable. Given the 
contemporary evidence of myoA-independent modes of parasite motility, it may be that such 
a strategy would be misguided in terms of the development of a clinical and effective drug; 
nonetheless a specific inhibitor of MTIP-myoA would represent a valuable tool for 
investigating myoA motility. 
Peptidic inhibitors 
In the 2006 paper describing the first crystal structure of the MTIP-myoA tail complex it was 
demonstrated that the C-terminal PymyoA tail peptide used for co-crystallisation with MTIP 
was capable of inhibiting P. falciparum blood-stage growth with a half maximal effective 
concentration (EC50) of 84 µM, while a randomised sequence or a peptide bearing the 
double R812A K813A mutation had no effect. It was also claimed that ‘examination of 
Giemsa-stained films from treated parasites revealed many extracellular merozoites, 
supporting the notion that the myoA-tail peptide inhibits invasion of red blood cells’.55 A 
phenotype where merozoites appeared stuck on the erythrocyte surface was also observed 
by others using an analogous PfmyoA tail peptide but could not be reliably reproduced (J. 
Green and A. Holder, personal communication). As described in the previous section, 
Thomas and co-workers made a number of PfmyoA tail peptide mimics that were able to 
displace a longer fluorescent ‘probe’ peptide in vitro with varying potency; several of these 
displayed substantially greater potency than the peptides used in the above experiments. 
However, none of the synthesised peptides had any effect on parasite growth.116 These 
results suggest either that (i) the assays are very sensitive to conditions and/or the stability 
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and cell permeability* of the peptides in blood cultures is variable, (ii) parasites were able to 
invade (albeit slower) despite MTIP-myoA inhibition as per the myoA KO parasites 
discussed above, such that growth was not impeded, (iii) a combination of these factors was 
at work or (iv) the inhibition observed by Bosch et al. was a false positive and/or the result of 
an assay artefact. The development of stabilised myoA tail peptide mimics is discussed in 
chapter 5. 
Small molecule inhibitors 
Little has been published on small molecule MTIP-myoA inhibitors. An in silico screen was 
conducted by Kortagere et al., reported in 2010, aiming to identify small molecules that bind 
to MTIP and thus prevent interaction with the myoA tail. The ‘extended’ crystal structure of 
MTIP was used for the computational docking experiment. Several of the ‘hit’ compounds 
from this screen inhibited parasite growth with EC50 values on the order of 10
-7 M and a 
subset perturbed gliding motility of Plasmodium sporozoites; however, all the hit compounds 
were ‘very hydrophobic’ and ‘the limited solubility of these compounds in other solvents 
[other than DMSO] hampered the ability to use other biophysical experiments…to provide 
direct evidence [for MTIP binding].’120 Further, none of the inhibitors formed hydrogen bonds 
with MTIP residues in the docked protein-ligand complexes, suggesting that specificity of the 
molecules for binding to the intended target may be low. An experimental fragment screen 
against MTIP is discussed in chapter 6. 
Using information gained by alanine scanning mutagenesis of model PfmyoA tail peptides 
and existing Y2H results, Thomas also designed a series of α-helix mimetics using an 
oligoamide scaffold reported by the Boger group121 (an example is shown in figure 1.12). 
The molecules were designed in an attempt to present the functionality of key side-chains 
Arg806, His810 and Lys813 on one face of the PfmyoA tail helix, each of which engage in 
polar interactions with MTIP according to the co-crystal structure of 
PfMTIPΔ60-PymyoA(803-817), are totally conserved and are not tolerant to alanine mutation 
(table 1.5). Moderate inhibition (IC50 ~ 10
-4 M) of the MTIP-myoA complex was observed in 
fluorescence-based assays; however, the intrinsic fluorescence of the molecules was 
problematic and quenching effects could not be ruled out.110 Chemical shift perturbation 
analysis with 15N-labelled PfMTIPΔ60 (Douse, Thomas et al., unpublished results) 
suggested that the molecules did not interact significantly with the intended protein target. 
This is not altogether surprising; the interactions of the three mimicked residues are 
undoubtedly important determinants of binding but more complex mimicry of more than one 
                                                     
*
 Crossing the merozoite plasma membrane by MTIP-myoA inhibitors is necessary to reach the 
putative site of action. 
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helical face is likely required to enable effective competition of the molecule with the myoA 
tail peptide in the buried binding pocket. This point is further discussed in chapters 3 and 5. 
 
 
Figure 1.12 Boger-type α-helix mimetic designed by Thomas to mimic important PfmyoA tail side-chains Arg806, 
His810 and Lys813.
110
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2 Thesis objectives 
The primary aim of this thesis is to further explore and refine the molecular features and 
dynamics of the interaction of Plasmodium falciparum myosin A (myoA) with its light chain, 
myoA tail domain interacting protein (MTIP) in solution. As described in chapter 1, this 
protein-protein interaction is thought to be of significant pathological relevance; myoA is a 
motor protein annotated to have roles in providing motive force and directionality for several 
crucial motility processes in the human malaria parasite and its intracellular localisation 
depends on complex formation with MTIP. The MTIP-myoA complex and the homologous 
system in related Toxoplasma gondii have been the subject of a number of biological studies 
illustrating their central role in the so-called ‘glideosome’ of apicomplexan parasites. 
Furthermore MTIP-myoA has been structurally characterised with X-ray crystallography and 
some of its determinants analysed using yeast two-hybrid and fluorescence-based 
measurements.  
This thesis seeks initially to extend this knowledge by examining for the first time the 
solution-state structure, thermodynamics, dynamics and unfolding of MTIP in the absence 
and presence of peptides derived from its binding partner, the myoA tail. It was anticipated 
that this understanding could then be employed to (i) uncover novel aspects of Plasmodium 
biology, (ii) investigate the validity of MTIP-myoA as an antimalarial drug target and (iii) 
inform the development of selective chemical tools that might be used to effectively 
modulate MTIP-myoA in parasites. Different strategies are considered in respect of the latter 
goal. In pursuing such objectives it was expected that more general insights would emerge 
in relation to the challenging and pressing issue of designing effective inhibitors of protein-
protein interactions.  
The following gives a brief description of the content of each of the following four results 
chapters. 
Chapter 3: Structural, dynamic and thermodynamic features of MTIP-myoA 
The crystal structure of MTIP-myoA using components solely from P. falciparum is solved 
and validated as a model of the solution-state complex using NMR spectroscopy, and 
provides a structural basis for previous data on the inhibitory potential of different myoA tail 
peptides. NMR is used to investigate the extensive backbone dynamics of ‘free’ MTIP, for 
which there is no crystal structure, and to map interaction ‘hotspots’ with myoA. Experiments 
are conducted to examine the thermodynamics and unfolding of the system. NMR is also 
used to make preliminary investigations into the solution-state conformations of (i) the myoA 
tail peptide and (ii) the disordered MTIP N-terminal extension. Lastly, the structural basis of 
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the specificity of MTIP for binding the myoA tail over the tail of another Plasmodium myosin 
(myoB) is discussed. 
Chapter 4: Predicting the effects of MTIP phosphorylation 
Several lines of evidence suggest that the glideosome is extensively phosphorylated by a 
number of kinases, with implications for the assembly, localisation and performance of this 
protein-based machinery. However, these events have not been the subject of structural 
investigations. Conserved MTIP residues Ser107 and Ser108, in the myoA binding domain 
of the protein, have been suggested to be phospho-sites in cultured blood stage parasites. 
This chapter seeks to predict the molecular effect of this post-translational modification, via 
phospho-mimetic mutations and comprehensive analysis of associated changes in the 
interaction and dynamics compared to wild-type data. 
Chapter 5: Constrained myoA helices as MTIP-myoA inhibitors 
Synthetic peptides based on helical binding epitopes, such as those derived from the myoA 
tail, do not generally form stable helical structures in isolation, which compromises their use 
as inhibitors of intracellular protein-protein interactions. Various methods have been 
employed to constrain the helical structure in other systems, including hydrocarbon ‘stapling’ 
and capping the helix with a ‘hydrogen bond surrogate’ (HBS). This chapter reports the 
introduction of such constraints, including a novel kind of hydrocarbon staple, into myoA tail 
peptides. Such a strategy has not so far been reported in the targeting of a buried protein-
helix interaction, and the careful design of the constraint position is considered in detail. A 
library of analogues is synthesised and tested for interaction with MTIP, the binding mode 
studied by NMR and three high resolution co-crystal structures are solved to validate the 
design strategy. 
Chapter 6: Fragment-based approaches towards MTIP-myoA inhibitors 
Fragment-based drug discovery has had some notable successes against protein-protein 
interaction targets like MTIP-myoA, where it is deemed essential to find molecules that target 
important interaction hotspots for subsequent, structure-guided elaboration. This chapter 
reports a screen of a 500-member fragment library against MTIP and the challenges 
associated with targeting such a dynamic system. Hit molecules from the screen are 
validated by NMR experiments, and the binding mode of one of the molecules is 
characterised by a crystal structure of a peptide-fragment ‘chimera’ bound to MTIP.  
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Chapter 3 Structural, dynamic and thermodynamic features of the MTIP-
myoA complex 
It is possible to reconstitute the MTIP-myoA complex in vitro using recombinantly-expressed 
MTIP constructs and peptides derived from the myoA tail. X-ray structures of the complex 
have been described using P. knowlesi and P. falciparum MTIPs lacking portions of the 
disordered N-terminal extension (PkMTIPΔ78 and PfMTIPΔ60 respectively) and the peptide 
covering the C-terminal 15 amino acids of P. yoelii myoA. The motions of the MTIP domains 
that contribute to ligand recognition and binding have only been inferred from different 
crystal structures.  
This chapter reports the structural and thermodynamic basis of myoA recognition by MTIP, 
including studies into the folding pathways of the protein in the presence and absence of its 
binding partner. Isothermal Titration Calorimetry (ITC) is used to define the enthalpic and 
entropic contributions to equilibrium binding affinities, which are known from fluorescence 
assays to be in the mid-nM range, and NMR backbone chemical shift assignments for free 
and bound states are used to map interaction ‘hotspots’. Molecular features of the 
P. falciparum complex are validated by per-residue measurements of secondary (chemical 
shift indexing) and tertiary (residual dipolar couplings) structure and extensive studies of 
backbone dynamics using solution NMR spectroscopic techniques. 
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The work described below follows on directly from previous work, in which the crystal 
structure of PfMTIP lacking the N-terminal 60 amino acids (hereafter referred to as 
PfMTIPΔ60) in complex with a peptide spanning the C-terminal 20 amino acids of PfmyoA 
(hereafter referred to as PfmyoA(799-818)) was solved and initial refinement performed. 
Recording of the NMR chemical shifts of correlated backbone nuclei in 13C, 15N- labelled 
PfMTIPΔ60 (13Cα, 13Cβ, 13C’, 1HN, 
15N) complexed with (unlabelled) PfmyoA(799-818) was 
also done, enabling assignment of 135 143 amide resonances in the ‘bound form’ 
1H, 15N-HSQC spectrum of the MTIP construct  (residues Ser61 to Gln204, excluding 
Pro106). These findings were reported in C. H. Douse, MRes thesis.119 The aim of the work 
was to provide a structural basis for the improved apparent affinity of PfmyoA(799-818) 
relative to a shorter peptide PfmyoA(803-818) observed by Thomas et al.110,116 Below, these 
preliminary investigations are extended to provide a thorough understanding of the structure, 
thermodynamics, dynamics and unfolding of the MTIP-myoA complex. 
3.1 The crystal structure of PfMTIPΔ60 in complex with PfmyoA(799-818) 
The 1.94 Å structure of PfMTIP-myoA (solved as reported in C. H. Douse, MRes thesis, 
where Rwork/Rfree were 21.4/25.9%)
119 was further refined in collaboration with Dr Paula 
Salgado using iterative model building in Coot122 and refinement in Phenix;123 the quality of 
the model was improved to final Rwork/Rfree values of 17.7/22.3%. The fold of the final 
structure (pdb code: 4AOM) resembles the ‘compact’ structure of PfMTIPΔ60-
PymyoA(803-817) reported by Bosch et al.56 (figure 3.1); both MTIP domains consist of pairs 
of non-calcium-binding EF-hands that each contribute to the interaction and clamp (via the 
interdomain linker) around the myoA peptide, which adopts an α-helical conformation. The 
sequences of different apicomplexan myoA tails are shown in table 3.1. 
 
Table 3.1 MTIP binding domains of several apicomplexan myoA proteins, extracted from plasmodb.org and 
toxodb.org.
114,124
 Highlighted are PfmyoA(799-818) and PymyoA(803-817), which are the peptides co-crystallised 
with PfMTIPΔ60 resulting in the X-ray structures shown in figure 3.1. * Full-length TgmyoA contains 831 residues 
i.e. it extends beyond residue 820 and its putative light chain binding domain is not at the extreme C-terminus. 
Table reproduced from C. H. Douse, MRes thesis.
119
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The two MTIP constructs overlay very closely with a root mean squared deviation of 0.28 Å 
between 933 atoms (from Val62 to Gln204). There are some subtle variations in side-chain 
conformations; for example, an intra-MTIP ion pair between Lys71 and Asp137, which was 
believed to stabilise the kinked conformation of the interdomain linker, is not observed in the 
latest model. Otherwise, the structure is supportive of the 2007 Bosch structure.56 
 
 
Figure 3.1 Cartoon representations of the X-ray crystallography-derived models of PfMTIPΔ60 in complex with 
PymyoA(803-817) (left) and PfmyoA(799-818) (right). Certain residues/features discussed in the main text are 
annotated. The two MTIP constructs overlay closely with a RMSD of 0.28 Å (N = 933 atoms). 
RMSD = √{
[∑(   )
 ]
 
} and dii is the distance between the ith atom. Reproduced from Douse et al.
115
 
 
 
 
 
The structure containing PfmyoA(799-818) shows that the extension to the N-terminus of the 
myoA tail peptide forms an extra turn of the α-helix; it is not clear whether Pro802 causes a 
kink in full-length myoA, which may direct the tail away from MTIP in a defined manner to 
allow assembly of other motor complex components. The highly-conserved Asn800 makes 
polar, water-mediated interactions with MTIP residues from helix α5 while Ile801 points 
towards a hydrophobic patch created by Trp171 and Gly172 (figure 3.2). These features 
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represent one explanation for improved affinity of the longer peptide. The basic residues 
known to be important for a tight interaction (including Arg806, His810 and Lys813) adopt 
the same orientation in both structures. A hypothetical structure of PfmyoA(803-817) based 
on the structure of the P. yoelii peptide suggested that the two inter-genus differences in this 
region (M805L and R814K) should not cause disruption in the interaction with MTIP56 and 
this is confirmed by the experimental structure presented here. The two termini (Lys799 and 
Gln818) are not conserved in homologous myoA sequences. The side-chain of Lys799 
engages in crystal contacts with Asp73 and Asp76 in a symmetry-related molecule, while no 
electron density is observed for Gln818; this is unsurprising since its inclusion is known to be 
dispensable for a tight interaction.115,119 
 
 
 
Figure 3.2 Interactions between the N-terminal part (blue; cartoon and stick representation) of PfmyoA(799-818) 
(yellow and blue cartoon) and the C-terminal domain of PfMTIPΔ60 (grey cartoon representation with relevant 
interacting sites highlighted in green). Waters involved in polar interactions are shown as magenta spheres. 
PfmyoA residue Asn800 makes water-mediated polar interactions with the side-chain of Lys146 and the 
backbone of Met147 in PfMTIP helix α5, while the side-chain of Ile801 points towards a hydrophobic patch in the 
loop connecting α6 and α7. Reproduced from Douse et al.
115
 
 
3.1.1 Summary of the available structures of MTIP-myoA 
In total, discounting related structures with designed ligands reported in subsequent 
chapters of this thesis, there are five structures of Plasmodium MTIPs published to date (see 
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table 3.2). The first structure reported, solved using crystals grown from a solution at pH 5.3, 
contained three protein molecules per asymmetric unit and showed P. knowlesi MTIP 
adopting an extended conformation with a long central helix connecting the N- and C-
terminal domains. Only one of the subunits was bound to the myoA tail peptide used in the 
co-crystallisation experiment, with the other two ‘unliganded’; these showed deviations 
suggestive of some conformational flexibility in the protein. In the remaining ‘bound’ subunit, 
the helical myoA tail was shown to be interacting solely with the C-terminal domain, 
hydrophobic pockets of which buried myoA residues Leu804, Val807 and Ile811.55 The 
subsequent structure, also published by the Hol group using crystals of a different 
(P. falciparum) MTIP construct at pH 7.5, shows only one complex in the asymmetric unit in 
which both MTIP domains are clamped around the myoA helix and participate in 
intermolecular interactions. The C-terminal domain still accommodates hydrophobic side-
chains of the myoA tail to form a hydrophobic core. However compared with the first 
structure, Asp139 is shifted by 6.7 Å and allows engagement of the N-terminal domain with 
the myoA tail and hydrogen bonding between Ser108 and Asp173 holds a ‘clamp’ in place; 
the two domains are connected by a kinked linker rather than the long central helix 
previously described.56 The structure described here backs up the second structure (see 
above). Since this was published, an identical P. knowlesi construct to that used in the first 
structure was co-crystallised again with the P. yoelii myoA tail peptide but at neutral pH, and 
also was found to be in the compact conformation.125 Thought to be key to the pH 
dependence is the protonation state of the imidazole ring of myoA residue His810; at pH 5.3 
it is mostly charged and cannot made interactions with both myoA Lys813 and MTIP Asp139 
simultaneously. This is thought to destabilise the compact conformation and weaken the 
interaction, resulting in the extended MTIP conformation (and variable occupancy of myoA in 
the binding site) observed at this pH. 
There is therefore a growing consensus in the literature that the clamped conformation best 
describes the Plasmodium MTIP-myoA tail interaction in physiological conditions, and this 
goes some way to explaining the strong interaction (and mutational studies) reported in 
biophysical analyses.57,116 By analysing all the crystal structures reported, it is tempting to 
infer information on the conformational flexibility of MTIP, but there are two limitations on 
doing this: (i) the variable pH at which the structures were solved (see above) and (ii) the 
lack of a crystal structure of the MTIP domains without the presence of the myoA tail. In 
regards to (ii), crystallisation of the free protein has been attempted (see section 3.1.2 and 
reference126) but was unsuccessful. 
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Table 3.2 Available MTIP crystal structures in the Protein Data Bank. CTD = C-terminal domain; NTD= N-
terminal domain; a.u = asymmetric unit. 
 
3.1.2 Attempts to crystallise ‘free’ PfMTIPΔ60 
Twelve 96-well sparse matrix screens for sitting-drop crystallisation* by vapour diffusion were 
set up, in which the drops contained 100 nL reservoir mixed with 100 nL or 200 nL protein 
solution (i.e. two drops per reservoir). This was carried out three times corresponding to 
three different protein concentrations (5 mg/mL, 10 mg/mL and 15 mg/mL PfMTIPΔ60 with 
the N-terminal His tag removed, in a buffer containing 20 mM HEPES pH 7.5, 50 mM NaCl, 
1 mM TCEP) i.e. a total of 6,912 (96 x 2 x 12 x 3) different conditions. The plates were 
inspected regularly up to a limit of one month, but no crystal growth was observed in any 
                                                     
*
 The components of the reservoir solutions for these screens (named ICL1-12 in the Centre for 
Structural Biology X-ray facility) are listed at www.imperial.ac.uk/xraycrystallography/crystn  
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condition. The increased protein concentration increased the fraction of sitting drops in which 
precipitated protein was observed, as expected. It has been reported elsewhere that similar 
attempts to crystallise a number of different constructs of free MTIP have also failed.125,126 
This may be explained in terms of the putative conformational heterogeneity of the free 
protein being unfavourable for crystallography. 
One MTIP structure has been reported without any myoA tail peptide being present in the 
protein solution; this was of a complex of the C-terminal domain (residues 137-204, called 
domain 3 in the paper) of PfMTIP with a nanobody raised against the protein used as a 
‘crystallisation chaperone’.126 In the structure, the nanobody binds adjacent to the myoA 
binding groove of this domain, which adopts a different conformation from those observed in 
myoA-bound forms. 
3.2 NMR spectroscopy of PfmyoA(799-818) binding 
Despite the availability of several atomic resolution crystal structures, several structural 
questions about the MTIP-myoA complex remained unexplored, including: 
 Do the crystal structures accurately reflect the solution-state complex? 
 How does PfMTIPΔ60 recognise its binding partner, and what motions are important 
in this recognition? More generally, what does ‘free MTIP’ look like under 
physiological conditions? 
 What are the key determinants (MTIP ‘hotspots’) of the interaction that may be 
targeted by designed MTIP-myoA inhibitors?  
To address these questions, analysis of the interaction and dynamics of MTIP-myoA in 
solution, via protein NMR spectroscopy methods, was reasoned to be valuable. In order for 
this information to be in per-residue detail, assignment of 1H, 15N-HSQC spectra of the 
protein was an essential starting point.  
 
3.2.1 Complete assignment of 1H, 15N-HSQC spectrum of PfMTIPΔ60 in complex with 
PfmyoA(799-818) 
Triple resonance NMR spectroscopic data on a sample of 13C, 15N-labelled PfMTIPΔ60 in 
complex with PfmyoA(799-818) were recorded and reported previously (C. H. Douse, MRes 
thesis).119 By further analysis of these data and tabulation of correlated 13Cα, 13Cβ, 13C’, 1HN 
and 15N chemical shifts, assignment of 141 of 143 backbone amide resonances* in the 
1H, 15N-HSQC spectrum for this ‘bound’ state of MTIP residues 61-204 were made with high 
                                                     
*
 PfMTIPΔ60 contains 144 residues (Ser61-Gln204) but one proline (Pro106) which is not present in 
1
H, 
15
N-HSQC spectra as it contains no amide hydrogen. 
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confidence, using the MARS program127 (see also section 3.2.2 for details of triple 
resonance data acquisition and analysis). Missing residues were N-terminal Ser61, electron 
density for which is missing in the crystal structure discussed above (it is presumed to be 
highly flexible) and Gly88, which is in a loop connecting MTIP helices α1 and α2 and distant 
from the myoA binding site. The chemical shift assignments were deposited in the 
BioMagResBank (http://www.bmrb.wisc.edu/, accession code 18377). 
3.2.2 Assignment of 1H, 15N-HSQC spectrum of ‘free’ PfMTIPΔ60 
Due to the tight binding of PfmyoA(799-818) and conformational changes upon complex 
formation, many backbone amide resonances in the 1H, 15N-HSQC spectrum (hereafter often 
referred to ‘HSQC’) of PfMTIPΔ60 in complex are in ‘slow exchange’ with the free form. This 
indicates that the difference in NMR frequency between the free and bound states is larger 
than the rate of interconversion between the two states (koff << Δω). As a result, when 
PfmyoA(799-818) is titrated into a solution of 15N-labelled PfMTIPΔ60, the signal disappears 
over the course of the titration, reappearing at the new frequency. For weaker binding 
leading to ‘fast’ (koff  >> Δω) or ‘intermediate’ exchange (koff  ~ Δω), it may be possible to 
track the stepwise change in frequency upon addition of ligand solution, and thus use the 
assignment of the ‘free form’ spectrum to assign the ‘bound form’  spectrum, or vice versa. 
However, this is not possible in the case of MTIP-myoA binding; therefore, the HSQC 
spectrum of ‘free’ PfMTIPΔ60 needed to be assigned separately. 
Sample preparation 
A protocol was previously established (C. H. Douse, MRes thesis)119 to enable production of 
a uniformly 13C, 15N-labelled NMR sample of PfMTIPΔ60 which would be of sufficient purity 
and stability to record triple resonance NMR spectra over the course of several days 
at  303 K. However, those experiments were conducted in the presence of three molar 
equivalents of PfmyoA(799-818) i.e. the protein was in its ‘bound’ form, which was thought to 
stabilise it. To test if the protocol was also appropriate for the ‘free’ form, an unlabelled 
sample (i.e. containing 1H, 12C and 14N nuclei, expressed in unlabelled rich media) was 
purified, concentrated to 300 μM in the same buffer (20 mM MOPS pH 7; 50 mM NaCl; 
1 mM TCEP; 0.005% [w/v] NaN3), and a 
1H spectrum recorded in a standard 5 mm tube 
(figure 3.3, left). The NMR tube was then left to incubate at 303 K for several days. After 32 
hours, there was little difference in the spectrum (data not shown); however, after 96 hours 
the 1H spectrum had significantly changed (figure 3.3, right).  
 58 
 
 
 
Figure 3.3 600 MHz 
1
H NMR spectra of 300 μM unlabelled PfMTIPΔ60 in 20 mM MOPS pH 7.0; 50 mM NaCl, 
1 mM TCEP and 0.005% NaN3 at 303 K, before (left) and after (right) incubation at 303 K in a standard 5 mm 
NMR tube. Insets are the same spectra, zoomed in on the region between 0-0.8 ppm (corresponding to methyl 
protons from protein side-chains); asterisks denote examples of peaks which have changed in intensity or line 
shape. 
 
 
 
Changes in the line shapes and position of signals, including those with chemical shifts 
between 0 and 0.8 ppm (characteristic of ring current shifted methyl protons, and thus of 
folded proteins), were observed; peaks in this region were broadened and had dropped in 
intensity (figure 3.3, insets). This, taken together with the observation of a small amount of 
precipitate in the NMR tube, suggested that the protein had at least partially oligomerised 
and that some aggregation had taken place. Soluble oligomers may be detectable in the 1H 
NMR spectrum but would exhibit broader signals due to their increased molecular weight 
and thus slower molecular tumbling, leading to faster relaxation of the signal; insoluble 
aggregates would be ‘invisible’ in conventional solution NMR experiments. The spectrum 
observed in figure 3.3 (right) thus likely represented an inhomogeneous mixture of MTIP 
species with different molecular weights. Although the majority of molecules may have been 
monomers of PfMTIPΔ60, this inhomogeneity was inappropriate for multidimensional NMR 
experiments, analysis of which depends on good resolution of signals.  
The oligomerisation of PfMTIPΔ60 had been observed previously and attributed to the 
oxidation of one or more of the three exposed cysteines in the construct to form 
intermolecular disulfide bonds. In this case, although 1 mM TCEP was present as a reducing 
agent in the buffer, it may have failed to maintain a reducing environment due to aereal 
oxidation. It is also possible that a higher concentration is needed to preserve the sample of 
free PfMTIPΔ60. The experiment was thus repeated with a new sample from the same 
protein purification, using slightly different conditions. The buffer was made fresh with 2 mM 
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TCEP, and the standard 5 mm NMR tube was exchanged for a Shigemi tube, designed to 
effectively exclude atmospheric oxygen from the protein sample. With these modifications, 
the protein sample was stable for several weeks during which time the spectra remained 
unchanged. Therefore, a sample of ~400 µM 13C, 15N-labelled protein was prepared in the 
same way and used for triple resonance experiments. 
Triple resonance NMR experiments 
The strategy for NMR assignment of the backbone amides of ‘free’ PfMTIPΔ60 was identical 
to that for the protein in complex with PfmyoA(799-818). A reference HSQC spectrum was 
recorded; this shows the correlations between amide 1HN nuclei and attached 
15N nuclei in 
the protein. This H-N ‘root’ was further correlated with different 13C nuclei in the protein 
backbone using different triple resonance experiments (namely the HNCACB, 
CBCA(CO)NH, HNCO and HN(CA)CO experiments;128 see figure 3.4 and table 3.3). The 
experiments are named according to the pathway of the magnetisation between nuclei 
(those whose frequencies are not recorded are in brackets). The resulting 3D spectra can all 
be thought of as the 2D reference HSQC extended into a third (13C) dimension, yielding 
different chemical shift information in this dimension (see table 3.3).  
 
 
Figure 3.4 Schematic diagram of part of the polypeptide backbone of a 
13
C, 
15
N-labelled protein. The scalar (J-) 
couplings exploited for magnetisation transfer in the triple resonance experiments (see Table 3.3) are shown in 
italics alongside the relevant bonds, and the nuclei are labelled as they are referred to in the text. Adapted from 
Sattler et al.
128
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Table 3.3 Summary of the NMR experiments used for the backbone assignment of 
13
C, 
15
N-labelled PfMTIPΔ60.  
 
The experiments – explained briefly in the following sections – were set up under the 
supervision of Dr Pete Simpson, facility manager of the cross-faculty NMR centre at Imperial 
College. 
HNCACB 
The HNCACB experiment correlates the backbone H-N root with aliphatic carbon nuclei (Cα 
and Cβ) of residues i and i-1, allowing up to four cross-peaks to be observed for each amino 
acid in the chain (see figure 3.5). Since the scalar coupling constants between the 15N 
nucleus of residue i and the 13Cα nuclei of both residue i (1JCα,N) and residue i-1 (2JCα,N) are 
of comparable magnitude (typically ~11 Hz and ~7 Hz respectively; see figure 3.4), transfer 
of magnetisation between these nuclei via the INEPT step occurs in both ‘directions’. 
Magnetisation is then transferred to the attached 13Cβ nucleus and the chemical shifts of Cα 
and Cβ are evolved simultaneously (avoiding the need for more than one carbon 
dimension); the way in which this transfer is achieved causes the alpha and beta carbon 
signals to have opposite signs. Owing to the relative scalar coupling constants and tuning of 
the INEPT delay to the 1JCα,N coupling, the cross-peaks arising from residue i-1 are usually 
less intense than those from residue i (see figure 3.5).  
CBCA(CO)NH 
The CBCA(CO)NH experiment correlates the backbone H-N root with aliphatic carbon nuclei 
(Cα and Cβ) of residue i-1 only. Two cross-peaks should be observed for each amino acid in 
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the chain (see figure 3.5) which should match two of the cross-peaks in the HNCACB 
spectrum. Magnetisation starts on 1Hα and 1Hβ and is transferred to the attached carbons 
and the chemical shifts evolved. After this evolution period it is refocused and transferred to 
13C’ (chemical shift is not evolved) and then to the 15N nucleus of the next amino acid. 
 
 
Figure 3.5 2D planes (or ‘strips’) of the four processed 3D spectra resulting from the four triple resonance 
experiments explained in the text, at the same position (δ 
1
H = 8.3 ppm; δ 
15
N = 126 ppm) in the reference 
1
H, 
15
N-HSQC spectrum (i.e. correlated with a peak in that spectrum, which is associated with a particular amino acid 
‘i’ in PfMTIPΔ60). The nuclei are marked in relation to this residue i. In the HNCACB and HN(CA)CO strips, the 
intensity of the cross-peaks resulting from correlations with residue i-1 are lower than from those with residue i; 
this is explained in the text. Positive contours are coloured in black and negative contours in red; in the HNCACB 
strip, this allows identification of Cα and Cβ resonances respectively.  
 
HNCO 
The HNCO experiment correlates the backbone H-N root with carbonyl carbon nucleus (C’) 
of residue i-1, such that one cross-peak should be observed for each amino acid (see figure 
3.5). The magnetisation is transferred ‘out and back’ from amide hydrogen to directly-bound 
nitrogen to the directly-bound i-1 carbon via two INEPT steps with delays set according to 
the one-bond coupling constants (1JH,N ~92 Hz and 1JN,C’ ~15 Hz). 
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HN(CA)CO 
The HN(CA)CO experiment correlates the backbone H-N root with carbonyl carbon nucleus 
(C’) of residues i and i-1, such that two cross-peaks should be observed for each amino acid 
(see figure 3.5). Magnetisation is transferred from the amide to the 13Cα of residue i and i-1 
(just like in the HNCACB experiment), but chemical shift is not evolved on these nuclei. Via 
1JCα,C’ magnetisation is transferred to adjacent 
13C’ nuclei, whose chemical shifts are 
recorded. It is an ‘out and back’ experiment i.e. the magnetisation is transferred back to the 
amide hydrogen for detection by the same paths. The peak for the cross-peak correlated 
with the 13C’ nucleus of residue i-1 is generally less intense than that for residue i (see figure 
3.5).  
Analysis of triple resonance experiments and assignment using MARS 
The chemical shifts of the backbone carbon nuclei are sensitive to amino acid type, with 
some particularly obvious examples which can aid assignment. Glycines do not contain a Cβ 
and exhibit Cα chemical shifts of ~45 ppm, which is different to all other amino acids. Serine 
and threonine residues contain γ-hydroxyl functional groups which cause unusually high Cβ 
chemical shifts (60-70 ppm), while the Cβ chemical shift of alanine is distinctively found at 
around 18-20 ppm (e.g. residue i in figure 3.5 is an alanine). 
For any given nucleus the chemical shift should be observed in three separate spectra. For 
example, the Cα and Cβ chemical shifts of residue i should be observed in the 13C 
dimension of (1) the HNCACB spectrum at the 1H and 15N coordinates defined by the H-Ni 
root; (2) the HNCACB spectrum at the 1H and 15N coordinates defined by the H-Ni+1 root and 
(3) the CBCA(CO)NH spectrum at the 1H and 15N coordinates defined by the H-Ni+1 root. 
Similarly the C’ chemical shift of residue i should be observed in the 13C dimension of (1) the 
HN(CA)CO spectrum at the 1H and 15N coordinates defined by the H-Ni root; (2) the 
HN(CA)CO spectrum at the 1H and 15N coordinates defined by the H-Ni+1 root and (3) the 
HNCO spectrum at the 1H and 15N coordinates defined by the H-Ni+1. This permits the 
sequential assignment of the resonances in the HSQC spectrum to individual residues in the 
protein, provided there is a sufficient signal to noise ratio in the relevant triple resonance 
spectra and no ambiguities arising from signal overlap. 
Spectra were processed in NMRPipe129 and viewed as 2D planes in a locally modified 
version of NMRView.130,131 Peaks of the reference HSQC were picked automatically to define 
all the available backbone H-N roots and obvious errors manually corrected (for example, 
where peaks of low intensity were missed by NMRView or where the peaks were due to 
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side-chains of glutamine or asparagine residues).* A module scripted by Dr Jan Marchant 
was used to navigate strips of the 3D spectra and to record the carbon chemical shifts 
arising from each H-N root in the reference 2D HSQC spectrum. A database of chemical 
shifts was thus established. 
This list of chemical shifts and the amino acid sequence of PfMTIPΔ60 were input into 
MARS, a program for automated backbone assignment.127 The program outputs a list of 
residues with the assignment (i.e. HSQC peak number) and a measure of confidence in the 
assignment (high/medium/low). Where there were gaps in the assignment the raw data were 
manually analysed to determine the cause of the ambiguities (for example, where there was 
close resonance overlap in the HSQC spectrum). This process was reiterated until all 
assignments were made with a ‘high’ confidence level and had been verified manually. 
Finally, 137 out of 143 backbone amide resonances were assigned with high confidence. 
The chemical shift assignments were deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu/, accession code 18376). The missing residues were: Gly87, 
Ser108, Asn153, Asn154, Ser189 and Gln200. Possible reasons for these missing 
assignments, given the data acquired, are: (i) rapid exchange of the amide hydrogen with 
the solvent (H2O), which is more likely in exposed loops in a protein
†; (ii) conformational 
exchange on ms-µs timescales that causes rapid transverse relaxation and thus failure to 
detect the peak either in the HSQC itself or the 3D spectra; (iii) excessive peak overlap 
causing ambiguity in the assignment. Excessive peak overlap was not apparent, and further 
analysis of the structure and dynamics of free PfMTIPΔ60 was required to hypothesise on 
the reasons for the missing assignments on a case-by-case basis. 
Annotated 1H, 15N- HSQC spectrum of ‘free’ PfMTIPΔ60 
The backbone assignment of free PfMTIPΔ60 (and that of the complex with 
PfmyoA(799-818)) required the production of 13C, 15N-labelled protein, since the strategy 
relied on observing correlations of the amide H-N roots with backbone carbon nuclei, which 
must be uniformly 13C-labelled i.e. NMR active. While 15N-labelling of recombinant proteins is 
relatively cheap (requiring only 0.7 g 15NH4Cl per litre of E. coli culture in minimal media, 
equivalent to <£20 of label), 13C sources (labelled glucose or glycerol) are much more 
expensive (e.g. E. coli require at least 2 g of glucose per litre of minimal media, equivalent to 
                                                     
*
 These are present in HSQC spectra as doublets at identical 
15
N frequency but different 
1
H 
frequencies due to the non-equivalent hydrogens in the side-chain amide functionality of Gln and Asn. 
†
 Solvent exchange is also dependent on pH; the experiments reported here were all performed at 
neutral pH to allow comparison with the X-ray structures and other biophysical assays. It may have 
been possible to detect and assign more peaks at a lower pH (at which the rate of solvent exchange 
is lower) but given the sequence coverage achieved at pH 7.0, this was not deemed worthwhile. 
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>£100 of label). The assignment also required a high (~400 µM) protein concentration in the 
NMR sample; the sensitivity of the triple resonance experiments (especially the HNCACB 
experiment) is much lower than a 2D HSQC experiment due to the complex magnetisation 
transfers involved, and acquisition time of such experiments is already on the order of days.  
However, once the assignment of the peaks has been made (see figure 3.6), 13C-labelling is 
no longer required for experiments using the standard 1H, 15N-HSQC spectrum as a read-out 
(e.g. measurement of protein dynamics, or ligand binding events).  
 
Figure 3.6 Assigned solution 
1
H, 
15
N-HSQC of ~400 µM ‘free’ PfMTIPΔ60 at 303 K and neutral pH. The 
symmetric doublets in the top-right corner of the spectrum belong to side-chain amides of glutamine and 
asparagine residues, while the unlabelled peak in the bottom-left corner is diagnostic of the side-chain N-H of the 
sole tryptophan (Trp171) in the construct. 
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Furthermore, 2D spectra with good signal to noise ratios may be acquired quickly (~5-10 
minutes, or even less if using specialised pulse sequences such as the SOFAST-HMQC 
experiment) with much lower (30-100 µM) protein concentrations. Since the expression of 
15N-labelled PfMTIPΔ60 is reasonable (5-10 mg of purified protein per litre of 15N-labelled 
minimal media), the cost of protein production is not a limiting factor in the use of HSQCs for 
such measurements. 
3.2.3 Using NMR to explore structural features of the MTIP-myoA interaction 
Chemical shift perturbations upon binding of PfmyoA(799-818) 
With near-complete assignments of both the ‘free’ and ‘myoA-bound’ HSQC spectra of 
PfMTIPΔ60, it was possible to analyse the chemical shift perturbations associated with 
binding to PfmyoA(799-818) in solution. The spectra were overlaid and the raw chemical 
shift changes for each nucleus (1H and 15N) weighted* on a per-residue basis (see figure 
3.7), then mapped onto the crystal structure of PfMTIPΔ60-PfmyoA(799-818) using a white-
red colour ramp in PyMOL (figure 3.8). This allowed the identification of ‘hotspot’ residues on 
the protein.  
The C-terminal domain of PfMTIPΔ60 show the greater perturbations upon binding and 
hotspots are found throughout the myoA tail binding groove, as well as regions more distant 
from the sites of direct interactions, presumably due to conformational changes associated 
with binding to the ligand. The C-terminal domain was hypothesised to be less well ordered 
than the N-terminal domain by observation of 1H spectra of each separate domain (with no 
myoA peptide present), which showed that the most well-dispersed amide peaks come from 
the N-terminal domain.116 This was supported by assignment of the HSQC spectrum for the 
free protein; resonances from the C-terminal domain are mainly localised in the congested 
region in the centre of the spectrum indicating a lack of well-defined tertiary structure in the 
absence of the myoA tail. Particularly affected by complexation were residues in the loop 
connecting helices α6 and α7 (Thr170-Thr176), which are not only involved in interactions 
with myoA side-chains (Ile801, Gln808 and Arg812) but also engaged in intra-MTIP 
interactions (e.g. the hydrogen bonding between Asp173 and Ser108, which holds the clamp 
around the myoA tail in place). In the N-terminal domain, which sits on top of the peptide 
groove created by the C-terminal domain, the main shifts are also surrounding residues that 
form the MTIP clamp (e.g. Ser107, adjacent to the clamping residue Ser108 and which also 
interacts via solvent with the side-chain of myoA Arg806). 
                                                     
*
 The range of the 
15
N chemical shifts changes was divided by that of the 
1
H chemical shift changes to 
give a weighting value of 7.5, and the overall backbone amide chemical shift perturbation was then 
calculated by: Δδoverall = (7.5 x Δδ
1
H) + Δδ
15
N 
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Figure 3.7 Analysis of chemical shift perturbations upon binding of PfmyoA(799-818) to PfMTIPΔ60. Top left: 
solution 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 in the absence (grey) and presence (red) of three 
molar equivalents of PfmyoA(799-818) at 303 K and neutral pH. Top right: distribution of 
1
H and 
15
N chemical 
shift perturbations; each purple circle represents one assigned backbone amide resonance. Bottom: weighted 
chemical shift perturbations plotted against PfMTIPΔ60 residue number. 
 
It was interesting to observe that Ser108, the hydrogen bond acceptor in the ‘clamping’ 
interaction with Asp173, was one of the residues that could not be identified in the HSQC 
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spectrum of the free protein, suggestive of an exchange process leading to broadening of 
the peak beyond detection. The peak for Ser108 in the ‘bound’ form spectrum is clearly 
visible and assigned in the dispersed region. It could be that Ser108 in the free protein 
exchanges its amide hydrogen rapidly with solvent, or that there is a conformational 
exchange broadening effect associated with transient adoption of this clamped conformation 
in the free state. Further investigation of this result was required. The motion of the two 
domains to clamp around myoA tail is thought to occur about a flexible linker between the 
domains, corresponding to residues Val135-Asn140. The chemical shifts of residues in this 
linker were also observed to be affected significantly by the interaction, for example that of 
Asp139, a residue which makes electrostatic interactions with PfmyoA residues Arg806 and 
His810. 
Another clear binding hotspot in the C-terminal domain of MTIP centres on Met147, which 
engages in a water-mediated polar interaction with Asn800 in the N-terminal portion of 
PfmyoA(799-818) according to the crystal structure of the complex (see figure 3.2). The 
contribution to binding of this N-terminal extension to the peptide was of interest, since 
PfmyoA(799-818) was found to be a more potent inhibitor of the MTIP-myoA complex than 
the shorter PfmyoA(803-818) by an order of magnitude.116 
 
Figure 3.8 Hotspots of the PfMTIPΔ60-PfmyoA(799-818) interaction as inferred from chemical shift perturbations 
in solution. Normalised, weighted perturbations were used to colour the surface of PfMTIPΔ60 (from the crystal 
structure of the same complex) as a white-red ramp in PyMOL. PfmyoA(799-818) is shown as a black cartoon 
with side-chains indicated (right). MTIP residues or features mentioned in the text are annotated. Reproduced 
from Douse et al.
115
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Comparison of PfmyoA(799-818) and PfmyoA(803-818) binding 
The structural basis for the improved affinity of PfmyoA(799-818) over PfmyoA(803-818) 
appears to lie in additional contacts of residues Asn800 and Ile801 with MTIP residues; 
these are evident in the crystal structure and as MTIP hotspots of chemical shift perturbation 
upon complexation with PfmyoA(799-818). This was further investigated with NMR 
spectroscopy; HSQC and HNCACB spectra were recorded on a complex of 300 µM 
13C, 15N-labelled PfMTIPΔ60 saturated with PfmyoA(803-818)*. The HSQC spectrum, which 
was substantially different to that of the PfmyoA(799-818) complex, was partially re-assigned 
by comparing the chemical shifts of the Cα and Cβ nuclei to those assigned to the complex 
with the longer peptide, assuming that the overall fold of the protein in each complex is 
essentially the same (as is apparent from the crystal structures shown in figure 3.1). Using 
this method, it was not possible to assign peaks from helix α5 (Val141-Phe151), indicating 
that the dynamics and/or chemical environment of this region are substantially different in 
the two complexes, presumably due to the additional interactions observed in the structure. 
 
Figure 3.9 Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 in complex with PfmyoA(799-818) (red) 
and PfmyoA(803-818) (blue) show substantial differences in backbone amide chemical environments. The helix 
α5, encompassing residues Val141-Phe151, is a site of interaction with the N-terminal portion of the longer 
peptide. This region could not be re-assigned via analysis of HNCACB spectra of each complex; the residues are 
annotated according to assignments described in section 3.2.1. Spectra were recorded at 303 K and pH 7.0. 
                                                     
*
 A titration was performed whereby aliquots of the peptide dissolved in the protein NMR buffer were 
added and HSQC spectra recorded at each interval, until there were no further changes in the 
spectrum upon addition of more peptide i.e. the binding was deemed to be saturated. 
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Chemical shift indexing 
It has been observed that the chemical shifts of 1Hα, 13Cα and 13C’ nuclei in a protein are 
affected by secondary structure; there tends to be a shift to lower chemical shift when the 
residue is part of an α-helix and to higher chemical shift when the residue is part of a β-
strand, relative to average random coil values (table 3.4). This correlation was used by 
Wishart and Sykes to construct a 13C chemical shift index (CSI), which can be used to 
predict secondary structural elements using information obtained in the backbone 
assignment (i.e. without any NOE data).132 The method briefly works as follows: 
(i) If the chemical shift of the given nucleus is greater than the random coil value 
(+0.7 ppm for Cα; +0.5 ppm for C’), the residue is assigned +1 
(ii) If the chemical shift of the given nucleus is less than the random coil value 
(-0.7  ppm for Cα; -0.5 ppm for C’ ), the residue is assigned -1 
(iii) If the chemical shift falls within the random coil range, the residue is assigned 0 
(iv) An α-helix is predicted when a ‘dense grouping’ of four or more ‘-1’ Cα C’ are 
found sequentially 
(v) A β-strand is predicted when a ‘dense grouping’ of three or more ‘+1’ Cα C’ are 
found sequentially 
(vi) All other regions are designated as random coil 
 
Table 3.4 Standard chemical shifts of 
13
Cα and 
13
C’ nuclei (± 0.7 ppm and ± 0.5 ppm respectively) for different 
amino acids used in the 
13
C Chemical Shift Indexing method. For proline, the ranges for both nuclei are 
± 4.0 ppm. Values taken from Wishart and Sykes.
132
 
 
The Cα and C’ chemical shifts tabulated during the assignments of the ‘free’ and ‘bound’ 
states of PfMTIPΔ60 were used to predict the secondary structure of the protein in solution 
using the CSI module in NMRView (figure 3.10). For the protein in complex with 
PfmyoA(799-818), all of the secondary structural elements observed in the crystal structure 
are also predicted in solution, with the exception of the N-terminal helix α0 (spanning 
residues Ile65 to Lys71). This helix is not thought to contribute to myoA binding and exhibits 
high B-factors in the crystal structure, indicative of flexibility; further investigation into the 
dynamics of this helix was required. 
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The CSI result for the free protein predicts a high proportion of α-helicity as observed by 
circular dichroism spectroscopy.57,110 Interestingly, it also maps closely to that observed for 
the bound form (and, by extension, in the crystal structure of the 
PfMTIPΔ60-PfmyoA(799-818) complex). This may indicate that complex formation with the 
myoA tail involves the reorientation of existing α-helices rather than formation of new ones. 
The result is in disagreement with the conclusions of Bosch and co-workers who presented a 
model of myoA binding in which the long central helix of MTIP in the unbound form 
(observed in the crystal structure of PkMTIPΔ78 at pH 5.3) melts,56 allowing the globular 
domains to wrap around the myoA tail in the compact conformation, since the CSI predicts 
the interdomain linker to be a random coil in both states. 
 
Figure 3.10 Chemical Shift Indexing of PfMTIPΔ60 in the absence (‘free’) and presence (‘bound’) of 
PfmyoA(799-818). The amino acid sequence of residues 61-204 is indicated; the position of the interdomain 
linker spanning Val135-Asn140 is also marked. The protein in each case was expressed from the pQE30 vector, 
which encodes a His6 tag at the N-terminus of the protein. Assigned/unassigned backbone amides are shown 
with red letters and black letters respectively. The ‘lollipops’ for Cα (CA) and C’ (C) nuclei have filled circles 
where there is a chemical shift assignment of this nucleus and are coloured red (-1, predicting helix), blue (+1, 
predicting strand) or grey (0, predicting coil).  
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Residual Dipolar Couplings 
Dipolar (through-space, D-) couplings between two nuclear spins in a protein can provide 
structural information according to equation 3.1. 
      
     
      
  [      
  ]   (3.1) 
 in which:  
Di,s is the dipolar coupling constant between two nuclear spins i and s 
γx is the gyromagnetic ratio of nucleus x 
ri,s is the internuclear separation 
θ is the angle between the inter-spin vector and the external magnetic field 
 
When a molecule is tumbling rapidly in solution (as in a ‘normal’ solution-state NMR 
experiment), dipolar couplings are averaged to zero since many conformations (θ) are 
rapidly sampled. However, if the molecule is partially aligned (e.g. in a liquid crystalline 
phase) then they may be incompletely averaged and therefore observable. 
In a standard HSQC spectrum of a protein in solution, the 15N-1H scalar (through-bond, J-) 
coupling, which has a magnitude of ~92 Hz* (figure 3.4), is not observed since the 15N is 
decoupled during 1H acquisition such that one cross-peak is observed for each H-N 
correlation. However, the J-coupling constant can be measured by using an In-Phase Anti-
Phase (IPAP) version of the experiment. 
 
Figure 3.11 N-H RDC measurements. Left: a portion of the assigned HSQC spectrum of 
15
N-labelled PfMTIPΔ60 
in complex with PfmyoA(799-818), where each peak corresponds to an individual backbone amide moiety. 
Centre: the splitting of each peak by the 
15
N-
1
H J-coupling is observed using an IPAP version of the HSQC 
experiment in isotropic solution. Right: the same IPAP experiment recorded on a partially aligned sample shows 
the splitting caused by the J-coupling and incompletely-averaged ‘residual’ dipolar couplings (RDCs). Values 
given are in Hz. The RDCs for the residues shown in this example are therefore: -14.4 Hz (G157); -4.0 Hz 
(T156); +23.5 Hz (S108) and -8.3 Hz (S96).  
                                                     
*
 The sign of the J-coupling is negative, since γ15N is negative. 
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If this experiment is recorded both in isotropic solution and in a partially aligned state (where 
the D-coupling is incompletely averaged), and the HSQC is assigned, then one can measure 
a per-residue N-H ‘residual dipolar coupling’ (RDC) by subtracting the frequency splitting 
observed in the former from that observed in the latter (figure 3.11). Since the internuclear 
separation in the N-H bond remains essentially invariant, the value of the RDC depends on 
the angle θ which is in turn related to the tertiary structure of the protein.  
With the X-ray structure of the PfMTIPΔ60-PfmyoA(799-818) in hand, it was possible to 
compare calculated RDCs with those determined experimentally for the same complex in 
solution, and therefore validate the crystal structure as a reasonable model of the solution-
state. Partial alignment of the 13C, 15N-labelled sample of PfMTIPΔ60 in complex with 
PfmyoA(799-818) was achieved using a filamentous bacteriophage Pf1 co-solvent. In total, 
88 N-H RDCs were measured for the complex, using an NMRView module scripted by Dr 
Jan Marchant.133 An analogous set of triple resonance data were acquired to measure Cα-C’ 
RDCs, using an IPAP version of the HNCO experiment (i.e. without 13C decoupling during 
evolution of the 13C’ chemical shift). This permitted measurement of 114 Cα-C’ RDCs. 
The experimental N-H and Cα-C’ RDCs were input along with the coordinates of the 
complex crystal structure (pdb code 4AOM, with hydrogen atoms modelled*) into the 
program MODULE134 to calculate the molecular alignment tensor. This enabled the 
correlation of calculated and experimental RDCs to be plotted (see figure 3.12). The ‘quality 
factor’ Q is a quantification of this correlation, as described by equation 3.2. Its value is 
between 0-1 with a lower value indicating better agreement.135 
 
   √
∑(           ) 
∑(     ) 
   (3.2) 
 
Using all 202 experimental RDCs, Q was calculated to be 0.43 for the PfMTIP-myoA 
structure, which compares poorly with the value (Q = 0.23) for a ubiquitin crystal structure of 
similar resolution (1.8 Å; pdb code 1UBQ)136 and with values for high resolution crystal 
structures of hen egg-white lysozyme.137 However, it is in line with values for lower resolution 
structures of the latter protein, and compares favourably to both data on arginine kinase 
crystal structures138 and with NMR structures calculated at the Centre for Structural Biology 
                                                     
*
 Hydrogens were modelled using the ‘Reduce’ program in Phenix. The crystal structure was not of 
sufficiently high (<1.0 Å) resolution to observe electron density for the hydrogens; however, back-
calculation of N-H RDCs clearly requires their inclusion. 
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at Imperial College (Dr Jan Marchant, personal communication). Further, the value obtained 
may be considered in light of several factors: 
(1) The proteins giving rise to crystal structures that exhibit much lower Q-values are usually 
used as model systems for NMR experiments, since they display favourable properties 
(e.g. very well-resolved NMR spectra) resulting from their well-defined and simple 
domain structures. 
(2) The Cα-C’ RDCs are associated with a relatively large error; due to the lower product of 
the gyromagnetic ratios and greater internuclear separation they are intrinsically 5-fold 
smaller than N-H RDCs (clustered in the middle of the plot shown in figure 3.12), but with 
a comparable uncertainty in the measurement. 
(3) The hydrogens in the input structure are modelled without any experimental data. 
(4) Regions of the protein which are flexible in solution may be outliers which artificially 
increase the Q-factor even if the structure is accurate for the majority of the protein.  
 
Figure 3.12 RDC analysis for PfMTIPΔ60 in complex with PfmyoA(799-818) performed in MODULE. Left: 
Cartesian vector components of the best-fit alignment tensor; PfMTIPΔ60 is shown as a yellow cartoon (without 
PfmyoA(799-818)). Right: a plot of all experimental N-H and Cα-C’ RDCs against those calculated based on the 
X-ray structure of the same complex.  
 
 
Table 3.5 Q-factor validation of the X-ray structure of PfMTIPΔ60-PfmyoA(799-818). 
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There are two major outliers observed in the RDC analysis: Ala63 and Glu143 (see figure 
3.12). The former residue is part of a highly flexible N-terminus according to both 
crystallographic B-factors and NMR relaxation data (see below); therefore it is reasonable 
that the static coordinates associated with this residue may not be corroborated by the 
solution-state structure. Removal of this single data point causes the Q-factor to drop from 
0.43 to 0.37 (see Table 3.5). Glu143 is found in helix α5 of PfMTIPΔ60, which is the region 
of the protein that interacts with the N-terminal part of PfmyoA(799-818) (see figure 3.2). The 
interactions in the crystal structure may be influenced by crystal contacts between the side-
chain of Lys799 and a symmetry-related molecule of PfMTIPΔ60, such that the positions of 
atoms in helix α5 (along with the flexible N-terminal residues) may be considered most likely 
to show discrepancies between solution and the crystal structure. If the data for this helix are 
removed from the analysis, the Q-factor drops further, to 0.32. The RDC analysis thus 
validates the atomic coordinates of the crystal structure, with the caveat that they may not 
completely capture the interactions and/or dynamics of localised regions of the protein.  
Conclusions from section 3.2.3 
The mapping of the NMR-based hotspots of the MTIP-myoA interaction in solution and at 
neutral pH adds complementary information to the interactions evident in the crystal 
structure of the complex (and existing yeast two-hybrid data, see chapter 1), and the detailed 
investigation of the dynamics of the protein-peptide interaction in the sections below gives a 
more complete description of myoA recognition by MTIP. It appears from chemical shift 
perturbation analysis that the binding groove formed by the C-terminal MTIP domain is 
critical in myoA tail recognition, with the N-terminal domain able to close around it via the key 
intramolecular clamp between residues Ser108 and Asp173. 
These insights from this section will be important in the following chapters of this thesis, 
since they will provide the basis for investigation of possible modes of modulating the 
complex, both in a biological context via post-translational modification (Chapter 4) and in 
terms of inhibitor design (Chapters 5 and 6). The latter point was evident here, as NMR 
spectroscopy, coupled with crystallography, was able to provide a structural basis for the 
enhanced affinity of a myoA tail peptide PfmyoA(799-818) that was demonstrated in 
previous studies. 
Interestingly, NMR chemical shift indexing suggests that the secondary structural elements 
of MTIP in complex with the myoA tail also appear to be present in its absence. These 
results strongly suggest that complex formation involves reorientation and clustering of 
existing α-helices rather than the formation of new ones. The N-terminus of the protein 
appears to be highly flexible and unimportant to both the interaction with myoA and the 
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tertiary structure of the remainder of the protein, and the coordinates and secondary 
structure of helix α0 (spanning residues Ile65-Lys71) in X-ray structures may not reflect the 
situation in solution. Nonetheless, the evidence from CSI and residual dipolar coupling 
analysis suggest that the overall ‘compact’, clamped conformation of PfMTIPΔ60 in complex 
with the myoA tail, and the secondary structural elements thereof, are reasonable 
descriptions of the solution-state structure at neutral pH. 
3.2.4 Using NMR to explore the dynamics of MTIP-myoA recognition 
Since Kay and co-workers described two dimensional pulse sequences for the study the 
backbone dynamics of staphylococcal nuclease in their seminal 1989 publication,139 NMR 
spectroscopy has emerged as the leading experimental technique to study the motions of 
proteins in solution. These motions occur on a variety of timescales and can be monitored in 
atomic detail by studying the relaxation properties of individual nuclear spins, provided 
assignments are available and spectra sufficiently well-resolved. In general, it is convenient 
to study the 15N nuclei in the protein backbone because assignments of backbone amides in 
the 1H, 15N-HSQC spectrum are easiest to obtain and tend to be well-dispersed for folded 
proteins. Since 15N spin-lattice relaxation times (T1s) are sensitive to high frequency motions 
of the N-H moiety (108 - 1012 Hz) and spin-spin relaxation times (T2s) to both these motions 
and lower frequency motions, it is possible to probe a broad window of timescales. 
[1H]-15N heteronuclear nuclear Overhauser enhancements (NOEs), which are also affected 
by high frequency motions, can also be measured easily and are much more sensitive than 
T1 and T2.  
Relaxation and molecular motion 
Relaxation is the process by which nuclear spins, perturbed from their equilibrium 
distribution during the NMR experiment, return to that equilibrium. Physically, it involves 
transitions between energy states of the nuclear spins of interest, induced by local 
fluctuating fields experienced by the nuclei that correspond to the frequency of the transition, 
as the molecule tumbles in solution. The distribution of these fields is described by the 
‘spectral density function’ J(ω), which is effectively the probability of finding motion in the 
system at any given angular frequency. 
For backbone 15N nuclei in a protein, the source of these fields (i.e. the ‘relaxation 
mechanism’) is chiefly the dipolar interaction with directly-bound hydrogen nuclei and, to a 
lesser extent, chemical shift anisotropy. If isotropic tumbling of the molecule is assumed and 
no local internal motions are allowed for (i.e. the N-H bonds are completely rigid, such that 
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the only molecular motion is random tumbling) it is possible to calculate the variation of the 
15N T1, T2 and [
1H]-15N heteronuclear NOEs with the correlation time TC (figure 3.13).  
 
Figure 3.13 Theoretical plots of log(Ti) (left) and [
1
H]-
15
N NOE (right) vs. log(TC) for a 
15
N nucleus relaxed by 
1
H-
15
N dipolar interactions at a nitrogen frequency of 60.81 MHz (
1
H frequency of 600 MHz). A rigid N-H bond 
tumbling isotropically was assumed. Adapted from Kay et al.
139
 
 
 
A plot of residue number against 15N relaxation parameters in this model scenario would 
thus provide accurate information on overall tumbling rate of the protein. For a real system, 
the variations from the mean values across the protein may be indicative of other, ‘internal’ 
motions of the N-H bond. For example, if the terminus of the protein is not involved in the 
tertiary structure and is highly flexible, the ‘effective’ correlation time experienced by 
residues in that region is much faster than that of the rest of the molecule, which may be 
reflected in changes in T1, T2 and the [
1H]-15N NOE.  
NMR relaxation data can thus be interpreted in terms of both the global tumbling of the 
molecule and what may be referred to as ‘internal’ dynamics of the backbone N-H bond 
vector; this is summarised in Table 3.6. It was of interest to understand not only the domain 
motions of PfMTIPΔ60 in the presence and absence of the PfmyoA tail, but also to examine 
whether localised regions of the protein move separately from the overall tumbling of the 
molecule, and on which timescale(s) this occurs. It was expected that this would lend insight 
into the functionally important motions of myoA recognition by MTIP. 
 
Table 3.6 Summary of motions experienced by backbone amides in a protein of ~15 kDa and the effect of these 
motions on relaxation parameters, as explained in the text. 
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Spin-lattice (T1) relaxation 
The spin-lattice relaxation parameter T1 is the inverse of the rate (R1) at which longitudinal 
(z-) magnetisation exponentially returns to thermodynamic equilibrium along the laboratory-
defined z-axis (i.e. the external magnetic field), following some perturbation e.g. a 90° RF 
pulse that flips it into the xy- plane (equation 3.3). T1 relaxation is caused by high frequency 
motions (108-1012 Hz) that match the energy gaps between the spin states of the nucleus of 
interest. 
  ( )        [     ( 
 
  
)]  (3.3) 
Backbone 15N T1 values can be obtained by recording a series of modified 
1H, 15N-HSQC 
spectra with different longitudinal relaxation delays (t in equation 3.3) and measuring the 
intensity of the amide cross-peaks as a function of this delay. Since the NMR signal relies on 
detection of magnetisation in the xy- plane, the intensities of the signal decrease as delay 
time increases due to longitudinal relaxation back to equilibrium on the z-axis (figure 3.14). 
The mean value of 15N T1s is useful in analysing the overall tumbling rates of the protein 
under investigation. However, molecules of the size of PfMTIPΔ60 (~16 kDa) tend to have 
correlation times on the order of 10 ns (i.e. –log(TC) ~8), where the variation of T1 with TC is 
near a turning point (figure 3.13). As a result, the values are relatively insensitive to internal 
motions.  
 
Figure 3.14 Experimental data for measuring 
15
N T1 relaxation of PfMTIPΔ60 in complex with PfmyoA(799-818). 
The 2D HSQC spectra were measured with delays of 50, 350, 650, 950, 1200, 1400, 1800 and 2500 ms (shown 
sequentially, left to right across two rows). Different amide signals decay exponentially with different rate 
constants (R1s) according to the dynamics of the protein and the N-H bond vector itself. 
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Spin-spin (T2) relaxation 
The spin-spin relaxation parameter T2 refers to the rate (R2) at which transverse (xy-) 
magnetisation exponentially decays following the 90° pulse which flips it into the xy- plane 
(equation 3.4).  
   ( )         [   ( 
 
  
)]  (3.4) 
This is due to an irreversible loss of phase coherence of the individual nuclear spins that 
make up the bulk magnetisation vector, as they precess around the z- axis. All of the same 
motions causing spin transitions contributing to T1 relaxation also contribute to T2 relaxation, 
since return of z- magnetisation must cause a loss of xy- magnetisation. Therefore T2 values 
are sensitive to the high frequency motions and flexibility on ns-ps timescales causes slower 
relaxation (i.e. longer T2s). However, transverse relaxation may also be caused by exchange 
processes on slower (ms-µs) timescales, which cause shorter T2s. This is due to a 
dependence of T2 on J(0), i.e. the spectral density at zero frequency.
* These timescales may 
be of particular interest in relation to protein backbone dynamics, as they correspond to 
motions which may be functionally relevant (for example, conformational changes in an 
enzymatic active site).140 
Measurement of T2 relaxation properties is complicated by the added contribution of static 
field inhomogeneities to the loss of transverse magnetisation. This is circumvented by the 
use of Carr-Purcell-Meiboom-Gill (CPMG) 180° pulse trains to refocus the bulk xy- 
magnetisation during the transverse relaxation period, so that any decay in signal detected 
in the xy- plane can be attributed solely to T2 relaxation. 
15N T2s are routinely measured in a 
manner similar to T1s, by measuring the intensities of amide cross-peaks as a function of 
transverse relaxation delay (t in equation 3.4) and fitting experimental data to an exponential 
decay function. 
[1H]-15N heteronuclear NOEs 
[1H]-15N heteronuclear NOEs are measured by recording 1H-15N HSQC spectra in the 
presence and absence of 1H saturation (i.e. when the populations of the spin states of 
hydrogen nuclei are equalised) and are stated as the ratio of the intensities for each amide 
resonance. Since 15N amide spins are relaxed by dipolar coupling to the attached 
hydrogens, 1H saturation causes a change in the relative populations of 15N nuclear spin 
states (and thus signal intensities). The value of the [1H]-15N heteronuclear NOE 
                                                     
*
 Due to this dependence, transverse relaxation rates continue to increase with correlation time; very 
short T2s are thus the cause of broad NMR signals in large proteins. 
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enhancement is dependent on ns-ps timescale dynamics, and drops from an average value 
when there are motions on this timescale in the protein backbone (figure 3.13). 
Relaxation data plots  
With the assignments described above, the backbone dynamics of PfMTIPΔ60 both ‘free’ 
and ‘bound’ to PfmyoA(799-818) were investigated on a per-residue basis. 15N T1 and T2 
relaxation times and [1H]-15N heteronuclear NOEs of backbone amides were measured using 
the same samples as those used for the triple resonance assignment experiments. For T1 
and T2 analysis, spectra at each delay time were processed in NMRPipe and plots of peak 
intensity versus delay time for each amide were analysed using a rate analysis module in 
NMRView. The relaxation times and NOEs were then plotted as a function of residue 
number PfMTIPΔ60 (figure 3.15). Where there are gaps in the sequence, this is either due to 
missing assignments or due to overlap in the raw spectra leading to intolerable imprecision 
in the measurement of peak intensity.  
Dynamics of ‘bound’ PfMTIPΔ60 
Overall, the relaxation properties of PfMTIPΔ60 in complex with the myoA tail are indicative 
of a compact complex with well-defined tertiary structure. The major exception to this is seen 
in the N-terminus of the protein, where T2 values rise and NOEs drop considerably from 
average values due to the presence of ns-ps timescale flexibility. These data suggest that 
this region (residues 61-75) marks the end of the unstructured ‘N-terminal extension’ of 
MTIP, as it neither appears to contribute to myoA binding nor the folding of the rest of the 
protein. This observation is supported by higher crystallographic B-factors for atoms found in 
this part of the protein in reported crystal structures of the complex. Shorter T2s in helix α5 
are presumed to be indicative of exchange processes due to interactions with the N-terminus 
of the myoA peptide. The increase in the average T1 in the bound form reflects increased 
molecular weight and thus overall correlation time of the molecule upon complexation with a 
~2.5 kDa peptide. Due to the elongated shape of PfMTIPΔ60-PfmyoA(799-818) complex, 
variations in T1 may occur in the ‘bound form’ plot appear to depend on the relative 
orientation of the H-N bond. For example, any N-H bonds pointing along the axis of the 
molecule should experience a slower rate of tumbling than those bonds perpendicular to it. 
Therefore, for residues in α-helices a systematic variation in T1 values for the helix may be 
expected. This is indeed observed; for example, the α-helix located in the N-terminal domain 
of the protein between residues 74 and 84 (α1) is perpendicular to the major axis of the 
molecule (therefore the N-H groups experience faster tumbling) whereas that between 
residues 195 and 202 (α8) in the C-terminal domain is almost parallel (therefore the N-H 
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groups experience slower tumbling). The mean 15N T1s in these helices are 0.73 s and 
0.87 s, respectively (see also figure 3.16). 
 
Figure 3.15 NMR backbone relaxation data for PfMTIPΔ60 and its complex with PfmyoA(799-818). The variation 
of backbone 
15
N T1 and T2 relaxation times and [
1
H]-
15
N heteronuclear NOEs for the ‘free’ (left) and ‘bound’ (right) 
protein are plotted against residue number. Error bars arise from the deviation of experimental data from the 
calculated fit for each residue. Reproduced from Douse et al.
115
 
 
 
 
 
 
Figure 3.16 The variation of 
15
N T1 relaxation times in the helices of PfMTIPΔ60 (red cylinders) bound to 
PfmyoA(799-818) (grey). The mean values (in seconds) are quoted in brackets for each helix, and show 
deviations depending on the orientation of the helix relative to the elongated shape of the complex. 
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Dynamics of ‘free’ PfMTIPΔ60 
Since an X-ray structure of ‘free’ MTIP has not been determined, the per-residue dynamics 
of the protein in solution, at physiological pH and in the absence of ligand were of particular 
interest. Different regions of the protein display a variety of dynamic properties according to 
the measurement of backbone 15N relaxation properties. A marked drop in NOEs (and jump 
in 15N T2s) relative to average values are observed at the N- terminus, as is seen for ‘bound’ 
MTIP, suggestive of flexibility. The remainder of the N-terminal domain (residues 75-134) 
have consistent NOEs indicative of a stable fold that does not undergo high-frequency 
‘internal’ motions. However, drops are a feature of the plot from residues 135-204; this is 
particularly clear in the interdomain linker (Val135-Asn140), a key myoA binding loop 
(Gly172-Leu175) and the C-terminus of the molecule (Gln204). The backbone of the protein 
in these regions therefore appears to be undergoing high frequency motions in the absence 
of the myoA tail. It is also apparent from the plot of 15N T2s that there are substantial motions 
on slower (ms-µs) timescales, indicated by drops relative to average values (which also 
causes broader signals in the HSQC spectrum). This may be due to exchange between 
conformations and, when taken together with flexibility on a faster timescale, this provides a 
plausible explanation for the observation that ‘free’ MTIP does not crystallize. Regions with 
reduced T2s in free MTIP are: (i) residues Ile133-His136, where the N-terminal domain joins 
the linker; (ii) residues Leu168 and Thr169, next to the loop containing Asp173 that makes 
the intra-MTIP hydrogen bonding interaction with Ser108; (iii) Ser107 and (iv) the C-terminal 
20 residues. The latter could be a manifestation of the reorganisation of secondary structural 
elements, allowing adoption of the conformation suitable for myoA peptide binding. 
Interestingly, Ser108 was one of the residues that could not be identified in the HSQC 
spectrum of free PfMTIPΔ60 during backbone assignment, and the reduced T2 of adjacent 
Ser107 (57.2 ms relative to the average value of 78.7 ms) suggests that this may be due to 
an exchange process causing very rapid 15N T2 relaxation and therefore broadening of the 
Ser108 backbone amide resonance beyond detection. Overall, the data are supportive of a 
model in which the tertiary structure of the C-terminal domain is not well-defined, and in 
which the protein exchanges between more than one conformation via the interdomain 
linker, with a transient adoption of the Ser108-Asp173 interaction.  
CPMG Relaxation Dispersion NMR Spectroscopy 
To investigate this apparent ‘slow’ (ms-µs) timescale conformational exchange in more 
detail, 15N CPMG relaxation dispersion NMR experiments were used. The CPMG pulse train 
is used routinely in the determination of T2 relaxation rates (R2s) to refocus transverse 
magnetisation lost due to static field inhomogeneities (see above). Conformational exchange 
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can contribute to R2 relaxation provided that it happens on a timescale faster than the 
spacing between refocusing pulses in the CPMG sequence.141 By varying the frequency of 
the refocusing pulses (νCPMG) during a fixed transverse relaxation period (Trelax) in an adapted 
version of the HSQC experiment, one may observe for affected residues a variation in 
‘effective’ R2 relaxation rate (R2
eff, given by equation 3.5), in which at low νCPMG there is a 
large exchange contribution to R2 while at higher νCPMG this is averaged out (figure 3.17).  
 
 
Figure 3.17 Schematic explanation of CPMG relaxation dispersion NMR. The ‘effective’ R2 relaxation rate is a 
function of the variable number of refocusing 180° (π) pulses during a fixed transverse relaxation period Trelax. An 
exchange process only contributes to R2 relaxation if it occurs on a timescale faster than the spacing between 
refocusing pulses. Therefore at higher CPMG frequencies (where the spacing between the refocusing pulse is 
shorter), there may be less exchange contribution compared to lower CPMG frequencies. The exchange 
contribution is Rex. Figure adapted from Hansen et al.
141
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in which:  
Trelax is the transverse relaxation period, 
I0 is the reference cross-peak intensity with no CPMG delay (Trelax = 0), 
IνCPMG is the peak intensity for a particular CPMG refocusing pulse frequency. 
 
In a two-state exchange regime in which major conformer A is exchanging with minor 
conformer B, the amplitude of the exchange contribution, Rex, is a function of the population 
of the conformers pA and pB, the rate of exchange kex and the 
15N chemical shift difference 
between the two states |Δω| (equations 3.6 and 3.7); one can determine these parameters 
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by fitting relaxation dispersion data to appropriate equations describing the 
phenomenon.*142,143 
Slow exchange (kex  << Δω)         
      
 
   
  (3.6) 
Fast exchange  (kex  >> Δω)         
       
  (
   
  
) 
  (3.7) 
in which:  
pA and pB are the populations of conformers A and B, 
Δω is the chemical shift difference between the two exchanging states, 
kex is the rate of conformational exchange. 
Data for free 15N-labelled PfMTIPΔ60 were obtained at two static magnetic field strengths 
(14.1 and 18.8 T, corresponding to 15N frequencies of 60.8 MHz and 81.2 MHz) at a fixed 
relaxation delay (Trelax) of 50 ms. The latter value was a compromise, since longer Trelax 
periods enable lower CPMG frequencies to be sampled (and thus detection of slower 
exchange events) but cause poorer signal to noise in the resulting spectrum.144 For this 
reason, a high protein concentration (500 µM) was also required to ensure sufficient signal in 
the spectra. To fit trajectories of R2
eff plotted against CPMG frequency, the program 
NESSY145 was used, enabling the appropriate exchange model to be found on a per-residue 
basis. The following models were tested, using the datasets from two field strengths (14.1 
and 18.8 T): (i) no exchange i.e. R2
eff = R2
0, the transverse relaxation rate in the absence of 
an exchange term; (ii) fast two-site exchange, described by Luz and Meiboom146 and (iii) 
slow two-site exchange, described by Carver and Richards.147  
It was found that a substantial proportion of backbone amides with observable resonances 
are subject to exchange processes, with others potentially undetected due to excessive 
exchange broadening (figure 3.18). Residues in the unstructured part of the N-terminus (e.g. 
Asp64 and Gln66), which were shown in the heteronuclear NOE experiment to be flexible on 
the ns-ps timescale display insignificant ms dynamics; other instances of low Rex were in 
isolated parts of MTIP, which could be a result of the backbone amides in exchanging 
conformers having very similar 15N chemical shifts. The largest values of Rex were found in 
the C-terminal domain but there is also clear evidence of ms timescale dynamics throughout 
the N-terminal domain, consistent with a model in which both domains move to clamp 
around the myoA tail. The linker (residues Val135-Asn140), about which the motion is 
                                                     
*
 Remarkably, Kay and co-workers have been able to extend such analyses by calculating accurately 
a near complete set of chemical shifts for minor conformers of certain proteins, and using these 
datasets to construct atomic resolution models of minor conformers. 
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thought to occur, was shown to be dynamic on the fast timescale probed by the 
heteronuclear NOE experiment and it appears from these data that it is also dynamic on 
slower timescales. Interestingly, Asp139 and Asn140 are clearly subject to exchange 
dynamics but did not show fast T2 relaxation, presumably because these residues are 
dynamic on both timescales which ‘averages’ the T2 relaxation rate. There are a number of 
other residues that fall into this category in free MTIP, for example C-terminal amino acid 
Gln204, for which the NOE enhancement was measured to be 0.28 ± 0.03 (relative to the 
average value of 0.73), Rex is 15.5 s
-1, and 15N T2 value of 89.7 ms. 
 
Figure 3.18 
15
N- CPMG relaxation dispersion plots for residues from different parts of PfMTIPΔ60 in the absence 
of the myoA tail. The unstructured part of the N-terminus (represented by D64 and Q66) is highly dynamic on the 
ns-ps timescale but shows negligible dynamics on the slower timescales probed by the relaxation dispersion 
experiments, while the linker (represented by D139 and N140) and C-terminal helix (represented by C199 and 
I202) appear to be involved in conformational exchange processes. Experimental data were obtained at neutral 
pH at static field strengths of 14.1 T (
15
N frequency of 60.77 MHz, blue lines) and 18.8 T (
15
N frequency of 
81.16 MHz, red lines) and for those residues that exhibited exchange dynamics, data were fitted to models for 
two site exchange. Rex values from experiments recorded at 18.8 T are mapped onto the crystal structure of 
PfMTIPΔ60 in complex with PfmyoA(799-818) (not shown) to reveal regions of elevated ms timescale dynamics. 
Where data are missing due to overlap or excessive line broadening, residues are coloured in blue. Reproduced 
from Douse et al.
115
 
 
The C-terminal helix α8 and the connected short β strand exhibited elevated Rex values 
relative to the rest of the protein, which may reflect a larger chemical shift difference 
between exchanging conformers and/or a different (slower) rate of exchange (kex). A good fit 
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was obtained using the Carver-Richards model and clustering together the measurable 
residues of α8, giving an exchange rate kex of 1665 ± 296 s
-1 and a minor state population of 
2.1%.  
Investigation of myoA tail conformation in solution 
All the available crystal structures of MTIP-myoA show that the C-terminal part of myoA 
adopts a helical conformation when bound to MTIP. Circular dichroism studies of myoA tail 
peptides have been recorded in isolation and the spectra were characteristic of a random 
coil. NMR spectroscopy was used to further investigate myoA conformational preferences 
using the δ2D program.148 The program takes the chemical shifts of 1Hα, 13Cα, 13Cβ, 13C’, 
15N and 1HN nuclei to predict the relative probability of finding secondary structural elements 
for each residue.  
Four spectra were recorded on a sample of ~3 mM PfmyoA(799-816) in 9:1 H2O:D2O at 
pH 5.5.* The high concentration was required to ensure the success of the heteronuclear 
experiments since the peptide was synthesised with no isotopic enrichment (i.e. the 
experiments relied on detecting the natural abundance of 13C and 15N nuclei). The strategy 
for assigning the chemical shifts of the backbone nuclei for δ2D analysis was as described in 
Table 3.7. A ROESY experiment was applied instead of a NOESY to establish connectivity 
via the ROE between 1HN(i) and 
1Hα(i-1); due to the size of the molecule, the NOE tends to 
be weak and this was indeed observed in the NOESY spectrum (data not shown).  
 
Table 3.7 NMR experiments used for assignment of PfmyoA(799-816) backbone chemical shifts (* indicates 
natural abundance heteronuclear experiments). 
                                                     
*
 pH 5.5 was a tolerable compromise between minimising amide solvent exchange rates and 
recreating physiological conditions. The lack of a buffering component resulted in a pH drift over the 
course of the experiments such that the chemical shifts of nuclei in residue His810 varied slightly. 
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Without isotopic enrichment, it was not possible to assign 13C’ chemical shifts; however, a 
full assignment of the remaining backbone chemical shifts was successful. The annotated 
HMQC spectrum is shown in figure 3.19, alongside the fingerprint region of the 1H-1H 
TOCSY. 
 
Figure 3.19 Left: Assigned 
15
N SOFAST-HMQC spectrum of PfmyoA(799-816) with N-terminal acetyl cap and C-
terminal amide cap. Right: 
1
H-
1
H TOCSY zoomed into the amide ‘fingerprint’ region to view 
1
HN J-coupling 
networks with 
1
H nuclei. Both experiments were recorded in 9:1 H2O:D2O at 303 K. 
 
 
 
Table 3.8 Results of δ2D analysis. The chemical shifts of the termini are discounted in the analysis. Shown are 
the calculated percentage populations (to the nearest unit) of α-helix, β-sheet, random coil and polyproline II helix 
(PP) for each residue, and the consensus secondary structure (SS; C=coil). 
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The chemical shifts were input into δ2D; the results are shown in table 3.8. As observed by 
circular dichroism, the peptide appears to strongly favour a random coil conformation despite 
folding as a helix when bound to MTIP. The analysis gives an overall value of 86% random 
coil population. 
Experimental investigation into the structure of the MTIP N-terminal extension 
A preliminary, NMR-based investigation of the structural features of PfMTIP N-terminal 
extension was carried out in collaboration with Xenia Snetkov (Imperial College).149 A 
complex of full-length 13C, 15N-labelled PfMTIP (produced by Xenia Snetkov) with the myoA 
tail was formed using three molar equivalents of unlabelled PfmyoA(799-818) and the same 
assignment experiments recorded as for the truncated construct PfMTIPΔ60 (Table 3.3). 
The HSQC of the full-length complex was overlaid with that of the PfMTIPΔ60-
PfmyoA(799-818) complex. The peaks corresponding to the myoA binding domains of 
PfMTIP overlay perfectly between the two spectra (figure 3.20), reinforcing the notion that 
complex formation with the myoA tail and the tertiary structure of that complex are not 
affected at all by the presence of the MTIP N-terminal extension. When the contour levels of 
the full-length PfMTIP spectrum were adjusted such that these peaks were no longer visible, 
the remaining peaks, i.e. corresponding to PfMTIP residues 1-60, were significantly more 
intense and therefore still visible above the threshold (figure 3.20).  
 
Figure 3.20 Left: Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled full-length PfMTIP (1-204, black) and 
PfMTIPΔ60 (61-204, red), both in the presence of three molar equivalents of myoA tail peptide PfmyoA(799-818). 
Right: the same spectrum of full-length PfMTIP, at a contour level set so as to remove peaks that correspond to 
residues 61-204. This shows that the residues giving rise to the remaining peaks, (corresponding to the MTIP N-
terminal extension), are in a different, faster tumbling regime, as explained in the main text. Sixteen of the peaks 
in the N-terminal extension were assigned and are annotated. Spectra were recorded at 303 K and pH 7.0. 
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Two features of the PfMTIP N-terminal extension are immediately apparent from analysis of 
these spectra: (i) its tumbling is separate to the rest of the system, and (ii) it is largely 
disordered. The greater intensity of the peaks corresponding to this region indicates that the 
backbone amide moieties of residues 1-60 are experiencing a faster rate of tumbling than 
those of the myoA binding domains*; this could in principle suggest that it forms a smaller, 
separately-folded domain, since this would tumble faster and therefore undergo slower T2 
relaxation leading to sharper signals (for related discussion, see section 3.2.4). However, it 
is evident from the low (<1 ppm) dispersion of amide hydrogen chemical shifts and many 
very intense peaks that the residues corresponding to 1-60 do not form a well-folded domain 
in the NMR tube and are, in general, highly flexible on sub-ns timescales. Indeed, the portion 
of the HSQC spectrum remaining after removal of the ‘structured’ peaks is characteristic of 
an intrinsically disordered protein. Closer inspection of this portion shows variable line widths 
within the N-terminal extension itself, perhaps suggestive that stretches of this sequence are 
more extended and disordered than others. The server DISOPRED2 was used to predict 
disorder in PfMTIP based on its primary sequence and identified residues 1-10 and 38-69 as 
the most likely regions of disorder.150 
Partial assignment of the N-terminal extension peaks was achieved using a combination of 
traditional backbone assignment approaches (as outlined in section 3.2.2), together with 
analysis of spectra recorded on samples with selective isotope labelling of particular amino 
acids (prepared by Xenia Snetkov).149 Backbone amides of residues Ser17, Thr18, Leu19, 
Gly20, Asp23, Asn24, Thr30, Trp31, Gly32, Gly34, Phe35, Glu36, Tyr37, Gln42, Leu46 and 
Ser47 were assigned with ‘medium’ or ‘high’ confidence according to MARS (figure 3.20). 
The presence of seven proline residues in the sequence (for which there is no backbone 
amide hydrogen nucleus, and therefore no HSQC peak), together with the peak overlap 
resulting from such poor chemical shift dispersion (and stretches of low sequence 
complexity), prevented high confidence assignment of more peaks. Nonetheless, the 
assignment of some of the peaks could aid binding site determination for interacting partners 
(e.g. GAP45, or other motor complex components), if these were to be produced in sufficient 
quantities, with appropriate purity, foldedness, post-translational modification(s), membrane 
associations etc. for NMR-based interaction measurements. It is worth noting that some of 
the conserved residues of the N-terminal extension thought to be important in the interaction 
                                                     
*
 As described in section 3.2.4, residues 61-74 may also experience the tumbling regime of the 
N-terminal extension; the amide resonances of these residues are generally more intense than those 
of residues 75-204 in both spectra. 
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of TgMLC1 with TgGAP45*  were assigned, and the peaks in these higher-complexity 
regions of the sequence do indeed appear less intense than those assigned to the low-
complexity region between residues ~40-70 (suggesting a propensity to adopt some degree 
of ordered structure). In the latter region, one of the assignments made was the backbone 
amide of Ser47, which is an in vitro phosphorylation site of CDPK1;82 it could be interesting 
to monitor chemical shift changes, and/or associated changes in local dynamics upon 
enzymatic modification of this residue. 
Conclusions from section 3.2.4 
Residues 1-60 of PfMTIP, a preliminary examination of which is reported, have been shown 
not to contribute to binding to myoA tail peptides. Furthermore, circular dichroism 
spectroscopy and NMR analysis have indicated that this region is unstructured and its role is 
thought to be in recognition of other elements of the glideosome and in anchoring the myosin 
motor to the inner membrane complex of Plasmodium parasites via post-translational 
palmitoylation of cysteine residues at the extreme N-terminus of the protein.64,65 In this 
section, detailed analysis of the backbone relaxation parameters of PfMTIPΔ60 by NMR 
spectroscopy showed that residues 61-77 are highly flexible on the ns-ps timescale in both 
the free and bound states of the protein and are thus likely not important for binding to the 
myoA peptides. This is supported by the absence of chemical shift perturbation in this region 
of MTIP upon addition of PfmyoA(799-818) (section 3.2.3). It appears that the N-terminal 
~15 residues of PfMTIPΔ60 are the beginning of the unstructured ‘N-terminal extension’ of 
MTIP. Computational analyses of MTIP-myoA, which predict that α0 moves independently 
from the rest of the N-terminal domain over a range of timescales, are backed up by these 
experimental data.151 
Using CPMG relaxation dispersion experiments together with more established NMR 
spectroscopic methods, extensive dynamics in free MTIP were observed, which may be of 
functional relevance in the assembly of the myoA motor complex. It was observed that both 
N- and C- terminal domains are subject to conformational exchange on the ms timescale, 
and there is evidence to suggest that this hinge motion occurs via the linker as 
hypothesised. Furthermore, it appears that the C-terminal domain may move in two parts, as 
observed by computational analysis, with two helical clusters α5-α8 and α6-α7 coming 
together to form a groove for the myoA tail. Together, the observations provide a clearer 
picture of the motions of MTIP as it recognises its binding partner, information that can only 
be inferred from static crystal structures. These dynamics also represent an interesting 
                                                     
*
 Specifically, these are: TgMLC1 residues Asp26, Glu28, Pro36, Gly37 and Phe38, which are 
equivalent to PfMTIP residues Asp23, Glu25, Pro33, Gly34 and Phe35 respectively. 
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example of the ‘conformational continuum’ observed for the EF hand protein superfamily,152 
in a system where target binding is calcium-independent. The dynamics of free MTIP are 
largely quenched in the bound state, when the protein appears to adopt a stable tertiary 
structure and clamps around the myoA tail. Using NMR it was shown that a peptide mimic of 
the latter is largely unstructured in solution and must therefore fold into a helical 
conformation for interaction with MTIP.  
3.3 Thermodynamics of MTIP-myoA  
The affinity of fluorescently-labelled myoA tail peptides for MTIP was measured in previous 
studies,57,88,110 giving dissociation constants (KD) on the order of ~10
-8-10-7 M (~10-100 nM) 
for those peptides encompassing the C-terminal 16 amino acids (myoA residues 803-818). 
Using assays in which fluorescent probe peptides are displaced from a complex with MTIP 
(i.e. ‘inhibition’ of the MTIP-myoA interaction) by unlabelled competitive myoA tail peptides, 
half-maximal inhibitory concentrations (IC50s) were measured. From these values, and 
knowledge of the affinity of the fluorescent probe peptide, apparent inhibition constants (Ki) 
could be calculated and compared in 96-well plate format. In the latter analysis, sequences 
incorporating PfmyoA residues 799-818 were more potent inhibitors than PfmyoA(803-818) 
by an order of magnitude, implying residues 799-802 with previously unrecognised binding 
roles (see above for discussion). Despite an understanding of some of the determinants of 
myoA tail binding from these assays, the contribution of enthalpy and entropy to the binding 
affinity had not been investigated. Further, the role of myoA in the folding/unfolding of MTIP 
is of interest given the observations of MTIP dynamics in section 3.2.4. 
3.3.1 Isothermal Titration Calorimetry (ITC) of WT MTIP-myoA 
The thermodynamics of PfMTIPΔ60 binding to PfmyoA(803-818) and PfmyoA(799-818) 
were investigated by ITC (figure 3.21). The high affinity interaction was confirmed 
(KD < 500 nM), for the first time without the use of any chemical labels or fluorophores. The 
absolute values of KD for the peptides are lower than those inferred from IC50 values.
110,115,116 
This was interpreted in terms of the different solution conditions used: given that electrostatic 
interactions play a key role in complex formation, the binding affinity of myoA peptides is 
expected to be strongly dependent on the ionic strength of the solution and the buffer used 
for the ITC experiments reported here contained half the concentration of NaCl (50 mM 
compared to 100 mM) than that used for the inhibition assays.  
The MTIP-myoA tail interaction is shown to be driven by a very large favourable enthalpy 
term; the unfavourable entropy term is supported by analyses of the dynamics of the protein 
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and the peptide (section 3.2.4). PfmyoA(799-818) binds to PfMTIPΔ60 with approximately 
four-fold higher affinity than PfmyoA(803-818).  
 
Figure 3.21 Binding isotherms following the titration of PfmyoA tail peptides into a solution of PfMTIPΔ60. 
Thermodynamic parameters fitted using Origin software are shown in the table below. Titrations were carried out 
at 303 K in 20 mM HEPES pH 7.5, 50 mM NaCl and 1 mM TCEP. Measurements were carried out in duplicate 
and control titrations of the peptides into buffer confirmed no significant heat of dilution for either sequence. 
Adapted from Douse et al.
115
  
 
The greater binding free energy of PfmyoA(799-818) relative to its shorter analogue has 
been interpreted in terms of extra interactions between MTIP and the N-terminal extension to 
the peptide, discussed in previous sections. The difference in binding enthalpy (18 kJ mol-1) 
may be attributed in part to these intermolecular interactions but could also reflect additional 
hydrogen bonding networks formed within the peptide itself or within the protein and/or 
solvent cage. It would be expected that the latter effect be compensated at least in part by 
the entropy term, which appears to be the case from these data.  
3.3.2 MTIP folding and unfolding by Differential Scanning Fluorimetry (DSF) 
Yet to be considered in the above sections is the folding pathway of the myoA binding 
domain of MTIP, and how this changes in the presence of myoA. Differential scanning 
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fluorimetry was used to investigate this, by examining the reverse process i.e. unfolding by 
thermal denaturation. 
Differential scanning fluorimetry 
DSF has emerged as a simple and efficient means to probe temperature-induced protein 
unfolding transitions (or ‘melting’), and has attracted particular interest in its application in 
screening molecules for the ability to stabilise a protein of interest.153 This might either be as 
part of a ligand screening campaign, or optimising buffers/additives to increase the stability 
of the protein for biochemical and/or structural analysis.  
The basic biophysical principle of the experiment is that the ‘melting temperature’ (Tm) of a 
protein i.e. the temperature at which half of the molecules in the sample are unfolded (where 
the free energy of unfolding ΔGu is zero, assuming a two-state equilibrium) will usually 
increase if a molecule binds to the protein. The unfolding transition is monitored indirectly 
using an exogenous dye (e.g. SYPRO orange), the fluorescence intensity of which changes 
significantly when it is bound to the hydrophobic surfaces that are revealed upon protein 
melting. By simply measuring the fluorescence of the dye in a protein solution over a range 
of temperatures, it is possible to follow the unfolding transition and extract Tm values (the 
mid-point of the transition). This experiment is easily multiplexed in a 96-well plate format 
using a real-time PCR instrument so a large number of compounds or buffers/additives can 
be screened in parallel. Further, the requirements for protein are very low: a protein 
concentration of 1-10 µM in a 20-µL sample typically provides sufficient signal to noise in a 
DSF experiment. 
Since peptide mimics of the myoA tail have been shown experimentally to be unstructured 
by circular dichroism and NMR spectroscopies, it was expected that DSF could be used to 
monitor MTIP-myoA unfolding, since excess peptide in the solution would not give an 
unfolding curve of itself.* The thermal denaturation of PfMTIPΔ60 in the absence and 
presence of PfmyoA(803-818) or PfmyoA(799-818) was thus monitored (figure 3.22).  
The data support several observations of the MTIP-myoA tail complex in above sections of 
this chapter. Firstly, the changes in Tm (ΔTms) upon peptide binding are qualitatively 
supportive of the ITC measurements in that: (i) the values are large suggesting substantial 
stabilisation of the protein by a high affinity interaction and (ii) the complex with 
PfmyoA(799-818) is significantly more stable to thermal unfolding than that with 
PfmyoA(803-818), with an increase in Tm of 5.8 °C. Secondly, in the raw fluorescence data of 
                                                     
*
 Protein-protein interactions may be complicated to measure by DSF unless the two signals can be 
deconvoluted reliably. 
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free PfMTIPΔ60 unfolding there is greater ground-state fluorescence than in the complexes 
with myoA peptides, suggesting that there are exposed hydrophobic sites on the protein in 
its unbound state where the SYPRO orange dye can bind. This is plausible; aside from 
secondary structural elements, which are maintained in both free and bound states, the 
clamped, well-folded conformation of the X-ray structures of the complex does not appear 
from other biophysical analyses to be a good description of the unbound protein. Further, the 
slope of the transition for free MTIP unfolding (0.05) is shallower than for the complex with 
myoA tail peptides (0.09 and 0.11), suggesting different unfolding pathways or changes in 
the ‘cooperativity’ of unfolding the MTIP domains (figure 3.22), which makes sense in light of 
the conformational flexibility of the protein. The steeper transitions for the MTIP-myoA tail 
complexes may be expected given the well-defined, compact conformation of the crystal 
structures (also supported by measured NMR relaxation parameters), in which the C-
terminal domain is seen to include the myoA tail helix in a hydrophobic groove and form the 
rigid Ser108-Asp173 ‘clamp’. 
 
Figure 3.22 DSF measurements of PfMTIPΔ60 unfolding in the absence (black) and presence of 
PfmyoA(803-818) (blue) or PfmyoA(799-818) (red). Left: raw fluorescence data; right: normalised fluorescence 
data for the same melting transitions with inset showing the linear part of the transition and the calculated slope 
of the best-fit line. Melting temperatures (Tms) for the protein and protein-peptide complexes are shown below. 
Experiments were conducted at a PfMTIPΔ60 concentration of 5 µM in a buffer containing 20 mM HEPES 
pH 7.5, 50 mM NaCl and 1 mM TCEP. Peptides were at a fixed concentration of 200 µM and the SYPRO orange 
dye was used at a nominal ‘10x’ working concentration. Data are representative of at least three repeat 
measurements. Adapted from Douse et al.
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Interestingly, there is no evidence of biphasic unfolding transitions for either the free or the 
bound state despite the domain structure of PfMTIPΔ60. Both domains contain 
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approximately the same amount of non-polar amino acids (table 3.9) so unfolding each 
domain should give rise to a DSF signal. In free PfMTIPΔ60, NMR data suggest that the N-
terminal domain may be well-folded at 303 K so exposed hydrophobic patches from the C-
terminal domain represent the likely cause of background fluorescence in the ground state. 
In the bound state, the unfolding transition is rapid and monophasic, suggesting a concerted 
unfolding of both domains. 
 
Table 3.9 Amino acid composition of PfMTIPΔ60 N-terminal domain (residues 61-134, NTD) and C-terminal 
domain (residues 140-204, CTD). Highlighted are residues with non-polar side-chains. 
 
3.4 MTIP specificity as a light chain for myoA 
Along with the in vitro, fluorescence-based measurements of PfmyoA peptides binding to 
PfMTIP, Thomas also reported a parallel investigation using sequences from another 
myosin, PfmyoB. As described in chapter 1, myoB bears close homology to myoA but its 
function has not been annotated. In order to ascertain whether MTIP was capable of acting 
as a light chain for myoB, Thomas used a peptide array, in which different PfmyoB 
sequences were synthesised as ‘spots’ on a membrane support. The membrane was 
incubated with recombinant, His-tagged PfMTIP and binding visualised by reaction of a 
horseradish peroxidase (HRP)-conjugated anti-His antibody with a chemiluminescent 
substrate (figure 3.23).110 Interestingly, peptides from the PfmyoB tail appeared to be 
capable of interaction with PfMTIP, with a peak in intensity for spots where residues 756-782 
were included in the synthesis. This was the first evidence that MTIP could bind to peptides 
derived from a different Plasmodium myosin, and interestingly the epitope appeared to be 
displaced towards the N-terminus relative to myoA, where the extreme C-terminus is 
responsible for MTIP binding. Several sequences of different lengths were re-synthesised on 
larger scales with fluorescent tags and a direct interaction with PfMTIP and PfMTIPΔ60 
confirmed. It was concluded from these studies that residues 761-775 contained the minimal 
region required for complex formation, and that like with myoA binding, the N-terminal 
extension of MTIP was dispensable. The affinity measured for unlabelled peptides indirectly 
via a displacement assay using a fluorescent probe was of the order of 1 µM. 
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Figure 3.23 Initial PfmyoB-MTIP interaction studies performed by Thomas using a peptide array technology. Top: 
workflow of the technique. Bottom: PfmyoB 20-mers were scanned across the tail region of the protein to map the 
binding epitope; the intensity refers to the chemiluminescence detected after incubation with His-MTIP and then 
α-His-HRP i.e. providing an indirect measure of binding. Figure adapted from Thomas.
110
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3.4.1 NMR analysis of PfmyoB peptide binding to MTIP 
Initial observations 
It was desirable to confirm the interaction observed by Thomas with a label-free method (i.e. 
not the indirect detection in the peptide array experiment, and not employing fluorescently-
labelled peptides). Therefore, NMR was used to analyse the interaction of a number of 
different unlabelled myoB peptides. Focusing initially on the region PfmyoB(761-775) that 
had been identified by Thomas as containing an MTIP binding sequence, peptides 
PfmyoB(761-775), PfmyoB(763-775) and PfmyoB(763-777) were tested for interaction with 
PfMTIPΔ60. This region of myoB is reasonably well-conserved across Plasmodium species 
(table 3.10) and working under the initial hypothesis that the MTIP binding mode may be 
comparable to that of myoA, it can be immediately seen that like the PfmyoA C-terminus, 
PfmyoB(761-777) contains a high proportion of basic residues. In the myoA tail, these 
residues make key interactions with MTIP and it seemed plausible that these might be 
conserved in the MTIP-myoB interaction. 
 
Table 3.10 Aligned putative MTIP binding sequences of several Plasmodium myoB proteins, extracted from 
plasmodb.org,
124
 based on the work of Thomas.
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 Full-length PfmyoB contains 801 residues.  
 
NMR samples were prepared containing 100 µM 15N-labelled PfMTIPΔ60 and 500 µM of the 
myoB peptide, and 1H, 15N- HSQC spectra recorded on each sample. By comparison with 
the spectrum of the unbound protein, a clear interaction was evident; there were several 
substantial chemical shift perturbations throughout the spectrum. Interestingly, the spectrum 
of the protein in complex for the three peptides overlaid well, suggesting that the key 
interactions were made by residues 763-775. As the N-terminus was shifted, the interaction 
appeared to be weakened and the spectrum of MTIP in the presence of five equivalents of 
PfmyoB(765-781) or PfmyoB(767-784) overlaid more closely with the unbound protein 
(figure 3.24), suggesting that the interacting residues 763-775 represented a specific binding 
motif.  
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Figure 3.24 Top: Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 (100 µM) in the absence (black) and 
presence (magenta) of PfmyoB(763-775) (500 µM). Centre: overlaid spectra of the same protein in complex with 
PfmyoB(761-775) (blue), PfmyoB(763-775) (magenta) and PfmyoB(763-777) (cyan). Bottom: overlaid spectra of 
the same protein unbound (black) and in complex with PfmyoB(763-777) (cyan), PfmyoB(765-781) (green) and 
PfmyoB(787-784) (yellow). All spectra were recorded at 303 K and pH 7.0.  
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Binding mode of PfmyoB peptides 
Although a clear interaction was observed with peptides containing PfmyoB residues 
763-775, the notion that the myoB sequences may bind to MTIP in a manner/mode 
analogous to the myoA tail was not supported by comparing the spectra of the complexes 
PfMTIPΔ60-PfmyoA(799-818) and PfMTIPΔ60-PfmyoB(763-775). Despite some sequence 
homology in the two myosin peptides, the chemical shifts of the MTIP backbone amides 
were substantially different leading to a poor overlay (figure 3.25). 
 
Figure 3.25 Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 in the presence of PfmyoB(763-775) 
(magenta) or PfmyoA(799-818) (red). 
 
In order to investigate the possible binding mode of myoB peptides, the chemical shift 
perturbations (CSPs) caused by PfmyoB(763-775) were annotated via the assignments for 
free PfMTIPΔ60 described above. Remarkably, no backbone amide resonances arising from 
residues in the N-terminal domain (NTD) of MTIP were perturbed beyond the line width of 
the resonance; all of the CSPs localised to residues in the C-terminal domain (CTD, figure 
3.26). Since there is no structure of free MTIP, detailed mapping of the CSPs to make 
assumptions about the structure of the MTIP-myoB complex may be misguided, but the 
approximate location of binding is clearly demarcated by domain boundaries. A titration 
experiment was carried out to investigate the dynamics of PfmyoB(763-775) complexation 
(figure 3.26). Aliquots of the peptide were added and HSQC spectra recorded after each 
addition. It was observed that the perturbed CTD resonances fell under an ‘intermediate’ 
exchange regime i.e. the difference in NMR frequency between the free and bound states 
was comparable to the rate of interconversion between the two states (koff ~ Δω), leading to 
 99 
 
broadening of peaks at the mid-point of the titration. Assuming that the ‘on-rate’ (kon) of the 
peptide is limited only by diffusion, this suggests that the interaction has an approximate 
affinity (KD) of 1-10 µM, as observed by fluorescence.  
 
Figure 3.26 Top: Chemical shift perturbations of backbone amides upon PfMTIPΔ60 complexation by 
PfmyoB(763-775) are localised to the C-terminal domain; where the CSPs result in a shift beyond the line width 
of the resonance, the residue in crystal structure of PfMTIPΔ60 in complex with PfmyoA(799-818) (not shown) is 
coloured in magenta. Bottom: Inset from the titration of PfmyoB(763-775) into a solution of 
15
N-labelled 
PfMTIPΔ60, as followed by HSQC spectra (annotated according to the backbone assignment made in section 
3.2.2). Spectra were recorded at 303 K and pH 7.0. 
 
A DSF experiment was also conducted to further study the binding of PfmyoB(763-775) to 
MTIP via examination of protein unfolding in the presence of the peptide. Interestingly, two 
transitions were observed for the complex (figure 3.27). It is plausible that this is due to 
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separate transitions from each domain, i.e. the unbound NTD and the bound CTD. Although 
the free protein does not show evidence of a biphasic unfolding transition, this is presumed 
to reflect the dynamic nature of the C-terminal domain and the notion that the myoB peptide 
might stabilise or ‘trap’ this domain is consistent with the NMR data shown above. 
 
Figure 3.27 DSF measurements of PfMTIPΔ60 unfolding in the absence (black) and presence of PfmyoB(763-
775) (magenta). Data are representative of three repeat measurements. 
 
3.4.2 Comparing the MTIP-interacting motifs of myoA and myoB peptides  
Therefore, the question remains: what is it about the binding sequence of myoB that 
prevents a simultaneous interaction with both MTIP domains, as observed with the myoA 
tail? By comparing the sequence of PfmyoB(763-775) with the minimal sequence of PfmyoA 
that enables a clamped, compact conformation according to crystal structures i.e. 
PfmyoA(803-816), it can be seen that a number of important non-polar and basic residues 
from the latter sequence can be aligned; for example, the basic motif 
(Arg812/Lys813/Lys814) of the myoA tail may be recapitulated by myoB residues 
Lys772/Lys773/Lys774 (figure 3.28). However, whichever way the alignment is made, 
equivalents for residues Arg806 and Gln808 are lacking in the myoB sequence. Arg806 
plays a particularly important role in interacting simultaneously with the NTD and the 
interdomain linker, which appears to template the clamping of the NTD around the myoA tail. 
In its absence, it makes sense that this conformation is not favoured. Gln808 makes 
interactions with the CTD loop that contains the critical clamp residue Asp173 and it might 
be argued that this further acts as a template for adoption of the compact conformation. 
Furthermore, the small methyl side-chain of myoA residue Ala809 that sits on the upper face 
of the helix (pointing towards the NTD, see figure 3.28) would be replaced by bulkier 
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residues that may sterically compromise the wrapping of the NTD around the myoB peptide. 
Lastly, there are no histidine residues in the myoB sequence to serve the function of myoA 
His810 – although the interaction made by the latter with Asp139 in the MTIP linker region 
could in principle be replaced by lysine (see alignment (b) in figure 3.28). 
 
Figure 3.28 ‘Alignments’ of the minimal MTIP binding sequence of PfmyoB with the minimal binding sequence 
from the PfmyoA tail (clashes of key basic/polar residues in the myoB sequence are shown in red). Below: 
Summary of the contacts made by myoA tail side-chains with the different parts of PfMTIPΔ60 (key polar basic 
residues shown in bold), alongside a view of the crystal structure of the PfMTIP-myoA tail complex illustrating the 
orientations of side-chains mentioned in the text. 
 
Taken together, it can be seen that the PfmyoB sequence that is capable of binding to MTIP 
in vitro is far from optimal and because of this, the binding affinity is at least an order of 
magnitude lower than for the myoA tail and the clamped, compact MTIP conformation is not 
formed. This may represent a structural explanation for the specificity of PfMTIP in acting as 
a light chain solely for PfmyoA; indeed, preliminary data suggest that PfmyoB engages a 
different light chain in the context of blood-stage parasites (Green, Holder et al. and 
Chatterjee, Bergman et al., unpublished results). Biochemical and structural investigations of 
the latter interaction will be of interest in further defining this specificity. 
 102 
 
3.5 Conclusions and perspectives 
As for all chapters reporting experiment results, a short conclusion is presented to discuss 
the data presented in the chapter, divided into two distinct but overlapping sections: (i) 
insights for Plasmodium biology and (ii) insights for inhibitor development.  
3.5.1 Insights for Plasmodium biology 
 The tertiary structure of the Plasmodium falciparum MTIP-myoA tail complex has 
been determined, and validated as a reasonable model for the solution-state 
structure. It has been demonstrated that the native interactions between MTIP and 
the myoA tail are better modelled using PfmyoA(799-818) as a peptide mimic. This 
peptide binds more tightly than PfmyoA(803-818), consistent with the crystal 
structure of the complex and NMR-based chemical shift perturbation analysis in 
solution.  
 The solution dynamics of complex formation and folding have been described for the 
first time. Extensive motions on a range of timescales in isolated PfMTIPΔ60 
molecules give insight into the requirements for complex formation with – and 
recognition of – the myoA tail (and by extension, motor complex assembly). It is 
thought that in the parasite, MTIP forms a complex with myoA co-translationally after 
synthesis on cytosolic ribosomes, and the data presented here build a detailed 
picture of molecular recognition in which the folding and stability of MTIP is intimately 
associated with ligand binding. 
 MTIP residues 61-75 are highly flexible and do not appear from these data to 
contribute to the interaction with myoA. It may be that this region is part of the N-
terminal disordered region of MTIP that anchors the actomyosin machinery to the 
inner membrane complex of the parasite via post-translational lipidation and/or 
interactions with other motor complex components like GAP45. 
 The structural basis for the specificity of MTIP as a light chain for myoA has been 
described. Although MTIP is capable of binding to myoB tail peptides in vitro, the 
affinity is lower and this is because the sequence of the epitope does not allow for 
the compact, clamped conformation seen in the MTIP-myoA complex. 
 
3.5.2 Insights for inhibitor development 
 The NMR assignments enable rapid binding site determination for inhibitors; this may 
be as part of a small-molecule screening campaign or, in the case of peptidic 
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inhibitors, via comparison with the ‘wild-type’ complex (using PfmyoA(799-818) as a 
probe to reconstitute this system).  
 Understanding MTIP-myoA protein-protein interaction (PPI) hotspots in solution is a 
crucial advance in the pursuit of small-molecule inhibitors of the PPI. The 
visualisation of these hotspots by chemical shift perturbation analysis adds detail –
along with understanding of the protein dynamics – to the crystal structures of the 
complex. Furthermore, given that one strategy for disrupting the interaction might be 
by using small molecule allosteric inhibitors, a fuller understanding of the dynamics of 
the free protein may be valuable in terms of selecting for ligands that promote non-
productive MTIP conformations. 
 The clamping of the myoA tail by MTIP is enthalpically driven and disfavoured 
entropically; the myoA tail needs to adopt a helical conformation in order to be 
recognised by MTIP, and the extensive flexibility of MTIP is mostly quenched upon 
interaction. This highlights an opportunity to enhance the affinity of the ligand by 
constraining the myoA tail, for example by stapling strategies. 
 As discussed at the end of chapter 1, mimicry of one polar myoA helical face 
(Arg806, His810 and Lys813) in Boger-type α-helix mimetics designed and 
synthesised by Thomas was not sufficient to produce a tight-binding MTIP ligand. 
The lack of functionality on other faces could be particularly problematic since 
Arg806, His810 and Lys813 make interactions with both MTIP domains, so effective 
inhibition would likely require the adoption of the compact, clamped interface. The 
clamping of the myoA tail is entropically disfavoured, so the enthalpy pay-off needs to 
be very high in this strategy. Given the tight binding of the C-terminal domain of MTIP 
with the hydrophobic face of the myoA helix (particularly Leu804, Val807 and Ile811), 
α-helix mimetics presenting this functionality may be more effective, with the aim of 
sequestering one domain only.  
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Chapter 4 Predicting the effects of MTIP phosphorylation 
Several studies have demonstrated that the proteins that make up the motor complex of 
Plasmodium and other apicomplexan parasites may be subject to a range of co- and post-
translational modifications, including myristoylation, palmitoylation, glycosylation and 
phosphorylation. Recently, a phospho-proteomic analysis reported PfMTIP (and homologue 
TgMLC1) to be a target of phosphorylation in live parasites.  
This chapter seeks to understand the structural effect of this modification. The precise site of 
phosphorylation could not be determined by the authors directly from the mass spectrometry 
data due to the presence of two adjacent serine residues (MTIP Ser107 and Ser108). The 
identity of the kinase responsible is also unknown, so for the purposes of biophysical 
analysis both serines are individually mutated to glutamic acid in order to approximately 
recreate the character of phospho-serine in those positions. Analysis includes NMR 
spectroscopic measurements of the interaction with the myoA tail and backbone dynamics of 
the mutant proteins, together with unfolding and calorimetric measurements, and pull-down 
experiments in parasite lysates. By comparison with analogous data from the wild-type 
system, reported in chapter 3, these data build towards a hypothesis of the possible in vivo 
effects of MTIP phosphorylation. 
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The research described below applies many of the techniques used in chapter 3, to 
investigate how phosphorylation of MTIP might regulate its dynamics and interaction with 
myoA. Throughout the chapter, the myoA tail peptide PfmyoA(799-818) is used to 
reconstitute the ‘bound state’ of the protein constructs in structural biophysical analyses. 
Where comparisons to the ‘wild-type’ (WT) interaction are made, this assumes that the data 
reported in chapter 3 on the complex between PfMTIPΔ60 and PfmyoA(799-818) represent 
a reasonable approximation to the native MTIP-myoA complex. 
4.1 Phosphorylation in Plasmodium parasites 
The first analyses of the Plasmodium falciparum phospho-proteome were published in 2011 
by Treeck et al. and Solyakov et al.,80,93 followed by another study by Lasonder et al. in 
2012.154 These landmark papers examined protein phosphorylation in the malaria parasite 
for the first time at a systems level, revealing its ‘expansive nature’.155 Each study focused 
on the schizont stage of the Plasmodium life cycle, but differences in the workflows* – e.g. 
precise time-points of analysis, sample handling, LC-MS/MS protocols, mass spectrometry 
hardware and data processing – led to substantial variations in the annotations of 
phosphorylation sites on Plasmodium proteins. The results of these global studies are briefly 
summarised in the following section, followed by a closer review of the literature on 
phosphorylation of the Plasmodium myoA motor complex. 
4.1.1 The Plasmodium schizont phospho-proteomes 
Treeck et al. (2011) 
The total number of phospho-sites identified by Treeck et al. was 8,463 (c.f. 1,171 and 2,541 
in the studies by Solyakov and Lasonder respectively) in 1,673 parasite proteins with a false 
discovery rate of under 1% in all cases.93 Interestingly, Tyr phosphorylation was found in 
both parasites despite there being an absence of genes predicted or known to encode 
classical tyrosine kinases; this was thought to be mostly, but not entirely, due to auto-
phosphorylation events. A major advantage of the study over the others was that the 
phospho-proteome of closely-related apicomplexan parasite Toxoplasma gondii was 
examined in parallel, enabling a comparison which strengthened confidence in phospho-
sites for which there are homologous proteins. One such protein was PfMTIP, which (like its 
homologue TgMLC1) was annotated to be phosphorylated on a loop positioned in a key part 
of one of the myoA binding domains of the protein. This observation is the major focus of this 
chapter (see below). 
                                                     
*
 Details on these differences are outside the scope of this thesis but are covered in the review by 
Lasonder et al. (2012).
155 
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Solyakov et al. (2011) 
As well as mapping the phospho-proteome, Solyakov used a reverse genetics approach to 
knock out members of the P. falciparum kinome, finding that 36 of the 65 eukaryotic protein 
kinases were essential for parasite survival. Further, in the course of mapping the phospho-
proteome they found that several of those kinases were phospho-proteins, suggesting that 
certain signalling pathways in Plasmodium may be cascades of phosphorylation, as in 
better-studied mammalian systems. Overall, the phospho-proteome suggested, like the other 
analyses, that phosphorylation regulates an array of parasite processes.80 
Lasonder et al. (2012) 
The paper of Lasonder et al. focused on building an understanding of the essential signalling 
pathways of schizogony by combining the phospho-proteomics data with a host of 
bioinformatics tools. The authors noted a pattern of phosphorylation of proteins involved in 
merozoite egress and red blood cell invasion, and particularly focused on the apparently 
widespread role of cyclic AMP-dependent protein kinase A (cAMP-PKA) signalling, revealing 
that myoA, GAP45 and kinase CDPK1 are all in vitro targets of PKA.154 
4.1.2 Phosphorylation of the Plasmodium motor complex and its role in assembly 
Previous work has suggested that the functions and interactions of the apicomplexan (and 
more specifically, Plasmodium) motor complex might be modulated in vivo by 
phosphorylation events.* Although detailed studies on the molecular/structural effects of 
these modifications are sparse, there has been much speculation that phosphorylation plays 
a central role in the regulation of processes thought to depend on this motor complex, such 
as parasite egress and host cell invasion. For example, taking the Solyakov and Treeck 
datasets only, 150 and 57 phospho-sites were found on proteins thought to be participating 
in T. gondii and P. falciparum motility, respectively.78 
As well as the sheer extent of modification seen in the motor complex in vitro and in vivo, 
perhaps the most compelling evidence for the role of phosphorylation in motility is via ‘knock-
down’ of relevant kinases either chemically or genetically. For example, small-molecule 
inhibition of calcium-dependent protein kinase 1 (PfCDPK1), which co-localises with the 
motor complex, has been reported to impair motility processes;81 in vitro this enzyme has 
been shown to extensively phosphorylate PfMTIP (at Ser47 and Ser51 according to Green 
et al.82 and at Ser85, Ser86, Ser107 and Ser108 according to Kato et al.81) and PfGAP45, 
                                                     
*
 For a fuller discussion of the putative roles of phosphorylation in apicomplexan host cell entry and 
egress, including modification of proteins involved in actin dynamics and microneme secretion, see 
the review by Jacot and Soldati-Favre (2012).
78 
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the motor complex protein thought to span the supra-alveolar space between the parasite 
plasma membrane and inner membrane complex. Inhibition of protein kinase B-like enzyme 
(PfPKB), which also acts on GAP45, prevented parasite invasion of red blood cells,156 while 
failed attempts to disrupt CDPKs at a genetic level have suggested their essentiality in 
P. falciparum and P. berghei.81,157 GAP45 phosphorylation in vitro and in vivo has been the 
subject of numerous studies,60,82,88 although no group has yet demonstrated conclusively 
that a particular combination of site-specific phosphorylation events, carried out by a 
particular kinase, correlates in a defined manner with a modulation of motor function. 
MTIP N-terminal extension and GAP45 
It has been established in this thesis and elsewhere that residues 75-204 of PfMTIP are 
capable of tightly binding the C-terminal helical tail of PfmyoA, while the roles of residues 
1-74 are less clear but appear independent of the folding and interaction of the remainder of 
the protein. It was recently demonstrated that the PfMTIP is palmitoylated at one or both of 
the N-terminal cysteine residues (Cys5, Cys8) and that inhibition of this modification by 2-
bromopalmitate* was destabilising to the protein,65 suggesting that MTIP may be able to 
directly associate with membranes. In T. gondii, double mutation to alanine of the 
corresponding cysteines in homologous TgMLC1 caused the protein to be cytosolic i.e. 
anchorage at the inner-membrane complex (IMC) was lost.64 However, this result could not 
be conclusively separated from the other observation that the binding to GAP45 was 
simultaneously impaired according to co-immunoprecipitation (co-IP) experiments. It is 
assumed in the literature that this N-terminal extension of PfMTIP (i.e. an extension beyond 
the myoA binding domains structurally characterised in chapter 3) is responsible for 
interaction with GAP45, which may or may not be phosphorylation-dependent; however, this 
interaction has never been demonstrated in vitro with recombinant and/or peptide constructs 
(unpublished data from Tate and Cota groups at Imperial College, and A. Holder, personal 
communication) such that biophysical details of the interaction are lacking. Nonetheless, 
co-IP of the motor complex of P. falciparum and T. gondii using MTIP (or MLC1) antibodies 
reliably pulls down a complex with GAP45 and other components. Further, in the T. gondii 
system, mutations of conserved residues in the MLC1 N-terminal extension prevent co-IP of 
GAP40, GAP45 and GAP50 (but not myoA, whose interaction with MLC1 appears to be 
unaffected, as expected).64 This could either suggest (i) a direct interaction between MLC1 
(MTIP) and GAP45 with these residues as key determinants, (ii) an indirect association via 
another member of the complex, or (iii) a less well-defined association at the membrane that 
is dependent also on the lipidation (palmitoylation/myristoylation) of the components.  
                                                     
*
 A broad-spectrum palmitoyl acyltransferase inhibitor. 
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MTIP phosphorylation sites 
As was noted by Green et al., it is plausible that the MTIP phosphorylation state is important 
in regulation of the myoA motor, as is the prevailing model in myosin regulatory light chains 
(RLCs) from other systems.82 Given that the protein does not bind calcium ions under 
physiological conditions, despite a calmodulin-like fold, phosphorylation might offer an 
alternative, rapid and reversible mechanism for the interaction and dynamics of the 
protein(s) to be controlled. In building a hypothesis on the possible role of MTIP 
phosphorylation in Plasmodium, an obvious starting point is the examination of the positions 
of putative phospho-sites in the protein.  
Green et al. found phospho-sites at Ser47 and Ser51 on PfMTIP by in vitro experiments with 
PfCDPK1,82 while Kato et al. found four different sites using the same enzyme (Ser85, 
Ser86, Ser107 and Ser108),81 suggesting that the in vitro assay is very sensitive to 
conditions and details of the protein constructs used. Ser47 and Ser51 are located in the N-
terminal extension of PfMTIP in a low-complexity region of the sequence that is highly acidic 
and disordered in recombinant constructs (see section 3.2.4). These phospho-sites have not 
been confirmed in vivo (it was demonstrated by Green et al. that the PfMTIP is a phospho-
protein in the parasite schizont extracts, but the sites were not identified);82 if such 
modification were to occur in parasites, it has been suggested that it could modulate the 
putative interaction with GAP45. Ser85 and Ser86 are in a loop connecting one of the EF 
hand-like helical bundles in the N-terminal myoA binding domain of MTIP, but are not 
hotspots of the MTIP-myoA interaction as judged by chemical shift perturbation (section 
3.2.3) and there has so far been no in vivo annotation of these residues as phospho-sites.  
Evidence from the work of Treeck et al. of PfMTIP phosphorylation at positions Ser107 or 
Ser108* in parasite culture is based on detection – in both replicates of the experiment – of a 
mono-phosphorylated peptide spanning residues Lys101-Lys112.93 However, the precise 
site of modification could not be determined from mass spectrometry data due to the 
presence of the two adjacent serines, leading to zero confidence in the assignment of either 
Ser107 or Ser108. This ambiguity was confirmed by the authors after manual inspection of 
the raw data was requested (M. Treeck, personal communication). In the study of T. gondii 
parasites, phosphorylation of this region of the MTIP homologue, TgMLC1, was also 
observed (along with other sites). Ser107 and Ser108 are totally conserved across 
Plasmodium MTIPs; in TgMLC1 (for which a crystal structure is lacking), Ser107 aligns with 
                                                     
*
 The numbering is important but inconsistent in the literature. Some publications incorrectly refer to 
these PfMTIP residues as Ser108 and Ser109 (their numbers in P. knowlesi MTIP), perhaps because 
PkMTIP was the first Plasmodium MTIP to be structurally characterised. 
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Ser113 and Ser108 aligns with Tyr114. A mono-phosphorylated peptide was identified 
containing pSer113, and so too was a di-phosphorylated peptide with both pSer113 and 
pTyr114. In a separate analysis of T. gondii parasites, Nebl et al. showed that TgMLC1 was 
indeed a target of phosphorylation, annotating Ser55, Thr98 and Ser132 as phospho-sites, 
of which the latter two were dependent on calcium stimulation.67 However, none of these 
sites align with Ser, Thr or Tyr residues in PfMTIP. The data are summarised in figure 4.1. 
 
Figure 4.1 Summary of experimental evidence for MTIP post-translational modification. A schematic view of the 
domain structure of PfMTIP is shown. Shown above the graphic (with dotted lines) are phospho-sites in T. gondii 
MLC1; the aligned MTIP residue is also shown (in grey if it is not a serine, threonine or tyrosine). Shown below 
the graphic are phospho-sites in P. falciparum MTIP, and are marked according to whether they were identified 
by in vitro phosphorylation or from parasite cultures. Data gathered from Green et al.,
82
 Kato et al.,
81
 Nebl et al.,
67
 
Treeck et al.
93
 NTD and CTD are N-terminal and C-terminal domains respectively. 
 
4.2 Thermodynamic analysis of the effect of phospho-mimetic mutations 
Since phosphorylation at Ser107 or Ser108 is the only phosphorylation event on PfMTIP to 
have been experimentally shown to occur both in vitro and in P. falciparum parasite cultures, 
it was decided to focus on this phosphorylation site for molecular-level analysis. To do this, 
some of the experiments reported in chapter 3 to study the unmodified WT protein were 
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used. The effect of modification of these positions on the thermodynamics of MTIP-myoA 
was of primary interest. 
4.2.1 Serine to Glutamic Acid mutations 
Ser107 and Ser108 are both found in the N-terminal domain of PfMTIPΔ60, at the beginning 
of helix α3 (figure 4.2).  
 
Figure 4.2 Positions for putative MTIP phosphorylation based on phospho-proteomic analysis of P. falciparum 
schizonts, shown on the co-crystal structure of PfMTIPΔ60-PfmyoA(799-818) (pdb code 4AOM, shown as green 
cartoon representation, viewed from the N-terminal end of the myoA tail helix). Annotated with stick 
representation to reflect key features discussed in the text; water marked as a red sphere. 
 
The former residue engages in a water-mediated polar interaction with myoA residue 
Arg806, while Ser108 does not directly contact the myoA tail but makes the crucial intra-
molecular hydrogen bonding interactions with the side-chain of Asp173 to form the MTIP 
‘clamp’ around the myoA tail. The importance of this interaction was highlighted via a yeast 
two-hybrid assay, in which Asp173 mutation to Ala caused a total loss of interaction.59 Both 
Ser107 and Ser108 (and Asp173) are deemed to be hotspots of the interaction by NMR 
chemical shift perturbation analysis; although in the case of Ser108, the backbone amide 
resonance is not detectable in the HSQC spectrum of the unbound protein, which is 
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presumed to be due to conformational exchange dynamics leading to excessive peak 
broadening via fast T2 relaxation (see section 3.2.4). Phosphorylation at either position was 
therefore predicted to have an effect on interaction with the myoA tail. 
To investigate the potential effect of this modification at a molecular level, it was decided to 
approximate the effect of via mutation of the substrate residues. In order to recreate the size 
and negatively charged character of phosphoserine at positions Ser107 and Ser108, two 
individual Ser to Glu mutations were made in PfMTIPΔ60 (figure 4.3), mimicking mono-
phosphorylation at each site. These will hereafter be referred to as phospho-mimetic MTIP 
mutants S107E and S108E. Although such a mutation is a crude way to test the hypothesis, 
the kinase responsible for the phosphorylation of MTIP has not been unambiguously 
identified, and for the purposes of structural studies, a large quantity of the suitably-modified 
protein was required. 
 
Figure 4.3 Chemical structures of amino acids serine, phosphoserine and glutamic acid at neutral pH. 
 
4.2.2 ITC and DSF analysis 
The same experiments as reported in section 3.3 for the WT MTIP-myoA tail interaction 
were repeated for the two phospho-mimetic MTIP mutants. ITC was used to measure 
binding thermodynamics (figure 4.4).  
A drastic decrease in affinity of the myoA tail was observed for MTIP S108E (KD = 3.86 µM) 
compared to the WT interaction (KD = 0.09 µM); the effect of neighbouring mutation 
neighbouring S107E was less marked but still measurable (KD = 0.19 µM). Although overly-
detailed analysis of relative enthalpy and entropy terms may be misleading due to the 
potential for compensation effects, it was observed that in all cases the interactions were 
driven by favourable enthalpy changes, with the strength of the interaction attenuated by 
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unfavourable entropy. The size of the enthalpy term was reduced substantially in the case of 
S108E, suggesting that key intra- and/or inter-molecular interactions are not established by 
this mutant. It might be expected that this would be observed if the MTIP Ser108-Asp173 
clamp were broken, which is plausible given the electrostatic repulsion that might arise from 
introduction of negative charge in position 108.  
 
Figure 4.4 Binding isotherms following the titration of PfmyoA(799-818) into a solution of PfMTIPΔ60 (WT and 
phospho-mimetic mutants, as annotated). Thermodynamic parameters fitted using Origin software are described 
in the table below. Titrations were carried out at 303 K in 20 mM HEPES pH 7.5, 50 mM NaCl and 1 mM TCEP. 
Measurements were carried out in duplicate. Adapted from Douse et al.
115 
 
DSF was used to examine the unfolding transitions of the MTIP mutants and the complexes 
made with the myoA tail (figure 4.5). The mutants displayed similar thermal unfolding profiles 
(i.e. Tms and slopes of the unfolding transitions) to the WT protein in the ‘free’ form, but when 
saturated with PfmyoA(799-818) substantial differences were observed. The ΔTm values 
measured followed the trend in binding affinities observed by ITC. Further, it was notable 
that the slope of unfolding of ‘bound’ S108E was shallower than for WT and S107E, 
suggesting a change in the cooperativity of unfolding as a result of a structural change in this 
modified complex. This observation would also make sense if the Ser108-Asp173 interaction 
were broken by S108E mutation; from the NMR analysis reported in chapter 3, the stability 
 113 
 
of the MTIP-myoA tail tertiary structure appears to a large extent to be governed by the 
adoption of this compact, clamped conformation. 
 
Figure 4.5 DSF measurements of WT and phospho-mimetic mutant PfMTIPΔ60 unfolding in the absence and 
presence of PfmyoA(799-818). Experiments were conducted at a PfMTIPΔ60 concentration of 5 µM in a buffer 
containing 20 mM HEPES pH 7.5, 50 mM NaCl and 1 mM TCEP. The myoA tail peptide was added at a fixed 
concentration of 200 µM and the SYPRO orange dye was used at a nominal ’10x’ working concentration. Slopes 
of the transitions are reported in normalised fluorescence units per degree. Data are representative of at least 
three repeat measurements. Adapted from Douse et al.
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4.2.3 Interaction with native PfmyoA 
The results of biophysical analysis point towards a hypothesis that phosphorylation at 
Ser107 or Ser108 would reduce the affinity of MTIP towards myoA. It was of interest to test 
this hypothesis in a more physiological context. Manipulation of the Plasmodium falciparum 
genome to generate parasites that stably expressed phospho-mimetic MTIP mutants was 
expected to be time-consuming; further, were such a manipulation to be successful, 
phenotypic analysis of the parasites would be complicated by the permanent presence of the 
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modification in the expressed protein, in contrast to post-translational phosphorylation which 
is dynamic and reversible.  
Therefore, in order to test whether observations of myoA tail peptide binding translated into a 
more physiological context i.e. interaction with full-length native PfmyoA, pull-down 
experiments were performed with lysates from P. falciparum schizonts using PfMTIPΔ60 
protein as the bait (in collaboration with Dr Judith Green at the National Institute of Medical 
Research, London, U.K.). To aliquots of parasite lysate, His-tagged PfMTIPΔ60 (WT and 
mutants) was titrated and each solution was then incubated with Ni-NTA resin. After a 
stringent washing protocol, the amount of myoA bound to the resin via the MTIP bait was 
analysed by Western blotting (figure 4.6). 
 
Figure 4.6 Schematic workflow for the pull down of native PfmyoA by recombinant, His-tagged PfMTIPΔ60 bait. 
In initial tests, the range of MTIP bait concentrations tested was 12.5-100 µg per aliquot (c.f. 
total parasite protein of 300 µg per aliquot). However, at these concentrations, the amount of 
PfmyoA pulled down was the same for each aliquot i.e. the binding was saturated. 
Therefore, the experiment was repeated with lower concentrations (1-20 µg per aliquot). The 
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results of the Western blotting for a representative run of the latter experiment are shown in 
figure 4.7. 
For MTIP S108E, it was observed that the amount of myoA pulled out from the lysate was 
dependent on the concentration of the bait protein, whereas for WT MTIP, it was saturated 
even at the lowest protein concentration tested. As this concentration (1 µg), the amount of 
myoA pulled down by WT MTIP is approximately five times greater than that pulled down by 
MTIP S108E, as judged by densitometry of the Western blot signal. This supports the 
observation that the binding of the S108E mutant to the myoA tail peptide is substantially 
weaker by ITC and DSF. For S107E, the pull down was, like WT, not seen to be 
concentration dependent, suggesting that the technique is not sufficiently sensitive to detect 
small changes in binding affinities. 
 
Figure 4.7 Analysis of PfmyoA pull down experiment from P. falciparum schizont lysate by Western blotting for a 
range of PfMTIPΔ60 (WT and phospho-mimetic mutant S108E, as annotated) bait concentrations. Lysate = 6 µg 
total schizont protein, representing 2% of the amount used in each sample. -C = pull down in which no 
recombinant MTIP was added. Coomassie staining of SDS-PAGE gels verified MTIP loading quantities for each 
variant. The histogram shows the amounts of myoA pulled out by 1 µg of bait. Adapted from Douse et al.
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4.3 NMR spectroscopy of phospho-mimetic MTIP mutants 
It was of interest to examine the structural basis for the observations made by ITC, DSF and 
pull-down assays. The results from these assays show that the S108E mutation has a more 
pronounced effect on binding to myoA than does S107E, which is plausible given the relative 
positions of the two residues and specific molecular interactions that each one makes. NMR 
spectroscopy was used to analyse the interaction with the myoA tail and the dynamics of the 
system on a per-residue basis, so that a comparison might be made with features of the WT 
interaction, described in chapter 3. 
4.3.1 HSQC spectra 
Uniformly 15N-labelled PfMTIPΔ60 S107E and PfMTIPΔ60 S108E were prepared according 
to protocols established for WT PfMTIPΔ60. HSQC spectra of the free proteins (WT, S107E 
and S108E) and bound proteins were recorded (figures 4.8 and 4.9). 
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Overall, the close overlay of peaks in the two ‘free states’ indicates a similar overall fold and 
therefore suggests that both mutations cause only minor structural changes relative to WT, 
supporting the observations by DSF of unfolding transitions (figures 4.8 and 4.9, left).  
 
Figure 4.8 Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 (WT and S107E) in the absence (left; WT 
in black, S107E in orange) and presence (right; WT in red, S107E in purple) of saturating amounts of 
PfmyoA(799-818). Spectra were recorded at 303 K and pH 7.0. Black boxes represent assigned peaks that are 
present in the WT spectrum but without obvious nearest-neighbour assignments in the mutant spectrum. 
 
For ‘free S107E’, the resonance in the dispersed region of the spectrum corresponding to 
the backbone amide of Ser107 is missing from its position, as expected. Other variations are 
likely due to local effects of the substitution of a neutral serine for a negatively-charged 
glutamate. Upon saturation of the MTIP mutants with PfmyoA(799-818), the HSQC of S107E 
overlays reasonably well with the bound form WT spectrum, with the exception of peaks 
corresponding to position 107 itself and surrounding residues. The resonance of Asp173, 
found at 9.1/131.5 ppm, is the most perturbed in the WT interaction (relative to the free state, 
see chapter 3), which was presumed to be due to formation of the MTIP clamp via 
interaction with Ser108 (figure 3.7). In the S107E bound state, this resonance overlays with 
its WT position (figure 4.8, right), suggesting that Ser107 modification does not interfere with 
the clamp interaction. Ser108 is perturbed from its position; by examination of the structure, 
this may be expected given the proximity of the 107 side-chain (now bearing a negatively 
charged functional group) to the backbone of Ser108. The backbone of Asp173 is much 
further from the mutation site and therefore it makes sense that the chemical shift of this 
amide be less affected. 
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For S108E, in the free state there is a very close spectral overlay. As described in chapter 3, 
the failure to detect Ser108 in the free WT PfMTIPΔ60 assignment was thought to be due to 
excessive exchange broadening, perhaps suggestive that the intramolecular hydrogen 
bonding that stabilises the clamped structure occurs transiently. In ‘free S108E’ this 
interaction may be prevented due to electrostatic repulsion and this could be a reason for the 
minor changes seen in the spectra. However, the overlay between the ‘bound’ states is 
poorer, suggestive of substantial changes in the structure of the complex. By contrast to the 
WT and S107E bound form spectra, the amide of Asp173 could not be identified in the 
HSQC spectrum of ‘bound S108E’. Furthermore, many of the most dispersed amide 
resonances, characteristic of the WT interaction, display substantially different chemical 
shifts and/or different line shapes (figure 4.9, right). 
 
 
Figure 4.9 Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 (WT and S108E) in the absence (left; WT 
in black, S108E in green) and presence (right; WT in red, S108E in blue) of saturating amounts of 
PfmyoA(799-818). Spectra were recorded at 303 K and pH 7.0. Black boxes represent assigned peaks that are 
present in the WT spectrum but without obvious nearest-neighbour assignments in the mutant spectrum. Adapted 
from Douse et al.
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4.3.2 NMR titrations 
In order to examine the dynamics of the interaction with the myoA tail peptide in more detail, 
titrations were carried out with the 15N-labelled phospho-mimetic MTIP mutants and the 
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unlabelled PfmyoA(799-818) peptide, where HSQC spectra were monitored after each 
addition of the myoA tail peptide.  
In the case of S107E and as observed for the WT protein, almost all the amide resonances 
perturbed by the presence of the peptide fell under a ‘slow exchange’ regime i.e. the 
chemical shift difference between the ‘free’ and ‘bound’ states (Δω) greatly exceeds the rate 
of exchange between the two (koff). This makes sense in light of the tight binding (KD of 
~10-7 M) observed by ITC: assuming diffusion-controlled (~108 M-1s-1) kon rates, koff would be 
of the order of 101 Hz, which is slower than a typical difference in NMR frequency between 
free and bound states of a protein (~102-103 Hz when the titration is run on a 600 or 
800 MHz spectrometer).  
In the case of S108E, a mixture of slow (koff << Δω), intermediate (koff ~ Δω), and fast 
(koff >> Δω) exchange regimes were observed (figure 4.10) indicative of weaker binding 
overall (faster koff) but still some substantial conformational changes and/or direct 
intermolecular contacts in certain regions of the protein leading to very large chemical shift 
perturbation (therefore Δω remains greater than koff).  
 
Figure 4.10 Titration of PfmyoA(799-818) into 100 µM 
15
N-labelled PfMTIPΔ60 S108E. Shown overlaid are the 
spectra corresponding to 0 (black), 0.2 (red), 0.4 (green), 0.6 (blue), 0.8 (yellow), 1.3 (magenta) and 3.0 (cyan) 
molar equivalents. Inset: a mixture of exchange regimes is observed, with some of the amides resonances in fast 
exchange with the bound state (Ser162 and Gly119) and others in slow exchange (Thr160 and Thr176) 
depending on the chemical shift perturbation. No further changes were observed in the spectrum up to eight 
molar equivalents of the myoA tail peptide. Spectra were recorded at 600 MHz 
1
H frequency, 303 K and pH 7.0. 
 
Although for amides in the ‘slow’ and ‘intermediate’ exchange regimes there was not 
sufficient signal to noise to accurately use peak positions or volumes as a quantitative 
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measure of binding, for the amides in the fast exchange regime, it was possible to track peak 
shifts as a function of ligand concentration and thus fit KDs via the resulting plots on an 
individual basis (figure 4.11).  By taking the average, an ‘NMR’ KD of 2.52 ± 1.69 μM (n = 13) 
was calculated, in line with that measured by ITC (3.86 ± 0.90 μM). Therefore, the striking 
result of the calorimetry experiment was supported by another line of evidence. 
 
 
Figure 4.11 Examples of equilibrium binding curves for individual backbone amide chemical shifts (where the 
resonance is in the ‘fast exchange regime’, see main text), showing chemical shift perturbation Δδ (ppm) as a 
function of PfmyoA(799-818) concentration over the course of the titration of the peptide into a solution of 100 µM 
15
N-labelled PfMTIPΔ60 S108E. Next to each curve is the best-fit KD calculated in MS Excel using a template 
spreadsheet provided by Dr Pete Simpson. 
 
4.3.3 Dynamics of phospho-mimetic mutant MTIP S108E 
Having (i) observed by ITC a remarkable reduction in binding affinity for the myoA tail 
peptide due to the introduction of the single-site phospho-mimetic mutation S108E into 
PfMTIPΔ60, (ii) confirmed the result using NMR spectroscopy and (iii) observed – in DSF 
and NMR experiments – behaviour suggestive that the structure of the complex is altered 
substantially by the substitution, it was deemed of interest to investigate whether the 
dynamics of the protein were also affected. As with the WT system, this was done by 
measuring NMR relaxation parameters. Specifically, 15N T1 and T2 relaxation times and 
[1H]-15N heteronuclear NOEs of backbone amides were measured on concentrated (300 µM) 
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samples of ‘free’ and ‘bound’* 15N PfMTIPΔ60 S108E using the same experiments, NMR 
spectrometer, processing software, analysis module and workflow as used for the WT data.  
It should be noted that the peaks for the S108E mutant spectra were not assigned by using 
triple resonance data, but by using the following method: (i) where the overlay with the WT 
‘free’ HSQC was within the line width of the S108E ‘free’ HSQC, which was the case for a 
large number of the peaks, a ‘nearest-neighbour’ assignment was made and (ii) where the 
exchange regime observed in the titration was fast or intermediate (see above), the peak 
(and therefore the assignment) was tracked from the ‘free’ to the ‘bound’ spectrum. For 
peaks falling under the slow exchange regime, this was not possible so either the residue 
was not analysed in the ‘bound’ form, or the final position of the peak in the S108E ‘bound’ 
HSQC was judged to be sufficiently overlapped with a peak in the WT ‘bound’ HSQC (and 
sufficiently separated from other resonances) that a ‘nearest-neighbour’ assignment was 
made.  Where there were ambiguities, the peaks were left out of the analysis. As for the WT, 
the relaxation times and NOEs were plotted as a function of residue number PfMTIPΔ60 
(figure 4.12). 
 
Figure 4.12 NMR backbone relaxation data for PfMTIPΔ60 phospho-mimetic mutant S108E and its complex with 
PfmyoA(799-818). The variation of backbone 
15
N T1 and T2 relaxation times and [
1
H]-
15
N heteronuclear NOEs for 
the ‘free’ (left) and ‘bound’ (right) protein are plotted against residue number. Error bars arise from the deviation 
of experimental data from the calculated fit for each residue. 
                                                     
*
 The ‘bound’ form S108E sample contained eight molar equivalents of PfmyoA(799-818), which was 
sufficient to saturate the binding event according to ITC and NMR. 
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In order to probe effects of the substitution on global tumbling properties, the ratios of 15N 
T1/T2 were used to estimate the correlation time (TC) of the system, according to equation 
4.1.139 
    
 
    
 √ (
  
  
)      (4.1) 
 in which νN is the Larmor frequency of the 
15N nucleus (60.81 MHz at 14.4 T). 
 
To make such calculations based on average T1/T2 for MTIP, residues for which T2 < 50 ms 
or NOE < 0.6 were removed from the analysis. As explained in section 3.2.4, the system is 
highly dynamic on a range of timescales and these residues were judged to be undergoing 
motions separate from the overall tumbling properties of the molecule or individual domains. 
The results, with comparison to WT values, are shown in Table 4.1. 
 
Table 4.1 Average T1/T2 values and calculated correlation times (using equation 4.1) for the following systems: 
WT = 
15
N-labelled wild-type PfMTIPΔ60; S108E = 
15
N-labelled PfMTIPΔ60 S108E; free = in the absence of myoA 
tail peptide; bound = in the presence of saturating amounts of unlabelled PfmyoA(799-818).  
 
Overall, the relaxation properties of ‘free’ S108E are comparable to those of WT (shown and 
discussed in detail in section 3.2.4) and the main features of the T2 and NOE plots are 
similar. The mean T1/T2 is slightly lower in the case of the phospho-mimetic mutant MTIP, 
suggesting faster tumbling on average. If the Ser108-Asp173 interaction indeed occurs 
transiently in the WT free state, it may serve to slow the average tumbling of each domain 
such that elimination of this interaction by Ser108 modification could lead to the observed 
effect.  
The differences in the relaxation properties between WT and S108E are much more 
pronounced when the bound forms are compared, in line with observations of the HSQC 
spectra themselves (figure 4.9). In the case of the WT protein, the T1/T2 ratio increases upon 
binding the myoA tail peptide, due to the independent domain dynamics of the free state 
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being quenched as the clamp forms around the peptide, causing the two domains to tumble 
as one folded complex. Although in the case of S108E, there is a small general increase in 
T1/T2 upon binding, it is not so pronounced and the mean value is close to that for the WT 
free state. This – together with observations of the HSQC spectra – strongly suggests that 
the S108E complex has very different tumbling properties to the WT complex, and may 
indicate that parts of the two domains are able to move independently despite the presence 
of the myoA tail. This is supported by three observations from other experiments: (i) the 
shallower transition observed for this complex by DSF, which is suggestive of a less 
cooperative unfolding process (figure 4.5); (ii) that NOEs in the interdomain linker (residues 
135-140) and parts of the C-terminal domain for the S108E bound state drop significantly (as 
with the WT free state), suggestive of ns-ps timescale flexibility not seen in the WT complex 
(figure 4.12), and (iii) binding of S108E to PfmyoA(799-818) by ITC showed a less 
unfavourable entropy change than for the WT (figure 4.4).115  
Taken together and by comparison to the WT system, the data from the NMR relaxation 
analysis with other biophysical results provide suggest a dramatic effect of Ser108 
modification, summarised in figure 4.13. 
 
Figure 4.13 Schematic models of the putative effect of phospho-mimetic mutation S108E on the clamping 
interaction and domain dynamics of PfMTIPΔ60 with PfmyoA(799-818). Above each cartoon are key biophysical 
data from the chapter. 
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4.4 Conclusions and perspectives 
Although several MTIP phosphorylation sites have been reported in vitro, the only residue to 
be annotated as phosphorylated in P. falciparum parasites is Ser108. Phospho-proteomic 
analysis identified mono-phosphorylated tryptic peptides derived from this region of MTIP; 
however, the assignment of phosphorylation to either of the adjacent Ser107 or Ser108 
directly from MS/MS spectra could not made with confidence. Ser108 establishes an 
essential intramolecular interaction with Asp173 to lock the orientation of domains in the 
bound form of MTIP. Although this residue is not in direct contact with the ligand, the large 
decrease in affinity of the S108E mutant and yeast two-hybrid screening results from other 
laboratories* reflect the importance of this interaction. Ser107 makes a water-mediated 
interaction with myoA hotspot residue Arg806, and modification in this position (S107E) has 
a much smaller but still measurable effect. Apart from these residues, other reported in vitro 
targets for phosphorylation in PfMTIP are Ser85/Ser86, located in the border between helix 
α1 and the α1-α2 loop (at the distal end of the N-terminal domain), and Ser47/Ser51 in the 
disordered N-terminal extension. Modification of these positions is less likely to affect 
complex formation with myoA, as they are surface exposed and face away from the binding 
site; this requires confirmation experimentally.  
 
4.4.1 Insights for Plasmodium biology 
 The results described here suggest that phosphorylation at Ser108 in vivo would 
likely have a major impact on myoA motor function since its localisation at the IMC 
appears to depend on interaction with MTIP, its light chain. MTIP is palmitoylated at 
the extreme of its N-terminal extension, a region of the protein which was shown by 
preliminary NMR analyses (chapter 3) to be highly flexible in vitro and has been 
suggested as containing the site(s) of interaction with other motor complex 
components. In addition to the substantially weakened affinity of the myoA tail for 
MTIP S108E evident by ITC, it has been demonstrated by unfolding analysis that the 
structure of the complex is significantly perturbed by S108 modification. NMR 
experiments have reinforced this in per-residue detail by showing that the phospho-
mimetic mutant MTIP does not form a rigid clamp around its ligand. Further, the 
interactions of recombinant MTIP constructs with the myoA tail peptide were 
corroborated by pull-down experiments in P. falciparum lysates, confirming that the 
model system using a myoA tail peptide mimic is relevant in the context of native, 
full-length myoA. The Ser to Glu substitution represents only an approximation to the 
                                                     
*
 The MTIP mutation D173A prevented a detectable interaction with myoA in the yeast two-hybrid 
system. 
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effect of phosphorylation, and in fact the double negative charge of a phosphate 
group could amplify the effects observed. Cell-based assays are required to further 
examine the effect of this phosphorylation event in the regulation of P. falciparum 
motor complex assembly/disassembly and/or activity. Since modification at the 
equivalent positions of T. gondii MTIP (called MLC1) was also detected, it is plausible 
that this is a conserved feature among apicomplexan parasites that depend on myoA 
motility for gliding and cell invasion.  
 Details of cellular assays to investigate such a hypothesis have, to date, not been 
reported; however, in the recent review by Jacot and Soldati-Favre, the authors cited 
unpublished data as follows: ‘the allelic replacement of TgMLC1 with phospho-
mimetic or phospho-null mutants* did not affect the localisation of the protein; its 
assembly with the rest of the glideosome and the motility and invasion of the 
transgenic parasites were unaltered.’78 Without an atomic-resolution structure of 
TgMLC1-myoA it is impossible to make such a molecular-level prediction as has 
been made in this chapter, and supported experimentally, for PfMTIP-myoA. Given 
that Ser108 is totally conserved in Plasmodium MTIPs but is Tyr114 in TgMLC1, it 
could be that the exact nature of the MTIP-myoA (Ser108-Asp173) clamp (and, more 
speculatively, a phosphorylation-dependent regulatory mechanism) is actually unique 
to Plasmodium. Alternatively, this lack of homology could suggest that PfMTIP 
Ser107 is the more likely phosphorylation site.  
 The possible effect of Ser107 phosphorylation is less predictable on the basis of the 
analysis presented in this chapter. The affinity for the myoA tail is only marginally 
reduced by the S107E mutation; whether or not this would be amplified by the double 
negative charge of a phosphorylated serine is unclear. Apart from homology (see 
above) to other apicomplexan light chains, on the basis of sequence analysis it is not 
obvious that one serine be a more likely kinase substrate than the other; while 
proline-directed phosphorylation is a widely-observed phenomenon (and Ser107 is 
preceded by Pro106, the only proline in PfMTIPΔ60), it is characterised by the 
presence of a directing proline residue at position i+1, not i-1, relative to the 
serine/threonine substrate. The Pro-Ser-Ser motif is totally conserved in Plasmodium 
MTIPs although T. gondii MLC1 contains Pro-Ser-Tyr. Di-phosphorylation of both 
residues is observed in the latter protein, and it is conceivable that this can occur in 
                                                     
*
 The details of these mutants and their expression are not disclosed, but it is emphasised that 
TgMLC1 Ser113 (PfMTIP Ser107) is the conserved residue; since there is no mention that the data of 
Treeck et al. was ambiguous, it is likely that the mutants investigated by the authors were at Ser113. 
If it is assumed that the TgMLC1-myoA complex assembles in a highly similar fold to PfMTIP-myoA, 
the unpublished data are supported by the results of this chapter, which suggest that Ser107 
phosphorylation has only a slight impact on the interaction of PfMTIP with the myoA tail. 
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PfMTIP; indeed, a di-phosphorylated peptide containing pSer107 and pSer108 was 
identified by Kato et al. in an in vitro PfMTIP phosphorylation experiment using 
PfCDPK1. The results presented in this chapter and examination of the available 
data on the structure, interaction and dynamics of the protein complex suggest that 
that the effect of Ser107/Ser108 di-phosphorylation on MTIP-myoA may be additive. 
Further investigations into the identity and regulation of the kinase(s) responsible, 
and the site(s) and timing of modification should be an essential focus of future 
research in the area. 
 It must be emphasised that the above analyses represent a prediction of the 
molecular effects of Ser107 or Ser108 phosphorylation, rather than an explicit 
assertion that either (i) phosphorylation at Ser108 is more likely because of the more 
drastic molecular effect, or (ii) MTIP phosphorylation does have an effect on the 
functions of the myoA motor in the context of a living parasite. 
 
4.4.2 Insights for inhibitor development 
 The Ser108-Asp173 interaction was shown to be a hotspot of the MTIP-myoA tail 
interaction in chapter 3 despite neither residue being in contact with myoA. This is 
because the hydrogen bonding between the residues is essential in allowing the two 
MTIP domains to form a ‘clamp’ around the myoA tail. The results of this chapter go 
some way towards validating this feature of the complex as a target for small 
molecule MTIP-myoA inhibitors, since the dramatic effect – on binding affinity and 
MTIP-myoA structure/dynamics – of breaking the single intramolecular interaction 
has been highlighted by analysis of MTIP mutant S108E. Because they inevitably fail 
to span the large surfaces typically buried by a protein-protein interaction (PPI), small 
molecule PPI inhibitors must target hotspots and identification of molecules capable 
of allosteric modulation of the complex via interruption of the MTIP clamp appears to 
be an attractive approach for inhibition of the myoA motor. 
 If the kinase(s) and/or phosphatases responsible for MTIP (de-)phosphorylation were 
to be unambiguously identified, it would be interesting to correlate inhibition of those 
enzymes with parasite phenotype, to examine further what role the phosphorylation 
state of MTIP might play in regulation of the parasitic life cycle. For example, working 
under the assumption that MTIP phosphorylation serves to modulate the myoA 
interaction and thus the assembly of the motor complex, it could be that 
phosphorylation or dephosphorylation of MTIP is a temporal control point for myoA 
motor function that could be perturbed by selective enzyme inhibitors. It has already 
been observed in two separate studies that inhibition of PfCDPK1, an enzyme which 
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was shown to phosphorylate PfMTIP and other motor complex components in vitro 
(including at positions Ser107 and Ser108), caused perturbations to life cycle 
progression in late schizogony, implicating the enzyme in regulation of processes 
dependent on motor function such as cytokinesis, egress and invasion. It would be 
interesting from a therapeutic/mode-of-action viewpoint as well as a biological 
viewpoint to understand this kind of phenotype in molecular detail. 
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Chapter 5 Constrained myoA helices as MTIP-myoA inhibitors 
Constrained peptides based on α-helical epitopes have emerged as an exciting class of 
molecule designed to disrupt protein-protein interactions (PPIs). With the molecular details of 
the MTIP-myoA interaction largely understood (chapters 3 and 4), this chapter reports the 
design, synthesis and in vitro validation of ‘stapled’ and hydrogen bond surrogate helix 
mimics of the myoA tail. The binding modes of the most potent analogues are explored in 
detail using X-ray crystallography and NMR spectroscopy, providing a structural basis for the 
high apparent affinity and giving insight into the targeting of buried protein-helix interactions 
such as the MTIP-myoA tail interaction. The molecules show promise for the development of 
specific chemical probes of myoA-based motility in parasites. 
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Over the past 15 years there has been a growing interest in the use of different synthetic 
methods to constrain the secondary structure in peptides, in an effort to: (i) improve binding 
affinities to receptors by lowering the flexibility of the molecule; (ii) increase the stability of 
the molecule with respect to proteolytic degradation and (iii) enable such large molecules to 
pass through cell membranes.158,159 The latter two aims are especially important if the 
peptides may be used effectively to interrogate biological systems either as a tool molecule 
(chemical genetics) or as a therapeutic. The research described in this chapter represents 
the application and structural comparison of state-of-the-art helix constraint technologies 
using the myoA tail as a template, i.e. using myoA helix mimics to target the P. falciparum 
MTIP-myoA tail interaction. The area will be briefly introduced with a short review* of these 
technologies and highlights of their application in biological settings. 
5.1 Disruption of α-helix mediated PPIs 
Targeted disruption of PPIs with designed molecules is regarded as a pressing aim in the 
overlapping areas of chemical biology and drug discovery, where the role of the particular 
PPI is of fundamental biological interest or an underlying factor in pathogenesis. Focusing on 
the former objective, this may be particularly desirable in cases where manipulation of the 
organism at the genome level in an attempt to dissect a particular PPI is inconvenient or 
impossible. A prominent example is the human malaria parasite Plasmodium falciparum, 
which is difficult to manipulate genetically. The ability to dissect the biological role(s) of 
protein-protein interactions (such as MTIP-myoA) by applying a rationally-designed and 
highly-specific molecule at a defined time point in the life cycle, thereby inducing an effective 
‘chemical knockout’, might be a very useful and complementary resource for understanding 
the roles of PPIs in basic parasite biology. The results of analogous chemical genetic 
strategies may be spectacular: for example, a recent paper from the Tate group used a 
potent and selective inhibitor of enzyme N-myristoyl transferase (NMT) as a tool to 
investigate the extensive and essential roles of protein N-myristoylation in the blood stage 
development of P. falciparum.66 It is also worth noting that through this investigation, the 
authors validated NMT as a new anti-malarial drug target by correlating enzyme inhibition 
with parasite death. Although the development of a potent, selective and cell-permeable 
inhibitor of a PPI like MTIP-myoA is more challenging than for an enzyme such as NMT, a 
growing body of literature, mainly in cancer biology (see below), suggests that the ‘chemical 
genetic’ modulation of PPIs could also be a useful and complementary approach in malaria 
parasite biology. 
                                                     
*
 For a more extensive review, see that published recently by Azzarito et al. (2013)
158 
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As described in chapter 3, the interaction between MTIP and the myoA tail is associated with 
the latter adopting an α-helical conformation. Out of the structurally-characterised PPIs in the 
Worldwide Protein Data Bank, a 2009 review from Jochim and Arora found that 62% 
featured a helix at the interface,160 and as a result of the widespread adoption of the α-helix 
and the greater tractability of helix mimics compared to β-strand mimics the literature on PPI 
inhibition has mostly focused on helical PPIs. Where hotspots of the interaction are found 
clustered within same helix of one interacting partner, one might describe the interaction as 
α-helix mediated and therefore wish to apply synthetic strategies to mimic those hotspots, as 
an approach towards the discovery of inhibitors of the PPI.  
5.1.1 Constrained peptides to disrupt α-helix mediated PPIs 
In terms of how to build design molecules to disrupt α-helix mediated PPIs, the literature 
may be divided into three main categories: (i) constrained peptide-based α-helix mimics; (ii) 
small-molecules, identified via high-throughput screening or fragment-based approaches 
followed by iterative (usually structure-guided) medicinal chemistry, and (iii) α-helix 
proteomimetics, which aim to mimic the spatial presentation of side-chains using a non-
peptidic chemical scaffold. This chapter focuses on the first of these classes. 
The α-helix contains 3.6 residues per turn and since amino acid side-chains are therefore 
presented on the same side every 3-4 residues, it may be considered that the helix has three 
distinct ‘faces’. The PfmyoA tail, according to the co-crystal structure reported with 
PfMTIPΔ60 (pdb code 4AOM, see also chapter 3), is helical from residue Asn800 to Val816 
(17 residues) and presents an array of functionality on three faces to engage in the tight 
interaction with its binding partner. As was observed by NMR spectroscopy (section 3.2.4) 
and has been observed by CD spectroscopy,110 PfmyoA tail peptides adopt random coil 
conformations in solution. This is illustrative of a wider trend: that when removed from a full-
length, folded protein or protein complex, peptides do not routinely form α-helices under 
physiological conditions; in such an isolated system, the entropic cost of adopting an ordered 
structure is not compensated by the favourable enthalpic terms associated with establishing 
the regular array of main-chain hydrogen bonding. 
ITC experiments showed that the MTIP-myoA interaction is driven by enthalpy with a large, 
unfavourable entropic term; while the latter may be due in large part to the quenching of the 
dynamics of PfMTIPΔ60 upon clamping the myoA tail peptide, chemical shift indexing 
suggests that the MTIP secondary structural elements are already present in the free protein 
(section 3.2.3), so the adoption of the helical conformation by the myoA tail is likely a 
significant factor in the negative entropy change upon binding. Nevertheless, the WT myoA 
tail mimic PfmyoA(799-818) binds PfMTIPΔ60 with high affinity, demonstrating that the 
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enthalpy terms more than compensate for this loss of entropy in the system. This may be 
one advantage of peptide mimics over small molecules in the area of PPI inhibitors: the 
ability to recreate the full array of side-chain functionality, and therefore interactions, found in 
the native amino acid sequences. However, as a result of this lack of defined secondary 
structure in isolated peptides, they may display poor stability with respect to proteolysis and, 
when coupled to their high molecular weights, poor cell penetration properties. The effective 
stabilisation of helical peptide structures using unnatural constraints is thus an attractive 
compromise. While the designed incorporation of naturally-occurring amino acids with high 
helical propensity161 or positioning of particular residues at particular positions in the chain 
may increase helicity (e.g. due to i, i+4 salt bridges162 or effective N- and C-capping 
residues163), the following short summary of available strategies focuses on the 
implementation of unnatural motifs. 
Disulfide-bridged and lactam-bridged helices 
 
Figure 5.1 Schematic diagram of disulfide and lactam-based bridging strategies to stabilise the α-helical 
conformation (represented as a white cartoon) of a synthetic peptide across [i, i+3/4] or [i, i+7] positions.  
 
In 1991, the Schultz group published the incorporation of unnatural thiol-containing amino 
acid 2-amino-6-mercaptohexanoic acid at i, i+7 positions as a means to stabilise a short 
peptide via intramolecular disulfide bridging; this peptide showed enhanced helicity relative 
to the reduced analogue according to circular dichroism spectra, prompting the authors to 
suggest such methods could be applied in the design of helical peptide ligands for 
proteins.164 More recently, simply by incorporation of D- and L-cysteine at i and i+3 positions 
and subsequent oxidation,165 or by replacement of the disulfide by a thioether linkage,166 
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Spatola and co-workers reported potent and selective peptidic inhibitors of the estrogen 
receptor α co-activator interaction. 
By insertion of glutamic acid or aspartic acid on the same face as a lysine residue, it is also 
possible to form an intramolecular lactam bridge to stabilise a peptide sequence. This has 
been widely examined; a related example came from the field of HIV drug discovery, when 
Kim and co-workers bridged two i, i+7 glutamic acid residues with a di-aminoalkane spacer 
to generate a library of constrained mimics of the C-terminal heptad repeat of HIV-1 gp41.167 
One of the resulting peptides displayed an ability to inhibit HIV-1 entry via gp41-mediated 
cell fusion with micromolar potency. Intriguingly, the constraint did not induce helicity in any 
of the peptides in solution at room temperature, and the report included comprehensive 
analysis of the thermodynamic consequences of its incorporation by ITC. The latter 
suggested the constraint was beneficial in terms of the entropy change of the interaction (i.e. 
the ΔΔS relative to the unconstrained control was favourable), and that the effect of 
positioning of the constraint at the N-terminus of the peptide rather than in the middle of the 
sequence was more pronounced in this respect. However, in the particular system under 
study, the N-terminal constraint caused the greatest enthalpic penalty, due to interference 
with key van-der-Waal’s and or hydrogen bonding contacts with the receptor, resulting in 
lower in vitro affinity overall (and no activity in cellular assays). The interactions of the 
peptide with the constraint positioned in the middle of the helix with the hydrophobic pocket 
of gp41 were not, by contrast, perturbed, and this was validated by a co-crystal structure 
demonstrating a close overlay of key side-chains with another structure of a linear peptide 
bound in the same pocket. The conclusion of the study was significant for the design of 
constrained peptides in general, stating that activity both in vitro and in vivo may not 
necessarily correlate with helicity,* but that the introduction of the constraint successfully 
reduces the number of conformational degrees of freedom available to the ‘unbound’ 
peptide. The high affinity but lack of cellular activity for one of the unconstrained analogues, 
which was an outlier from the trends of the library, was explained in terms of an increased 
susceptibility to proteolysis.167 
β-peptides 
β-peptides contain β-amino acids, which have an extra methylene (-CH2) unit compared to 
α-amino acids. Despite this additional group, β-peptides have been shown to be capable of 
adopting staple helical structures and have the advantage of being more resistant to 
                                                     
*
 Furthermore, excessive constraint on the structure of the peptide was suggested to be a reason for 
the lack of activity of one of the peptides, since it was thought to be ‘locked’ in an inactive 
conformation.  
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proteolysis. They have been extensively characterised by the laboratories of Schepartz and 
Gellman, amongst others, leading to several examples of β-peptide mimics binding to 
therapeutically-relevant proteins such as hDM2, hDMX168,169 and gp41170 and concomitant 
demonstration of in vitro inhibition of the helix-mediated PPIs. In general, the major problem 
with these molecules is that they tend not to be cell permeable; however, it has been shown 
that this may be optimised via the addition of cationic ‘patches’ or hydrocarbon stapling 
approaches; interestingly, a recent paper by Bautista et al. compared these strategies for β-
peptide mimics of p53 and demonstrated a correlation between in vitro hDM2 affinity and the 
cell permeability of the peptide.159 The Gellman group have gone further in pioneering mixed 
α β peptide ‘foldamers’ for targeting a number of different systems, with some success. For 
example, the careful placement of constrained β-residues in a long, mixed α β gp41 
oligomer resulted in successful structural and functional mimicry of a gp41 subunit and 
therefore potent inhibition of HIV infection via the same mechanism as the lactam-bridged 
gp41 mimic described above.171 
Hydrocarbon tethers 
Although notable successes have been reported using the above strategies, each strategy 
has disadvantages. The disulfide and lactam-bridged peptides suffer from the fact that the 
motifs are naturally-occurring and therefore are not necessarily protected against 
degradation (via reduction and or proteolysis) in cell culture, while β-peptides may require 
substantial, iterative optimisation to achieve cell penetration and/or successful mimicry of 
secondary structure such that the range of functionality presented by the natural ‘template’ 
helix is faithfully reconstructed. In the case of the MTIP-myoA tail interaction there are 
important interactions on all sides of the myoA helix that should ideally be maintained, to 
avoid incurring enthalpic penalties. Moreover, the myoA tail binding groove created by the 
clamped MTIP conformation is extremely congested; as a result of these features, 
employment of β-amino acids was not deemed to be an appropriate design strategy. 
In terms of the simple mimicry of short α-helices, the most general and prominent categories 
of constrained peptidic helix mimics to have emerged in the literature are: (a) hydrogen bond 
surrogate (HBS) helices and (b) hydrocarbon ‘stapled’ peptides. These employ simple, all-
hydrocarbon tethers to conformationally restrict the peptide, and have been shown in a 
variety of systems to enhance helicity, metabolic stability and, importantly, cell penetration 
(presumed to be via an active endocytic mechanism) of peptides. These are discussed in 
turn in the following sections. 
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(i) Hydrogen bond surrogate helices 
 
 
Figure 5.2 Chemical structure of the hydrogen bond surrogate (HBS) α-helix constraint. Left: a 5-residue portion 
of a generalised α-helix, with one intramolecular [i, i+4] main chain hydrogen bond highlighted. Right: the N-
terminal HBS strategy replaces this hydrogen bond with a carbon-carbon covalent bond. 
 
HBS helices, pioneered by Arora and co-workers,172 feature replacement of the N-terminal 
intramolecular i to i+4 main chain hydrogen bond by a covalent bond. Since the spontaneous 
adoption of the α-helical structure is energetically demanding for a peptide in isolation and 
tends not to occur readily as a result, the introduction of this constraint is thought to 
overcome some of this barrier, therefore nucleating helix formation in short peptide 
sequences. By ‘paying’ the cost of constraining the N-terminus of the peptide during 
synthesis, the HBS product should be capable of populating the helical conformation more 
readily in isolation. 
Chemically, the constraint is achieved in (now-established) solid-phase synthesis 
protocols173 through installation of one N-allyl amino acid* in the chain and capping the N-
terminus with 4-pentenoic acid. A bis-olefin intermediate is thereby generated that yields the 
final HBS product upon on-resin catalytic ring-closing olefin metathesis (RCM) and 
subsequent resin cleavage/deprotection (figure 5.3). Conditions for the RCM reaction have 
                                                     
*
 Although this could be any amino acid, it is synthetically most convenient for it to be N-allyl glycine. 
Therefore it may be beneficial to select a residue for ‘mutation’ that does not engage in key side-chain 
interactions with the target protein (P. S. Arora, personal communication, 2012). 
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now been optimised after a careful comparison of catalysts and reaction 
times/conditions.174,175  
 
 
Figure 5.3 Generalised synthetic scheme for the solid-phase synthesis of hydrogen bond surrogate (HBS) 
peptides, where the N-allyl amino acid is glycine. Spheres represent Rink Amide resin. Further details of the 
synthetic methods are given in chapter 8. SPPS = solid-phase peptide synthesis. 
 
To date, structural studies of HBS helices in complex with their protein targets have not been 
published, although a crystal structure of a short HBS helix has been determined in isolation 
(CCDC entry 675526, figure 5.4). This structure,176 together with solution-state studies on 
the same molecule by NMR and CD spectroscopy reported separately,177 demonstrated that 
the trans-olefin in the HBS constraint can indeed organise a helical conformation. Previously, 
the in vitro target affinity and stability with respect to proteolysis of peptides constrained in 
this way had been investigated in a different system: the HBS version of a BH3 helix from 
Bak (Bcl-2 homologous antagonist/killer, a pro-apototic regulator) bound Bcl-xL (B-cell 
lymphoma-extra-large, a pro-survival protein in the mitochondrial membrane) with 
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comparable affinity to the unconstrained peptide analogue but demonstrated enhanced 
metabolic stability in an HPLC-based trypsin proteolysis assay, being degraded 30-fold less 
quickly.178  
 
Figure 5.4 Crystal structure of an isolated 11-mer HBS helix solved to a resolution of 1.15 Å (CCDC entry 
675526) shown as stick representation.
176
 The alignment of the backbone carbonyl groups clearly demonstrate 
the helicity of the molecule in the crystal form (water molecules and second HBS helix present in the asymmetric 
unit cell have been removed for clarity), and the trans-olefin of the HBS constraint is highlighted. The amino acid 
sequence of the molecule before RCM is presented next to the structure and the spacing of the tether indicated; 
X = 4-pentenoic acid and ‡ = N-allyl alanine. 
 
Design and optimisation of HBS peptides based on a variety of helical PPI epitopes has 
enabled their successful application in a variety of cellular assays, mainly in the field of 
cancer biology. For instance, the HIF-1α transcription factor is an important regulator of 
hypoxia-inducible gene expression and a crystal structure shows that its C-terminal 
activation domain (C-TAD) binds to co-activator p300 through two α-helix mediated PPIs (αA 
and αB). In initial reports, a HBS helix designed to mimic the key features of HIF-1α C-TAD 
αA was shown to bind p300 with good affinity but was not able to inhibit transcription of 
vascular endothelial growth factor (VEGF), a gene important for production of new 
vasculature in solid tumours. This was explained in terms of the poor cell penetration 
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properties of the initial HBS helix, and by adding a single arginine at the C-terminus of the 
sequence the extent of transcription inhibition in the cellular assay increased dramatically, 
presumably due to an improvement in this regard.179 In recent work, another HBS mimic, this 
time of C-TAD αB, was developed that showed efficacy not only at the gene transcription 
level but also lowered the overall tumour burden in vivo, using a mouse xenograft model.180 
These studies demonstrate the potential of such molecules in both therapeutic applications 
and also in mechanistic studies of fundamentally important biological processes, via the 
predictive and specific modulation of PPIs. Other examples of their successful application to 
different PPIs have been reported.181,182 
(ii) Hydrocarbon stapled peptides 
 
Figure 5.5 Chemical structure of the hydrocarbon stapling α-helix constraint technology. Left: a 5-residue portion 
of a generalised α-helix, with one intramolecular [i, i+4] main chain hydrogen bond highlighted. Right: stapled 
peptides feature a covalent cross-link between side-chains, typically those of residues i and i+4.  
 
Since a communication on their synthesis183 via on-resin RCM by Blackwell and Grubbs in 
1998 and the demonstration in 2000 by Schafmeister et al. of their enhanced helicity and 
metabolic stability,184 peptides based on naturally-occurring α-helices that are stabilised by 
installation of unnatural hydrocarbon ‘staples’ have emerged as an exciting and 
now-patented class of protein-protein interaction (PPI) inhibitor.* Stapled peptides are 
typically constrained through hydrophobic linkers established by the RCM reaction between 
                                                     
*
 Aileron therapeutics, dedicated to the development of stapled peptides for clinical applications, was 
founded in 2005. 
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α,α-di-substituted alkenyl alanine residues positioned at appropriate positions along the 
sequence during solid-phase peptide synthesis (SPPS, figure 5.6), which combines the 
helix-stabilising potential of both cyclisation and methylation of Cα.  
 
Figure 5.6 General scheme of the synthesis of hydrocarbon stapled peptides, by placement of olefin-containing 
amino acids at chosen positions in the sequence during solid-phase peptide synthesis (SPPS) and subsequent 
on-resin metathesis. Shown is an example of a [i, i+4] pAla staple (see below).  
 
The success of the strategy requires careful tailoring of the positioning, length and 
stereochemistries of the unnatural amino acids, which may link together residue i with i+3, 
i+4 or i+7 upon RCM.184-192 Details of the amino acids used for staples that have been 
implemented in peptide sequences to date are summarised in table 5.1. As is evident from 
the table, the majority of staples reported contain α-methylated amino acids; however a 
recent report on a BAK peptide stapled through [i, i+4] spacing of mono-substituted pentenyl 
glycine (pGly) actually suggested minimal differences in helicity, stability or Bcl-xL affinity in 
vitro from one employing di-substituted pentenyl alanine (pAla) in the same positions.190 
Most significantly, it has been found that stapling confers cell penetrative properties to 
peptides via an active endocytic mechanism.193 Indeed, over the past ten years, there have 
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been numerous examples of the application of stapled peptides as PPI inhibitors in living 
systems.  
 
Table 5.1 Summary of alkenyl amino acids required for reported hydrocarbon stapling methods with different 
spacings in the peptide chain. pAla = α,α pentenyl alanine; aAla = α,α allyl alanine; pGly = pentenyl glycine; 
oAla = α,α octenyl alanine. In all cases the staples are formed after RCM, such that the final composition of the 
staple would have eliminated an ethylene (C2H4) unit. 
 
The study that showed their bioactivity for the first time was published in 2004 by Walensky 
et al.,187 who developed an [i, i+4]-pAla-based stapled analogue of the helical BH3 domain 
from the BID protein (BH3 interacting-domain death agonist, a pro-apototic regulator). They 
demonstrated its increased stability, helicity, affinity for Bcl-xL (see above) and correlated 
this with specific activation of cytochrome c release from mitochondria in vitro, its ability to 
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penetrate cells and finally the consistent suppression of tumour growth in mice bearing 
established human leukaemia xenografts. In 2007, Bernal et al. optimised an [i, i+7] stapled 
peptide based on a helical sequence of tumour suppressor p53 for helicity, in vitro binding 
affinity to p53 negative regulator MDM2 and cell permeability (via removal of negatively-
charged amino acids in the WT sequence), and found one of the library was capable of 
killing cancer cells via reactivation of p53-mediated apoptosis.191 It is interesting to note that 
in this example, the peptide was not the most potent of the library synthesised but was 
judged by CD spectroscopy to be the most helical. This may point to a correlation between 
helicity and permeability or proteolytic stability, but a lack of correlation between helicity and 
target affinity, as observed for the lactam-bridged gp41 mimics discussed above.167 Other 
recent examples include the use in 2009 of stapled MAML1 (mastermind-like protein 1) 
derivatives to antagonise NOTCH transcription resulting in potent anti-proliferative effects in 
a mouse model of T-cell acute lymphoblastic leukaemia,188 and in 2013 a stapled dual 
inhibitor of the p53-MDM2/MDMX* interactions, developed by scientists at Aileron 
therapeutics, showed encouraging tumour suppression in models of human osteosarcoma 
and breast cancer.192  
The structures of three isolated estrogen receptor (ER)-binding stapled peptides have been 
solved by a group at Pfizer using solution NMR spectroscopy, complementing the more 
standard CD analysis by confirming that they all adopt stable helical conformations in water 
beyond the stapling position (one is shown in figure 5.7).194  
 
Figure 5.7 Solution NMR structure of an isolated stapled peptide helix solved (pdb code 2LDD) shown as cartoon 
and stick representations. The hydrocarbon staple containing a cis-olefin is labelled. The amino acid sequence of 
the molecule before RCM is presented next to the structure and the spacing of the tether indicated; * = (S)-α,α 
pentenyl alanine (pAla). The α-methyl groups of the unnatural amino acids are also labelled. 
 
                                                     
*
 MDMX is another member of the MDM2 family that also regulates p53 tumour suppression 
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Structures of stapled peptide-protein complexes 
Structural biology has been an important discipline in rationalising the design and validating 
the introduction of stapling motifs in helical peptide sequences. As shown above, structures 
of isolated HBS and stapled peptides (figures 5.4 and 5.7 respectively) have been reported. 
More significantly, several structures of stapled helical peptides bound to their protein target 
have been solved; aside from the data reported later in this chapter, Table 5.2 summarises 
all those published to date. No structure of a HBS helix bound to a protein target has been 
published. 
The first structure, of a stapled helical peptide inhibitor of HIV-1 particle assembly in complex 
with a portion of the viral capsid protein, was solved by solution NMR.195 It showed that the 
hydrocarbon chain did not perturb the predominantly-hydrophobic interactions made by 
Phe3, Tyr9 and Tyr10 of the inhibitor peptide at the buried PPI interface. By contrast, the first 
co-crystal structure – determined by the Walensky laboratory  – of a stapled MCL-1 (induced 
myeloid leukemia cell differentiation protein) BH3 helix in complex with MCL1 itself showed 
the staple engaging in hydrophobic interactions at the periphery of the ‘core interaction site’, 
and the α-methyl groups pointing into discrete hydrophobic pockets of MCL1.196 The 
potential for the interactions of the hydrophobic staple to cause perturbation of the natural 
helical register was later identified by Philips et al. via their crystal structures of two estrogen 
receptor-binding peptides (see above) with two different receptors (ERα and ERβ). In both 
cases, the staple was seen to engage in hydrophobic interactions with the target protein. 
However, in one case this appeared to dominate the interaction such that stapling caused a 
quarter turn of the peptidic helix relative to the wild-type structure, while a more judicious* 
placement of the staple in the other (one residue towards the C-terminus) preserved the 
register of the template helix.  The conclusion of the study states clearly that ‘in the design of 
stapled peptide inhibitors of protein–protein interactions, the question of how the 
hydrophobic nature of the hydrocarbon linker perturbs the interaction must be considered’.194 
Unsurprisingly, this was also shown to be an issue for [i, i+7] staples; the first structure of a 
peptide stabilised by this longer hydrocarbon tether was solved by Baek et al. in 2012, which 
also demonstrated an unexpected perturbation of the p53 peptide orientation in the MDM2 
binding pocket caused by interactions of the staple.197 These interactions were largely 
preserved in the structure of the ‘stapled dual inhibitor of p53-MDM2 MDMX’ (see above) in 
complex with MDMX.192 
                                                     
*
 In this case, replacement of Ile and Leu with the stapling pAla residues was better tolerated than 
replacement of adjacent Lys and Gln, since the natural hydrophobic interactions could be successfully 
mimicked. 
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Table 5.2 Cartoon representations and details of the structures of stapled peptides bound to their protein targets, 
presented in chronological order from top to bottom, with the positions of the staple indicated. Where the crystal 
contains more than one protein-peptide complex per asymmetric unit, these are removed for clarity. In each case 
the one-letter amino acid sequence of the peptide is given, which represents the sequence before RCM. 
* = (S)-α,α pentenyl alanine (pAla); ω = (R)- α,α octenyl alanine (oAla); □ = 3-cyclobutyl-L-alanine. Whether or not 
the hydrocarbon staple is seen engaging in interactions with the protein is indicated in the final column. 
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5.1.2 Targeting a buried protein-helix interaction, MTIP-myoA 
As described above, constrained peptides based on α-helical epitopes are an exciting class 
of molecule that may be designed to disrupt protein-protein interactions (PPIs). However, the 
applicability of such constrained helix mimetics has so far been limited to surface-exposed 
PPIs dominated by hydrophobic interactions. It has been established by systematic analysis 
of structurally-characterised PPIs that more than a third of the protein-helix interactions are 
buried, with two or all three faces of the helix presenting ‘hotspot’ residues.198,199 These are 
particularly challenging targets for constrained peptides, since any constraining motif needs 
to preserve this array of native interactions by design. X-ray crystal structures of stapled 
peptide complexes, listed above, have demonstrated that the staple may unexpectedly 
engage in interactions with hydrophobic sites on the receptor protein, while the mode of 
recognition of an HBS helix has yet to be described in atomic detail. When targeting a buried 
PPI, association of the constraint with the protein is a primary design consideration since it 
must not perturb hotspot side-chain orientations or change the register of the helix. 
The determinants of the MTIP-myoA interface were explored in chapter 3 using X-ray 
crystallography, NMR spectroscopy and other biophysical methods, showing that the C-
terminal tail of myoA forms a helix (figure 5.8) that is tightly clamped by two MTIP domains in 
an enthalpy-dominated interaction.  
 
Figure 5.8 Two views of the wild-type PfmyoA tail helix (grey cartoon) according to the crystal structure of 
PfMTIPΔ60-PfmyoA(799-818) (reported in chapter 3; pdb code 4AOM). Some residues have been omitted for 
clarity; validated hotspots of the interaction are annotated in red. Left: side-on view of PfmyoA(799-818), 
presented from N- to C-terminus (left to right). Right: rotated view looking down the helix from the N-terminus 
shows the array of functionality (side-chains shown as white sticks) presented by the PfmyoA tail, and that 
hotspots are located on all three faces.  
 
 143 
 
The structural data and previous biophysical interaction studies have shown that the myoA 
tail helix contains numerous basic residues that are indispensable for a high-affinity 
interaction and presented on one side, while hydrophobic amino acids on the other face form 
a compact and folded core with the C-terminal domain of MTIP. Many of the residues of the 
helical portion of the myoA tail (spanning Asn800-Val816) make important interactions with 
MTIP i.e. are ‘hotspots’ of the interaction. 
Library design of constrained myoA tail peptides 
Since a buried protein-helix interaction like MTIP-myoA has not been the subject of any 
detailed structural studies in the field of constrained helical peptides, it was of interest to 
compare existing hydrocarbon constraint technologies both to examine their potential as 
MTIP-myoA inhibitors, and possibly gain more general insights into the targeting of this sort 
of buried interaction. Recent reviews of the area from the Wilson158 and Arora199 groups 
surmised that peptide stapling might interfere with the molecular recognition of one of the 
three helical faces, while the HBS approach should, in principle, preserve the interactions of 
all three faces.  
With these molecular features in mind, a library of constrained myoA tail peptides was 
designed to compare the different approaches. Positions for incorporation of unnatural motifs 
were carefully selected based on analysis of the PfMTIPΔ60-PfmyoA(799-818) structure and 
other work on the key determinants of binding. For stapled myoA tail peptides, pairs of non-
polar WT residues were replaced that were appropriately spaced (at [i, i+4] or [i, i+7] relative 
to one another, where i is the residue nearer to the N-terminus) in the sequence. Discounting 
Ala809, the available non-polar residues for ‘mutation’ to alkenyl amino acids in the helical, 
MTIP binding region of the myoA tail are: Ile801, Pro802, Leu804, Leu805, Ile811, Met815 
and Val816. Of these residues, Leu805, Val807 and Ile811 are experimentally-verified 
hotspot residues; therefore, it was not possible to introduce [i, i+4] or [i, i+7] staples without 
alteration of at least one hotspot residue. Nonetheless, the following staple positions were 
selected on two faces of the helix: (i) Ile801-Leu805 (left face looking down the helix from the 
N-terminus, pointing towards the intra-MTIP clamp), (ii) Leu804-Ile811, (iii) Val807-Ile811 
and (iv) Ile811-Met815 (all on the bottom face, pointing towards the MTIP C-terminal 
domain); it was hoped that by stapling across these positions, which have large aliphatic 
side-chains, the native hydrophobic interactions with MTIP could be recreated or even 
enhanced. Stapling across positions on the right-hand face of the helix, which is populated 
by polar and charged amino acids was not tested, as the hydrophobic character of the staple 
would not be able to recreate the native interactions, and many of the residues on this face 
are not tolerant to mutation. Figure 5.9 summarises these design principles. 
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Figure 5.9 Design of stapled myoA tail peptides. Left: the view down the myoA tail helix in the 
PfMTIPΔ60-PfmyoA(799-818) crystal structure from the N-terminus, as shown in figure 5.8 except that the non-
polar residues selected for stapling (i.e. those with appropriate [i, i+4] or [i, i+7] spacings) are coloured purple, 
and the designed staples are shown with a connecting line. The protein (surface representation, with the N- and 
C-terminal domain coloured in cyan and light cyan respectively) is annotated to highlight key molecular 
recognition features on each face of the helix. Right: a helical wheel showing the three faces of the myoA tail 
helix and their amino acid composition (polar/charged/non-polar side-chains). 
 
 
The clamped MTIP-myoA binding interface is sterically congested, as evident in figure 5.9, 
and it was considered that the α-methyl groups in the conventional, di-substituted pAla 
staple may adversely affect binding. A recent paper from Yeo et al. reporting a peptide 
stapled through mono-substituted pGly suggests similar properties to pAla, but this peptide 
was designed to target a surface exposed binding site.190 It was hypothesised that the 
substitution pattern at Cα may become more important when targeting a buried protein-helix 
interaction. To this end, (S)-N-Fmoc pentenyl glycine (pGly) was synthesised by Sabrina 
Maas using a nickel-based chiral auxiliary200 for incorporation in the myoA tail sequence in a 
series of analogues using the same three [i, i+4] spacings as for the pAla series. 
For the introduction of the HBS motif, replacement of residues Lys799 and Pro802 – with 
4-pentenoic acid and N-allyl glycine respectively – was chosen since: (i) it is a requirement 
that the motif is positioned at the N-terminus of the peptide (see above); (ii) this region of the 
myoA tail lies outside the buried PPI interface; (iii) the side-chains of neither residue engage 
in hotspot interactions with MTIP, and (iv) it would ensure a comparable chain length to the 
stapled peptides in the library. 
For all HBS and stapled peptides that were designed, the final C-terminal residues (Ala817 
and Gln818) of WT PfmyoA were removed since they are dispensable for a tight interaction 
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(indeed, no electron density is observed for the latter residue in the PfMTIPΔ60-
PfmyoA(799-818) crystal structure reported in chapter 3).  
Negative control: myoA R806A 
A PfmyoA point mutation (R806A) was used as a negative control for each constrained 
peptide series (HBS, stapled pAla and stapled pGly); according to crystal structures, the 
side-chain of Arg806 (which is totally conserved across apicomplexan myosins, see table 
3.1) interacts with the MTIP interdomain linker and several residues in the N-terminal domain 
(figure 4.4); as a result, mutant peptides fail to show an interaction with MTIP according to 
yeast two-hybrid (Y2H) analyses and display no activity in fluorescence-based inhibitory 
assays up to concentrations of 100 µM.54,55,110,116 
The structural basis for the effect of R806A was explored further using solution NMR 
spectroscopy. Five molar equivalents of peptide PfmyoA(803-818) harbouring ‘mutation’ 
R806A were added to a solution containing 100 µM 15N-labelled PfMTIPΔ60, and 
1H, 15N-HSQC spectra recorded before and after (figure 5.10).  
 
Figure 5.10 Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 unbound (black) and in the presence of 
five molar equivalents of PfmyoA(803-818)R806A (green) show substantial differences in backbone amide 
chemical environments. The most perturbed residues are annotated according to the assignments reported in 
chapter 3. Spectra were recorded at 303 K and pH 7.0. 
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NMR spectroscopy is more sensitive to weak ligand binding events than Y2H experiments 
and fluorescence-based assays, and chemical shift perturbations of backbone amide peaks 
were consistent with an unambiguous (albeit weak) interaction for the mutated peptide. 
Notably, according to the assignments of free PfMTIPΔ60 made in chapter 3, the peaks that 
were perturbed in the presence of the ligand mainly originated from the MTIP C-terminal 
domain, with the chemical shifts of the Ser107 amide and other important myoA binding 
residues in the N-terminal domain not perturbed beyond their line width. This suggested 
strongly that the array of interactions made by PfmyoA Arg806 templates the formation of 
the MTIP clamp around the myoA tail, and when the functionality of this residue is removed, 
the participation of the N-terminal domain is modulated. It is plausible that this is the root 
cause of such a dramatic reduction in affinity that was observed by Y2H and fluorescence.  
Significantly, the lower affinity of peptides containing R806A should also be seen for the 
constrained analogues if the MTIP binding mode of the native myoA tail is preserved as 
intended by the design strategy. For the stapled peptides, the R806A control was made for 
the analogues in which the staple was furthest from the mutation site i.e. between Ile811 and 
Met815. 
Synthesis and naming of the library of constrained myoA tail peptides 
The library of peptides were synthesised according to established Fmoc solid-phase 
chemistry protocols173,201 and purified by semi-preparative LC-MS, as described in the 
experimental section (chapter 8). For the stapled pGly series, the solid-phase synthesis, 
purification and characterisation was done in collaboration with Sabrina Maas.200  
RCM was a key step in the synthesis of all the constrained peptides. It has been shown 
elsewhere in the stapled peptide literature that there tends to be a good general correlation 
between the success of the RCM step with helical stability of the product.186 This may be 
attributed to the fact that the metathesis reaction is performed in 1,2 dichloroethane, which 
(as a low dielectric solvent) is thought to stabilise helical conformations and thus template 
the reaction by bringing the two olefin groups into close proximity, increasing the local 
concentration of the reacting groups.  
Two notable observations were made during this key step. Firstly, RCM on the resin-bound, 
fully protected pGly peptides using the method reported by the Verdine laboratory201 yielded 
~8:2 mixtures of two products with the desired mass but different HPLC retention times. This 
is comparable to observations made by Blackwell and Grubbs using O-allylserine derived 
macrocycles,183 but in contrast to the pAla stapled myoA peptides and HBS myoA peptides 
where essentially a single product was observed. For the control peptide (pGly R806A) it 
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was possible to isolate the two products and 1H NMR was used to assign the major and 
minor RCM products as cis and trans isomers, respectively. The circular dichroism (CD) 
spectra of these isomers were obtained to investigate their relative helical abundance, and 
as expected it was found that the cis staple confers substantially more helicity (53%) than its 
trans isomer (18%, figure 5.11).200 
 
Figure 5.11 Circular dichroism spectra of cis- and trans- pGly R806A from 190-260 nm. The calculated peptide 
helicity is 51% and 18% respectively. Figure adapted from Sabrina Maas (Imperial College, 2013).
200
 The spectra 
represent an average of five scans and were recorded on 200 μM of peptide solution in H2O at 25 °C. 
 
Secondly, during the synthesis of all the constrained peptides, the resin was significantly 
discoloured by this step, presumably due to by-products of the metathesis reaction, which 
was catalysed by two ruthenium-containing catalysts Grubbs I (for the stapled peptides) and 
Hoveyda-Grubbs II (for the HBS peptides). Since in small-scale tests, the presence of these 
impurities caused problems with the purification of the metathesised product, a resin ‘clean-
up’ protocol was followed prior to cleavage of the peptides from the resin and purification. 
This is described in the experimental section. 
The library is shown in table 5.3. The hydrogen bond surrogate myoA tail peptide will be 
referred to in the text as ‘HBS myoA’. [i, i+4] stapled peptides will be referred to as ‘pAla’ or 
‘pGly’ followed by the stapling position in the PfmyoA sequence, e.g. ‘pGly[807,811]’. The 
[i, i+7] stapled peptide will be referred to as oAla-pAla[804,811]. 
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Table 5.3 Library of constrained myoA tail peptides used in this study. Shown are the sequences before RCM, 
with: X = (4’)-pentenoic acid; † = N-allyl glycine; * = (S)-pentenyl alanine (pAla); ω = (R)-octenyl alanine (oAla); 
γ = (S)-pentenyl glycine (pGly). The pGly library was synthesised and purified in collaboration with Sabrina Maas. 
All peptides have an acetyl cap on the N-terminus except HBS myoA, and all bear a C-terminal amide except 
WT, which has a free C-terminal acid. 
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5.2 Biophysical characterisation of constrained myoA tail peptides 
5.2.1 Analysis of MTIP binding by DSF and NMR 
The interaction of the constrained myoA tail peptides with MTIP was explored firstly using 
differential scanning fluorimetry (DSF) and HSQC NMR spectroscopy.  
Stapled pAla series 
 
Figure 5.12 DSF analysis of PfMTIPΔ60 unfolding in the absence and presence of stapled pAla myoA tail 
peptides. Experiments were conducted at a PfMTIPΔ60 concentration of 5 µM, and the myoA tail peptides were 
added at a fixed concentration of 200 µM. Changes in melting temperatures (ΔTms and ΔΔTms) for the protein-
peptide complexes are shown below. Data are representative of at least three repeat measurements; ΔTm values 
relative to the free WT protein (Tm = 38.3 °C) are quoted as mean ± standard deviation.  
 
Introduction of the constraining pAla staples does not appear to improve the affinity of the 
WT myoA tail peptide towards MTIP according to DSF; in each case, the ΔTm (relative to 
unbound PfMTIPΔ60 protein) decreased (ΔΔTm relative to the WT complex is negative). 
Although it is not a quantitative measure of affinity, it was observed in chapter 4 that the 
trend in ΔTm followed the trend of KD for the phospho-mimetic mutant MTIP binding studies, 
so for related binding events (e.g. a series of different molecules binding in the same mode 
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to the same molecule) such trends may be instructive. The negative control pAla R806A 
displayed the lowest affinity of the series, suggesting that the peptides bind in approximately 
the same orientation as the WT myoA tail, but overall, the presence of the pAla staples 
seems disruptive to complex formation according to the DSF assay. To substantiate this 
observation, an HSQC spectrum was recorded on 15N-labelled PfMTIPΔ60 in the presence 
of the analogue with the highest ΔTm, pAla[811,815]. This spectrum was overlaid with that of 
the WT spectrum in order to investigate the effect on the staple (figure 5.13). 
 
Figure 5.13 Left: solution 
1
H, 
15
N-HSQC spectra of uniformly 
15
N-labelled PfMTIPΔ60 in complex with the WT 
myoA tail PfmyoA(799-818) (red contours) and stapled pAla[811,815] (cyan). Right: residues whose backbone 
amide resonances are perturbed beyond their line width are highlighted in red on the adjacent X-ray structure of 
the WT complex (pdb code 4AOM; pAla stapling positions, Ile811 and Met815, are shown as cyan sticks). Key 
features of the MTIP structure are annotated; NTD and CTD indicate N-terminal and C-terminal domain. 
 
The close overlay of the two spectra is suggestive that the complex adopts a comparable 
conformation in the presence of the pAla[811,815] staple, with the chemical shifts of 
residues responsible for MTIP clamp formation (Ser108 and Asp173) completely unaffected. 
Although chemical shift perturbation of backbone amides is found in regions around the 
myoA stapling positions (when visualised on the protein structure, figure 5.13) as expected, 
several residues that are affected are distal to the myoA binding groove (e.g. Ile79 and 
Tyr80 at the tip of the N-terminal domain), suggesting subtle changes to the tertiary structure 
that may cause the lower ΔTm for this constrained peptide.  
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Without an atomic resolution structure of this or any pAla stapled myoA peptide complex in 
hand, it is impossible to fully explore the basis of this effect, but it is plausible that such 
perturbations arise from steric clashes in the MTIP binding groove caused by introduction of 
both the hydrophobic staple motif itself and or the methylated Cα atoms. 
Stapled pGly series 
 
Figure 5.14 DSF analysis of PfMTIPΔ60 unfolding in the absence and presence of stapled pGly myoA tail 
peptides. Experiments were conducted at a PfMTIPΔ60 concentration of 5 µM, and the myoA tail peptides were 
added at a fixed concentration of 200 µM. Changes in melting temperatures (ΔTms and ΔΔTms) for the protein-
peptide complexes are shown below. Data are representative of at least three repeat measurements; ΔTm values 
relative to the free WT protein (Tm = 38.3 °C) are quoted as mean ± standard deviation. 
 
When compared to the pAla stapled myoA tail peptides, where a reduction in Tm was 
observed in all cases relative to the WT complex and (in terms of Tm) 
[811,815]>[807,811]>[801,805], the pGly stapled myoA tail peptides – which are chemically 
identical to pAla analogues except for the presence of the two α-methyl groups – showed 
substantial improvement in their ability to stabilise MTIP to thermal unfolding (figure 5.14). 
Experiments carried out by Sabrina Maas showed that the cis isomer of pGly[811,815] 
stabilised MTIP to a significantly greater extent (ΔTm, cis 16.7 ± 0.1 °C cf. ΔTm, trans 
12.7 ± 0.1 °C), as expected. pGly[801,805] and pGly[807,811] matched or even appeared to 
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improve on the affinity of the WT myoA tail, and furthermore the Tm trend in stapling position 
was reversed, with [801,805]>[807,811]>[811,815]. As expected, the R806A mutant peptide 
displayed the lowest Tm, again suggesting that the mode of interaction was comparable to 
the WT system. HSQC analysis of the complex of MTIP with pGly[801,805] (figure 5.15) 
again revealed protein-staple interaction sites as judged by chemical shift perturbations 
relative to the WT spectrum; in this case these appear to increase rather than decrease the 
affinity of the peptide for the protein. The perturbations are more specifically localised than in 
the case of pAla[811,815], and include residues in the MTIP clamp (Ser108, Asp173 and 
surrounding residues). It is interesting that the apparent interactions made by the staple are 
not disruptive of this critical feature of the MTIP-myoA tail interaction.  
 
Figure 5.15 Left: solution 
1
H, 
15
N-HSQC spectra of uniformly 
15
N-labelled PfMTIPΔ60 in complex with the WT 
myoA tail PfmyoA(799-818) (red contours) and stapled pGly[801,805] (blue). Right: residues whose backbone 
amide resonances are perturbed are highlighted in red on the adjacent X-ray structure of the complex of 
PfMTIPΔ60-pGly[801,805], reported later in this chapter (staple shown as blue sticks). Key features of the MTIP 
structure are annotated; NTD and CTD indicate N-terminal and C-terminal domain respectively. 
 
While the chemical shift perturbation analysis provides per-residue information, it was of 
interest to investigate further the apparent improvement of pGly stapling of the myoA tail 
over pAla stapling at atomic resolution. These investigations are reported later in the 
chapter. 
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HBS and [i, i+7] stapled myoA 
 
Figure 5.16 DSF analysis of PfMTIPΔ60 unfolding in the absence and presence of HBS and [i, i+7] oAla-pAla 
stapled myoA tail peptides. Experiments were conducted at a PfMTIPΔ60 concentration of 5 µM, and the myoA 
tail peptides were added at a fixed concentration of 200 µM. Changes in melting temperatures (ΔTms and ΔΔTms) 
for the protein-peptide complexes are shown below. Data are representative of at least three repeat 
measurements; ΔTm values relative to the free WT protein (Tm = 38.3 °C) are quoted as mean ± standard 
deviation. 
 
The [i, i+7] oAla-pAla staple appeared to be disruptive to complex formation as judged by its 
complex with MTIP displaying the lowest ΔTm of the entire library; further, the shallow 
melting transition suggests major changes to the cooperativity of thermal unfolding. Given 
the results of the pAla series, it is again plausible that the long, di-substituted alkenyl 
alanine-based staple causes steric clashes in the congested binding pocket; alternatively, 
the result of the DSF assay could be misleading if the hydrophobic reporter dye (SYPRO 
Orange) were to bind to this greasy tether and thus impede the protein-peptide interaction. 
By contrast, although HBS myoA also gave a slightly lower ΔTm than WT myoA 
(ΔΔTm = 3.2 °C), the unfolding transition was notably steeper, suggesting a highly 
cooperative unfolding process indicative of a compact complex. HSQC analysis of the MTIP-
HBS myoA complex showed a very close spectral overlay with the WT complex, with the 
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exception of amides from residues clustered around helix α5. Since the HBS tether itself is a 
backbone constraint, it may not be expected to make substantial contacts or interactions 
with the protein target as for the side-chain staples; however, the manipulation of the 
chemical functionality of the PfmyoA(799-818) N-terminus (which was shown in figure 3.2 to 
make a number of interactions with α5), may be the cause of the slight perturbations 
observed. 
 
Figure 5.17 Left: solution 
1
H, 
15
N-HSQC spectra of uniformly 
15
N-labelled PfMTIPΔ60 in complex with the WT 
myoA tail PfmyoA(799-818) (red contours) and HBS myoA (orange). Right: residues whose backbone amide 
resonances are perturbed are highlighted in red on the adjacent X-ray structure of the complex of PfMTIPΔ60-
HBS myoA, reported later in this chapter (HBS motif shown as orange sticks). Key features of the MTIP structure 
are annotated; NTD and CTD indicate N-terminal and C-terminal domain respectively. 
 
5.2.2 Analysis of MTIP-myoA inhibition by FRET 
FRET inhibition assay 
The potential of the constrained myoA tail peptides to disrupt the MTIP-myoA complex was 
investigated using a FRET-based inhibition assay developed and validated previously by Dr 
Jemima Thomas (Tate Group, Imperial College).110  
The MTIP construct used throughout this study (PfMTIPΔ60, i.e. lacking the N-terminal 
extension known to be dispensable for interaction with myoA) contains a single tryptophan 
 155 
 
residue (Trp171), located close in space to the N-terminal end of the myoA tail according to 
crystal structures. By forming a complex of this construct with an N-terminally dansylated 
myoA tail (dGmyoA, which corresponds to PfmyoA residues 791-818, with an N-terminal 
dansyl functionality connected to the sequence via a glycine spacer), and exciting Trp171 at 
280 nm, FRET occurs to the dansyl group, which absorbs at the tryptophan emission 
wavelength and emits at 525 nm (see figure 5.18). 
 
Figure 5.18 FRET inhibition assay: example fluorescence spectra (excitation 280 nm) of PfMTIPΔ60 and 
complexes, which a schematic representation of the MTIP-dGmyoA complex. The protein contains one 
tryptophan (Trp171), which fluoresces at 330 nm; in complex with a dansylated myoA probe (dGmyoA), FRET 
between Trp171 and dGmyoA results in emission at 525 nm. As the probe is replaced by an unlabelled 
competitive inhibitor peptide, the FRET effect is diminished. Data reproduced and figure adapted from 
Thomas.
110
 
 
Results of FRET assay 
As seen in figure 5.18, replacement of the dGmyoA probe by competitive myoA peptides 
reduces the FRET effect; by titrating the inhibitors and monitoring the 525 nm emission, it 
was possible to generate IC50 plots (figure 5.19) and used the Cheng-Prusoff relationship to 
calculate apparent inhibition constants (app. Ki).  
The dGmyoA probe was synthesised and purified according to previously established solid-
phase protocols and the FRET inhibition assay carried out for the library of constrained 
myoA tail peptides. 
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Figure 5.19 Example FRET IC50 plots for inhibitors WT myoA (grey) and HBS myoA (red) against a complex of 
PfMTIPΔ60 (600 nM) and dGmyoA (500 nM). Background-corrected IC50 values calculated by GraFit (Erithacus 
Software) were 4.4 ± 0.7 µM and 2.4 ± 0.3 µM respectively. The KD of dGmyoA has been measured to be 
86 nM
110
 enabling estimation of Ki values for each inhibitor. 
 
Table 5.4 shows a summary of the FRET inhibition data alongside the results from the DSF 
assay. Although there was limited absolute correlation between ΔTm and apparent Ki there 
was good correlation within related structural series (pAla, pGly and HBS). The domain 
structure of MTIP may complicate the analysis since the DSF signal arises from unfolding 
each domain; for example, the R806A mutant peptides can stabilise the C-terminal domain 
but display low affinity (IC50 > 100 µM in all cases) since the contribution of the MTIP N-
terminal domain and the clamping interaction is modulated. Furthermore, as observed 
elsewhere,190 the Hill coefficients of the IC50 plots for some of the constrained peptides may 
suggest a more complex equilibrium than simple 1:1 competition between inhibitor and 
dGmyoA probe. It should also be noted that buffer conditions used for the FRET inhibition 
assay are different to those used for NMR, DSF and ITC experiments reported in this thesis. 
The higher ionic strength of the FRET buffer is likely a major reason for the lower apparent 
Ki of WT myoA compared to its KD from ITC (section 3.3.1), since it has been shown before 
that affinity of myoA peptides is strongly dependent on the concentration of NaCl in assay 
buffers.110 
From the FRET inhibition data, it was observed that four constrained peptides, namely HBS 
myoA, pAla[811,815], pGly[801,805] and pGly[807,811] either match or improve on the 
potency of WT myoA.  
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Table 5.4 Summary of biophysical characterisations, by DSF and FRET, of the library of constrained myoA tail 
peptides. 
a
 Numbering refers to Plasmodium falciparum 3D7 myosin A sequence;
 b
 Tm of MTIP Δ60 is 38.3 ± 0.2; 
c
 Apparent Ki calculated according to the Cheng-Prusoff relationship; KD of MTIP-dansyl myoA probe 
interaction = 82 nM. X = (4’)-pentenoic acid; † = N-allyl glycine; * = (S)-pentenyl alanine; ω = (R)-octenyl alanine; 
γ = (S)-pentenyl glycine. The sequences represent the structures prior to ring-closing metathesis. Values quoted 
as mean ± standard deviation (n  ≥ 3). 
 
5.3 X-ray crystallographic studies of constrained myoA tail peptides  
In order to investigate further the structural features of constrained myoA tail peptides 
binding to MTIP, room-temperature sitting-drop co-crystallisation experiments were 
attempted with the four most potent analogues from each series: pGly[801,805], 
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pGly[807,811], HBS myoA, and pAla[811,815]. Expecting from NMR experiments that the 
overall conformation of the complex should be comparable to the WT complex, reservoir and 
buffer conditions similar to those used to crystallise WT PfMTIPΔ60-PfmyoA(799-818)* were 
screened and, if necessary, optimised to produce diffraction-quality crystals. No such 
crystals were observed for the complex with pAla[811,815], but crystals were obtained in 
several conditions and >95% complete datasets were recorded to high resolution for 
PfMTIPΔ60 in complex with pGly[801,805], pGly[807,811] and HBS myoA, as summarised in 
Table 5.5.  
Data were collected at 100 K at 1° oscillations (pGly[801,805] and pGly[811,815]) or 0.5° 
oscillations (HBS myoA) at the Diamond Light Source synchrotron, Oxfordshire, U.K. 
Datasets were processed either with the xia2 bundle202 (running XDS,203 XSCALE, Pointless 
and Aimless)204,205 or indexed in Mosflm206 and scaled in Scala.204 Phasing of the data by 
molecular replacement was achieved in Phaser207 using the structure of WT PfMTIP-myoA 
(pdb code 4AOM) as the search model. 
5.3.1 Model building and refinement 
pGly[801,805] and pGly[807,811] 
Inspection of electron density maps and model building was done in Coot, and initial 
refinement was done in REFMAC.208 After one round of refinement with the wild-type 
peptide, positive electron density for the non-natural [i, i+4] staple was clearly observed in a 
difference map (Fobs - Fcalc) between the correct modified residues (shown in figure 5.20), 
with negative peaks evident for branched side-chains of the natural amino acids.  
No structure of a pGly stapled peptide has been reported in the protein data bank, so the 
modelling and refinement of the stapled peptide could not use an existing template structure. 
However, norleucine residues (monomer code: NLE) could be introduced in place of 
Ile801/Leu805 and Val807/Ile811 in Coot; this residue contains the required number of 
carbon atoms on each side of the olefin formed upon RCM. The cis double bond linkage, 
with its associated geometric constraints was then defined in a crystallographic information 
file (.cif) using JLigand209 with the kind assistance of Dr Garib Murshudov (Laboratory of 
Molecular Biology, Cambridge University, U.K.) and input into REFMAC in subsequent 
rounds of refinement, along with the appropriate header in the model coordinates file. 
                                                     
*
 Protein solution: 6 mg/mL (~400 µM) with three molar equivalents of the myoA tail peptide  in 20 mM 
HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP; reservoir solution: 20% (v/v) PEG 3,350 and 200 mM 
K(SCN). Similar conditions are arrayed in the Imperial sitting-drop crystallisation screen ICL3, 
components of which are listed at http://www3.imperial.ac.uk/xraycrystallography/crystn/xstalscreens  
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Table 5.5 X-ray data collection and refinement statistics for three co-crystal structures of PfMTIPΔ60 in complex 
with constrained myoA tail peptides. Rmerge is defined as R = (ΣhklΣi|Ii-<I>|)÷(ΣhklΣiIi), where Ii is the intensity of 
reflection hkl and <I> is the average intensity for multiple reflections. Rwork and Rfree are defined as R = (Σhkl||Fobs|-
|Fcalc||)÷(Σhkl |Fobs|), where h,k,l are the indices of the reflections (used in refinement for Rwork; 5%, not used in 
refinement, for Rfree), Fobs and Fcalc are the structure factors, deduced from measured intensities and calculated 
from the model, respectively. * Values in parentheses are for highest-resolution shell. 
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Figure 5.20 Graphics from Coot showing expanded portions of the modelled coordinates and electron density 
maps (as annotated) for pGly[801,805] and pGly[807,811] complexes with PfMTIPΔ60 after initial phasing of 
datasets by molecular replacement and an initial refinement step. Shown in each case are the positions of the 
staple incorporation, before modification of wild-type myoA residues. γ = (S)-pentenyl glycine (pGly). 
 
Final refinement steps, including Translation/Libration/Screw (TLS) parameters, were 
performed in Phenix,123 and an analogous link definition for the staple was created with the 
kind assistance of Dr Nigel Moriarty (Lawrence Berkeley National Laboratory, California, 
U.S.A.). In both the pGly[801,805] and pGly[807,811] structures, which were solved to 
resolutions of 1.47 and 1.82 Å respectively, 100% occupancy of the cis olefin was observed, 
as expected from the biophysical analyses of separated isomers of pGly[811,815] and pGly 
R806A. 
HBS myoA 
Two copies of the protein-peptide complex were identified in each asymmetric unit using the 
Matthews cell content analysis module in the CCP4 interface,210 and Phaser run accordingly 
to search for the two copies of the MTIP molecule, related by non-crystallographic symmetry. 
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Inspection of electron density maps and model building was done in Coot, and initial 
refinement was done in REFMAC. Since there has been no structure of a hydrogen bond 
surrogate peptide reported in the protein data bank, the unnatural tether again needed to be 
modelled without a template. As with the pGly stapled peptide complexes, electron density 
was observed between the nitrogen atom of myoA tail position 802 (modified from Pro802, 
the WT residue, and modelled as a glycine) and the N-terminal peptide bond connecting 
Asn800 to the N-terminal acyl group of pentenoic acid (X799, see figure 5.21).  
 
Figure 5.21 Graphic from Coot showing expanded portions of the modelled coordinates and electron density 
maps (as annotated) for the complex of HBS myoA with PfMTIPΔ60 after initial phasing of datasets by molecular 
replacement and an initial refinement step. Shown are the position of the HBS motif incorporation, i.e. an olefin 
tether formed by RCM between N-allyl glycine at position 802 (†) and pentenoic acid (X799, the acyl portion of 
which is shown). 
 
It has been shown in structural studies of an isolated HBS helix176 that upon RCM a trans 
olefin is formed in the HBS tether, which agreed with the experimental electron density, and 
this information was used to model the tether at the N-terminus of HBS myoA (figure 5.22). 
Position 799 was modelled as an acetyl group (named ‘ACE.cif’) and a monomer unit of 
trans but-2-ene was generated in JLigand (named ‘HBS.cif’) and placed appropriately in the 
electron density using Coot. With the kind assistance of Dr Garib Murshudov, three link 
records were then generated with associated geometric constraints: (i) the link (peptide 
bond) between Asn800 and ‘ACE’, (ii) the link (single carbon-carbon bond) between the 
methyl carbon of ‘ACE’ and one end of ‘HBS’ and (iii) the link (single carbon-nitrogen bond) 
between the other end of ‘HBS’ and the nitrogen of position Gly802. These three links 
(ASN-ACE.cif, ACE-HBS.cif and HBS-GLY.cif), were signposted in the model coordinates 
file and input along with the monomer units in REFMAC refinement.  
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Figure 5.22 Modelling the HBS tether in HBS myoA for refinement in REFMAC and Phenix. ACE and HBS 
‘monomer’ cif files defined all the necessary atoms and the trans olefin in the tether, while three link cif files 
defined the geometry and connectivity between the nitrogen of myoA position 802 and the N-terminus. 
 
Final refinement steps, including Translation/Libration/Screw (TLS) parameters, were 
performed in Phenix, and an analogous series of link definitions was created with the kind 
assistance of Dr Nigel Moriarty. The two complexes in the asymmetric unit, related by non-
crystallographic symmetry (NCS), were treated as explicitly separate TLS groups. 
Final refined models of the constrained peptides 
The final models of the three constrained myoA tail peptides are shown in figure 5.23, 
showing excellent agreement in all cases with the experimental electron density maps, most 
notably around the constraint atoms. 
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Figure 5.23 (this and previous page) Refined 2Fobs-Fcalc electron density maps of the three constrained myoA 
tail peptides bound to PfMTIPΔ60 (not shown), contoured at 1.5σ, shown as a mesh around the final structural 
models. Constraints are marked with asterisks. 
 
 
5.3.2 Structural features of MTIP-constrained peptide complexes 
The three co-crystal structures are shown in figure 5.24 alongside the WT 
PfMTIPΔ60-PfmyoA(799-818) structure. 
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Figure 5.24 Cartoon representations of PfMTIPΔ60 in complex with the WT myoA tail and three constrained 
myoA tail peptides, along with pdb codes of each complex. The helices of the WT structure are annotated. In the 
case of HBS myoA, there are two complexes in each asymmetric unit; only one is shown for clarity. 
 
Overall the MTIP conformations are very similar to the wild-type structure, with all adopting 
the same largely helical folds and the clamped domain structure discussed in chapters 3 and 
4. In all cases, electron density was not observed for the flexible N-termini of PfMTIPΔ60; in 
the case of the pGly stapled peptide structures all residues but Ser61 and Val62 were 
observed, while in the HBS myoA structure residues 61-66 were not observed. Observations 
reported in chapter 3 confirm that this region of the protein is highly dynamic in both the 
solution state (NMR relaxation data) and in the crystal (B-factors) and does not contribute to 
the interaction with the myoA tail. 
The design of the constraints was validated by several key features of the structures when 
compared to the WT structure: (i) the fold of MTIP is maintained with the two domains 
clamped around the constrained myoA helices via the Ser108-Asp173 interaction; (ii) the 
side-chains of all key hotspot residues coincide nearly exactly between the structures, with 
RMSDs compared to WT of 0.11 Å, 0.13 Å and 0.17 Å respectively; and (iii) the pGly staples 
follow the same trajectory as the hydrophobic residues that were replaced. The latter two 
features are illustrated when the four ‘bound’ myoA tail helices were overlaid, as shown in 
figure 5.25 where the side-chains are shown in different colours. 
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Figure 5.25 Comparison of the overlaid helices (grey cartoon; two views rotated by 180°) formed by different 
myoA peptides in complex with PfMTIPΔ60: the native myoA tail (side-chains in black) and three constrained 
peptides (pGly[801,805] side-chains in blue; pGly[807,811] in magenta; HBS myoA in orange, respectively). 
 
pGly[801,805] 
The observations of solution NMR spectra of PfMTIPΔ60 in complex with pGly[801,805] 
were corroborated by the co-crystal structure of this peptide to provide a structural basis for 
its high apparent affinity. By highlighting the perturbed residues (i.e. those that did not 
overlay with the assigned WT spectrum) on the solved structure, the staple is shown to be 
interacting productively with the residues in the intramolecular ‘clamp’ without disrupting this 
essential feature of the MTIP-myoA complex (figure 5.15). While the interactions of WT 
residues Ile801 and Leu805 are maintained, the middle of the aliphatic chain slots between 
the side-chain of Ile109 and the backbone of Gly172 (figure 5.26). 
 
Figure 5.26 Interactions of the aliphatic staple of pGly[801,805] (grey cartoon and sticks; staple shown as blue 
sticks and spheres) with PfMTIPΔ60 (surface representation, coloured by atom identity). The side-chains of the 
replaced WT myoA residues are shown overlaid in black for comparison. 
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pGly[807,811] 
The coincidence of the pGly staple with the replaced WT residues is particularly striking in 
the case of pGly[807,811], in which the staple exactly tracks the bond vectors of the Val807 
and Ile811 side-chains (figure 5.25), and is effectively incorporated into the small 
hydrophobic core of the MTIP C-terminal domain (composed of residues Phe148, Leu168, 
Leu175, Phe198 and Ile202; see figure 5.27). This is in line with the strategy for staple 
incorporation detailed above and as such, the structure represents the first time that a 
stapled peptide has been designed to occupy a deeply buried α-helix binding site. It is 
presumably due to this effective incorporation that the affinity for the protein target is 
maintained; the ΔTm and apparent Ki of WT myoA and pGly[807,811] are the same. 
 
Figure 5.27 X-ray structure of MTIP bound to pGly[807,811] viewed down the myoA helix (grey) from the N-
terminus; the placement of the pGly staple (magenta spheres) in the centre of the helix allows the aliphatic chain 
to plug into the small hydrophobic core of the MTIP C-terminal domain (inset). NTD and CTD are N- and C-
terminal domains, respectively. 
 
HBS myoA 
The asymmetric unit in the crystal structure of the complex between PfMTIPΔ60 and HBS 
myoA is a dimer, with contacts between two MTIP C-terminal domains (figure 5.28). It was 
observed in the structure of WT PfMTIPΔ60-PfmyoA(799-818) that the N-terminal lysine 
(Lys799) of the myoA peptide makes crystal contacts with two aspartate residues from an 
adjacent MTIP molecule,119 so it is plausible that the removal of this functionality by 
introduction of the N-terminal HBS motif causes the change in packing and thus the 
symmetry of the crystal. It does not appear that the complex forms a dimer in solution; this 
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change would be obvious in NMR spectra on the complex, which display comparable line 
widths and chemical shifts in both complexes (figure 5.17).  
It was observed by DSF that the ΔTm of HBS myoA is slightly lower than WT myoA, although 
a sharpening of the melting transition was also observed suggesting a compact, well-folded 
complex that undergoes highly cooperative thermal unfolding. Despite the lower ΔTm, the 
apparent Ki observed by FRET suggested a slight increase in affinity. In terms of the 
structure, the main features are very similar to the WT complex except for a clear kink in the 
middle helix α5 (figures 5.24 and 5.28) adjacent to the HBS tether. This is corroborated by 
the HSQC spectrum of the complex, in which the chemical shifts of amides in this part of 
MTIP are perturbed most from their WT positions (figure 5.17). 
 
 
Figure 5.28 Features of the co-crystal structure of PfMTIPΔ60 with HBS myoA: top left, two protein-peptide 
complexes (green cartoon and surface representation) are found in the asymmetric unit of the structure; top right: 
the hydrogen bond surrogate (HBS) motif is positioned at the N-terminus of the myoA peptide and avoids steric 
clashes in the myoA binding groove; bottom: comparison of the HBS constraint in the crystal structures of an 
isolated HBS helix (CCDC entry 675526, left, white sticks, side-chains removed for clarity) and HBS myoA bound 
to MTIP (centre, orange), together with the chemical structure (right). 
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The conformation of a HBS helix has been previously reported in isolation,176 but to date this 
class of mimetic has not been crystallised in complex with a target protein. The crystal 
structure of HBS myoA bound to MTIP demonstrates that the geometry of a HBS constraint 
can be maintained in the complex, providing the first direct structural evidence that this motif 
pre-organises the helix to enhance interaction with its target. Markedly lower B-factors in the 
HBS helix (see table 5.5) also support the hypothesis that improvement in binding affinity 
over WT myoA may be driven by effective helix stabilisation. Since the HBS constraint is 
positioned at the N-terminus of the helix, steric clashes of the tether with the congested 
MTIP binding groove are avoided, as designed. 
5.3.3 Structural insights for targeting a buried protein-helix interaction 
Comparison of pGly and pAla staples 
As described above and elsewhere in the literature, when targeting a buried protein-helix 
interaction with stapled peptides, the interaction between the staple and the protein is an 
important design consideration, since it must not modulate WT hotspot side-chain 
orientations or change the register of the helix. By contrast, in the type of interaction targeted 
in the literature to date, i.e. largely hydrophobic and surface-exposed, there is far greater 
flexibility for introduction of the staple and mutation of the other peptide residues, and 
therefore greater scope for improving on the WT affinity. This was illustrated with the recent 
crystal structure of the oAla-pAla stapled p53-MDM2 interaction,197 in which the authors 
made five amino acid mutations (plus introduction of the staple) in improving the KD for 
MDM2 binding from 410 nM (WT) to 55 nM (SAH-p53-8). In making this eight-fold 
improvement, the register of the helix was shifted dramatically as the staple engaged in 
interactions with hydrophobic sites on MDM2. One structural comparison of two different 
stapled peptide complexes has been published to date, again targeting a surface-exposed 
interaction. In that study, the authors demonstrated 2.5-fold and 7-fold increases in affinity 
relative to WT, and co-crystal structures revealed that the staple again perturbs the register 
of the helix.194 
Biophysical analysis showed that pGly stapling is better tolerated in the MTIP-myoA 
interaction than staples based on alkenyl alanine derivatives. Crucially, despite engaging in 
productive interactions, the pGly staples do not affect the register of the helix as observed in 
other structures, and therefore they do not interfere with key protein-helix interactions. 
Analysis of the binding pocket supports the hypothesis that pAla stapled myoA peptides bind 
less tightly on the basis of steric hindrance; when the MTIP clamp forms, the central binding 
groove is highly congested and replacement of Hα by methyl groups is not well-tolerated. 
For example, the side-chain functionality of conserved myoA hotspot residue Gln808, which 
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makes an array of polar contacts with MTIP residues Leu168, Trp171 and Asp173, would 
clash with an α-Me group on the i˗3 residue (figure 5.29). Likewise, the key role of the 
conserved residue His810, which interacts with Asp139 in the MTIP interdomain linker, may 
be compromised by pAla substitution of Val807 (also i-3 relative to the modification site).  
 
Figure 5.29 Potential for steric clash of pAla staples with i+3 residues in a buried protein-helix interaction, using 
the co-crystal structures of MTIP with pGly[801,805] and pGly[807,811] as illustrative examples. The side-chains 
of myoA hotspot Q808 (left) and H810 (right) would clash with an α-methyl group on residue 805 or 807. 
However, in case of pGly stapling, Q808 and H810 can pick up native interactions with MTIP. 
 
The hypothesis is supported by the observation that pAla[811,815] is the least disruptive 
pAla staple (highest ΔTm by DSF, and lowest IC50 by FRET); in this peptide the i+3 residues 
are unconserved residues Lys814, which makes an interaction with the flexible MTIP C-
terminus (Gln204), and Gln818, which is dispensable. Therefore, the α-Me group may be 
better accommodated at positions 811 and 815. These results suggest that at a buried 
protein-helix interaction site, carefully designed pGly staples may represent a more 
successful strategy than pAla analogues. 
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Although the pGly staples are sterically less demanding than pAla analogues and may 
confer comparable resistance to proteolysis and helical propensity, some backbone flexibility 
appears to be permitted. Further evidence for this can be seen in the mixture of cis/trans 
isomers upon ring-closing metathesis of the pGly-substituted peptides, and – in the 
pGly[801,805] structure – higher than average B-factors for the atoms on the ‘801’ side of 
the staple compared to the ‘805’ side (24.4 Å2 and 16.7 Å2 respectively), suggestive that the 
pGly staple is not rigid across its entire length. The importance of this rigidity in cell 
penetration is not clear, but as discussed above, excessive rigidity in the constraint may in 
some cases be detrimental to protein binding since it may lock the peptide in an 
unfavourable conformation. It could also be that this is the root of the lower affinity of the 
pAla stapled myoA peptides. 
Employment of a HBS constraint 
It has been predicted that the HBS strategy is suitable for targeting buried helix interactions 
by remotely reinforcing existing interactions, without interfering with a complex multi-face 
helix binding interface. The results and structure presented above experimentally validate 
this prediction. 
5.4 Conclusions and perspectives 
5.4.1 Insights for Plasmodium biology 
 Although no new insights have been gained on Plasmodium parasite biology in this 
chapter, there is significant potential for the molecules reported above to be used as 
tools to investigate myoA function in living parasites. Although constrained peptides 
have not yet been used in the field of parasitology, there is precedent for both stapled 
peptide analogues and HBS helices to be used in a variety of other cellular contexts, 
as described above. Whether the molecules reported above are able to efficiently 
access the target site in intracellular parasites (by passing through e.g. the plasma 
membranes of both red blood cells and merozoites) will clearly be a key limiting 
factor in the use of constrained myoA tail peptides to disrupt the MTIP-myoA 
interaction, but it has been shown elsewhere that this property may be rationally 
optimised. If this goal can be met, the affinity of the constrained analogues should be 
sufficient to disrupt the interaction and thereby block myoA attachment to the inner 
membrane complex. Once validated, it should be possible to use such tool molecules 
to induce a temporally-controlled, chemical myoA ‘knockdown’ without recourse to 
altering the parasite at the genetic level; further, it could be envisaged that this 
experiment could be performed at different points in the Plasmodium life cycle. 
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5.4.2 Insights for inhibitor development 
 As described above, a number of new insights have been provided by the design and 
structural analysis of constrained myoA tail peptides into targeting buried protein-
helix interactions in general and the MTIP-myoA interaction in particular. The 
molecules reported above represent the first examples of stapled and hydrogen bond 
surrogate (HBS) peptides designed to disrupt a buried PPI in which the target protein 
not only discriminates for functionality presented by all faces of the myoA helix, but 
also forms a tight clamp around the ligand to include the helix in its hydrophobic core. 
As a result of these features, alkenyl alanine stapling approaches did not lead to 
improvements in affinity over the WT sequence. In contrast, myoA mimics containing 
mono-substituted pentenyl glycine (pGly) staples or an N-terminal HBS motif provide 
a means to constrain the myoA helix without disrupting native side-chain interactions, 
resulting in peptides that match or improve on WT affinity. 
 In order to optimise the cell penetration properties of other stapled peptides, 
mutations in sequences have been made chiefly to introduce positively charged 
amino acids and/or remove unnecessary negative charge, with the expectation that 
this will facilitate productive interactions between the peptide and membrane bilayers. 
The myoA tail does not contain any negatively charged residues in the MTIP binding 
sequence; however, it may be necessary to optimise the length and/or add extra 
positive charge to the constrained analogues in order to maximise the penetrative 
capacity of the molecules. 
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Chapter 6 Fragment-based approaches towards MTIP-myoA inhibitors 
There is a growing recognition that protein-protein interactions may be ‘druggable’ i.e. 
targeted by small molecules, and fragment-based approaches have had some success in 
this area. With a number of biophysical assays established to measure binding to MTIP and 
an understanding of the key MTIP-myoA interaction hotspots that might usefully be targeted, 
this chapter reports the results of a screen of the Maybridge Ro500 fragment library against 
MTIP. Differential Scanning Fluorimetry is used as the initial hit identifier i.e. searching for 
compounds capable of stabilising MTIP with respect to thermal denaturation. Hits are 
verified and false positives discarded on the basis of the analysis of 1H, 15N- HSQC spectra 
of 15N-labelled MTIP spiked with different compounds, which also enables approximate 
binding site determination. The subsequent development of one particular hit compound is 
also described, including the crystal structure of a tethered peptide-fragment ‘chimera’. 
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In contrast to chapter 5, which focused on the development of constrained peptidic myoA 
mimics as tools to modulate the MTIP-myoA interaction, the work described in this chapter is 
focused on the initial, de novo identification of low molecular weight compounds that may be 
developed into small molecule MTIP-myoA inhibitors. Due to a combination of several 
features of protein-protein interactions (PPIs), particularly the large interfacial surfaces 
(typically 750-1500 Å2;211 ~2400 Å2 in the case of the MTIP-myoA tail interaction) and the 
lack of natural small-molecule ligands as starting points, PPIs have historically been 
considered outside the remit of conventional drug discovery. However, fragment-based 
strategies, which will be outlined below and initially succeeded for more traditional enzyme 
targets, have emerged as a generic approach for a number of challenging targets including 
protein-protein interactions (PPIs). 
6.1 Fragment-based drug discovery (FBDD) 
The workflow of a typical fragment screening campaign is shown in figure 6.1. In contrast to 
more traditional high-throughput screening (HTS) approaches, in which very large 
(~106-member) libraries containing compounds of ~500 Da are screened for high (nM-µM KD 
or Ki) affinities towards the target, fragment screening searches for small (<300 Da), weakly-
binding (µM-mM) molecules.212 Since the hit rates may be much higher than for high-
throughput screens, the libraries are smaller (102-103 members) but consist of chemically 
diverse scaffolds that have precedent in existing drugs. Library design is an important 
feature of this technique213 and is constantly evolving.* Despite the low free energies typically 
associated with fragment binding to the protein target, their small molecular size can 
translate into a high ‘ligand efficiency’ (binding energy in kcal mol per non-hydrogen atom). 
The hits therefore represent high-quality starting points for rational design and medicinal 
chemistry and it is this efficiency that is the emphasis of FBDD (in contrast to HTS, where 
potency is the emphasis).214-216 The workflow is heavily reliant on biophysical and structural 
information throughout in order to first identify and validate initial hits, and then inform their 
elaboration into more potent molecules that may be bioactive.212 
The weak binding of fragments gives rise to a number of experimental requirements. Firstly, 
the members of a fragment library must be soluble to a high concentration, which is itself an 
advantage in relation to subsequent development.216 Secondly, specialised methods of 
detection are required.217 The chosen method depends absolutely on the protein target – 
particularly (i) whether it may be produced in large amounts, (ii) its purity/solubility and ease 
of crystallisation and/or suitability for different NMR experiments, (iii) its domain structure.  
                                                     
*
 For example, the pharmaceuticals company Astex was on its sixth-generation library as of January 
2013. 
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Figure 6.1 Overview of fragment-based drug discovery. All the images are from this research except for the 
fragment electron density map which is reproduced with the permission of Prof. David Stout, Scripps Research 
Institute, CA, U.S.A. and the EC50 plot which comes from Bosch et al.
55
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Thermal shift (DSF), surface plasmon resonance (SPR), ITC, ligand- and protein-detect 
NMR spectroscopy and X-ray crystallography have all been employed to initially screen 
fragment libraries. These biophysical techniques are compared in Table 6.1. 
 
Table 6.1 Comparison of some different biophysical methods widely used in fragment screening. [a] Typical 
relative throughputs are shown for an academic laboratory; automation (e.g. by using NMR sample changers or 
specialised crystallographic software/workflows) may increase throughput. [b] KDs that are routinely measured 
are given but these values are highly dependent on the protein; exceptions to these values exist (e.g. ITC may be 
used to measure mM binding, but it is usually experimentally challenging and a reporter ligand may be required). 
[c] The ligand-detected NMR methods considered are STD NMR, Water-LOGSY and CPMG experiments (see 
main text for details). 
 
The screening of the fragment library usually relies on a combination of several biophysical 
and structural techniques. This should have the combined benefit of reducing the number of 
false positive hits and gaining complementary information from different experiments. A 
variety of combinations have been used; this is highly dependent on different features of the 
target protein and on the availability of instrumentation/expertise. The techniques are briefly 
outlined in relation to their usefulness in screening fragments below. 
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Differential Scanning Fluorimetry  
DSF, introduced in chapter 3, is an inexpensive and simple technique that can be performed 
on a fragment library of 1,000 compounds within a week once conditions and workflow are 
optimised. Although this optimisation is necessary, it is usually a straightforward task; 
however, proteins in which multiple folded domains exist may present a complex unfolding 
curve and thus complicate analysis of binding. In general, the interpretation of results from 
DSF requires some care; for example, binding of hydrophobic fragments that is mainly 
driven by entropy tends to give larger Tm shifts. Nonetheless, compounds that result in no 
change or a negative thermal shift (ΔTm ≤ 0) may be discarded and those that cause positive 
thermal shifts (ΔTm >0) retained
* and ranked.  The presence of false positives may be 
detected in the subsequent validation phase. 
Isothermal Titration Calorimetry 
ITC provides a full set of thermodynamic parameters but in the context of weak protein-
fragment interactions, it may be experimentally challenging due to (i) the requirement of a 
very high protein concentration and (ii) the requirement of DMSO to solubilise the high 
concentrations of fragment molecule, with associated artefacts. Further, it is low throughput 
and for these reasons not appropriate for an initial fragment screen. However, it may be 
appropriate for validation and, along with crystallography, would be the gold standard at the 
characterisation stage. 
Surface Plasmon Resonance 
SPR usually involves immobilising the protein on the sensor chip (e.g. via an affinity tag) and 
injecting the fragment solution across the surface. Changes in the refractive index at the 
surface due to the protein-fragment interaction are detected. While it may be used in the 
initial screen (and can, unlike DSF,† directly provide dissociation constants), SPR may 
require a significant amount of optimisation and expertise. 
Ligand-detected NMR spectroscopy 
Numerous ‘ligand-detect’ 1D NMR methods for screening protein-fragment interactions have 
been reported, which provide a label-free and medium-throughput method for identifying 
binders in a library.218,219 A CPMG-type experiment is conceptually simple in that it relies on 
the slower T2 nuclear relaxation rates of a fragment molecule tumbling rapidly in solution 
                                                     
*
 Assuming zero error in the measurement; in practice it is important to define a hit as significant 
based on the standard deviation of the assay (see below). 
†
 Calculation of KDs from Tms is possible but requires an accurate value for the enthalpy of unfolding.  
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compared to when it is bound to a slow-tumbling protein. By delaying acquisition of the 
spectrum, a filter is introduced that removes, or broadens, the NMR signals of molecules 
exhibiting fast relaxation (due to transient association with the protein). Saturation Transfer 
Difference (STD) NMR experiments are more complex, but basically involved the transfer of 
magnetisation from the protein (by saturating protein-specific resonances, e.g. ring current 
shifted methyl protons at <1 ppm) to bound fragment molecules via the NOE; transfer will 
only occur when the fragment is bound.220 Water-ligand observed via gradient spectroscopy 
(waterLOGSY) is a variant in which the transfer of magnetisation to the ligand takes place 
from water molecules in the solvation shell of the protein.221 These techniques require 
optimisation but can be used to screen large numbers of fragments reliably and quickly, 
particularly since cocktails of different fragments may be screened simultaneously and 
deconvoluted subsequently (provided they exhibit non-overlapping NMR spectra and are 
soluble in combination). Such methods have had considerable success in both academia 
and industry; however, because all of the three experiments discussed rely on the difference 
in tumbling regimes between the protein and the solvent/fragment, they all work best for 
large, globular proteins (>30 kDa) and are less suitable for smaller and/or highly dynamic 
proteins. 
Protein-detected NMR spectroscopy 
The use of ‘protein-detect’ NMR experiments to measure ligand binding events has been 
exemplified extensively in previous chapters and requires the isotopic labelling of the protein 
and assignment of its spectra (usually the 1H-15N correlation spectra that report on backbone 
amides,222 but 1H-13C correlations may also be used to report on methyl side-chains).223 The 
peptidic myoA ligands reported tended to have high (nM) affinity for the protein target, but 
NMR chemical shifts are also sensitive to weaker (mM) interactions. Although low-
throughput and therefore more suitable for validation rather than identification of fragment 
hits, these methods have the added advantage of providing binding site information via 
chemical shift perturbation mapping. In order to develop the potency of hit molecules, it is 
virtually essential to have structural information,212 ideally in the form of high resolution X-ray 
crystal structures since NMR alone does not usually provide sufficient accuracy with respect 
to the fragment bond vectors unless a structure of the complex is calculated.*  
X-ray crystallography 
Fragment libraries can be screened directly by high-throughput crystallography if ‘soakable’ 
crystals of the target are easily produced, but the resources required mean that this strategy 
                                                     
*
 These points were emphasised in a talk by Dr. Elisabetta Chiarparin (Astex pharmaceuticals) at the 
12
th
 annual Collaborative Computing Project for NMR (CCPN) conference, 2012. 
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will usually be beyond the capacity of an academic laboratory. For example, for 13 different 
targets worked on by Astex pharmaceuticals between 2001 and 2009, a total of 2,462 X-ray 
structures were solved with crystallography being used as the primary screening method. 
Although this is an exceptional case, crystallography remains an essential way of validating 
and characterising fragment binding to proteins for virtually all projects.  
The suitability of different techniques for each stage of a fragment screening cascade is 
summarised in table 6.2. 
 
Table 6.2 Traffic light representation of the suitability of different biophysical techniques for different stages of a 
fragment screening cascade in an academic laboratory, assuming that the protein allows for all techniques and 
the equipment is available; green = highly suitable, red = not suitable, amber = suitable but with exceptional 
requirements of time/experimental design/resources. 
 
Detailed structural information allows rational development of the fragment scaffold 
(fragment ‘growing’ or ‘merging’), thereby avoiding recourse to the synthesis of large libraries 
of molecules. If adjacent binding sites are found, fragment ‘linking’ may also be an option.215 
6.1.1 FBDD against PPI targets 
Enzymatic drug targets are often characterised by well-defined ligand pockets that may be 
engaged by small molecules, either using FBDD224 or more traditional methods based on 
mimicking natural ligands, ‘piggy-backing’ on existing drugs for related targets or developing 
high-throughput screening hits. By contrast, non-enzymatic proteins do not tend to present 
defined, deep pockets when interacting with partner proteins and as such PPI targets are 
considered to be challenging drug targets, which were historically avoided by mainstream 
pharmaceuticals. In general, the interacting surface is large and therefore cannot be 
occupied in its entirety by small molecules. However, the recognition – via mutational and/or 
biophysical studies – that particular protein-protein contact(s) and associated pockets may 
account for a large proportion of the binding free energy (i.e. interaction hotspots) has 
provided a focus for drug discovery efforts, including those employing fragment-based 
strategies. Below, two examples of targeting of PPIs by fragment screening are discussed. 
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Although both are from the field of oncology, the projects reflect two different strategies, are 
at different stages of development, and come from industrial and academic laboratories 
respectively. 
ABT-263 (navitoclax): targeting Bcl-xL225 
 
Figure 6.2 Structure-guided development of ABT-263 (Navitoclax) by Abbott Laboratories. Two fragment hits 
bind with low affinity to adjacent sites on Bcl-xL, as shown by the ternary complex NMR structure (top, pdb code 
1YSG).
226
 By tethering of this fragments and subsequent elaboration, the potency was greatly increased leading 
to the clinical candidate (bottom; shown is the co-crystal structure of ABT-263 binding to the homologous pocket 
with Bcl-2, pdb code 4LVT).
227
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The pro-survival mitochondrial protein Bcl-xL was introduced in chapter 5 as an anti-cancer 
target for which stapled and hydrogen bond surrogate helical peptides have been 
developed. Abbott Laboratories have successfully applied fragment-based approaches to 
target the PPIs of the same protein. The interaction is mediated by a hotspot groove on the 
surface of the protein where BH3 peptides bind. Using protein-detected NMR experiments to 
find fragments (1 and 2) that bind to this groove from a library of ~10,000, two hits were 
found to bind at adjacent sites with low affinity (figure 6.2). Remarkably, a ternary NMR 
structure was determined between the protein and the two fragments.226 Structure-activity 
relationships were established for the two fragments (‘SAR by NMR’)222 which were initially 
joined via an alkene linker, giving a compound 3 with single-digit micromolar affinity. 
Optimisation of this linkage increased the potency substantially and structure-guided 
elaboration of the molecule at several sites finally produced ABT-263 (navitoclax) with sub-
nanomolar potency. This molecule, although large (MW 975 Da), has progressed to phase II 
clinical trials for leukaemia and is the most advanced example of FBDD applied to PPIs. 
Fragment screening against the BRCA2-RAD51 interaction228 
Researchers from the Abell and Hyvönen groups have recently reported identification of 
fragments that bind at the interface between recombinase RAD51 and tumour suppressor 
BRCA2 (breast cancer 2 susceptibility protein), a PPI that is important in the repair of DNA 
double strand breaks and thus the sensitivity of cells to radiation and/or genotoxic drugs. By 
humanising a recombinant RAD51 orthologue (RadA from Pyrococcus furiosa), a 
monomeric, soluble protein was produced that was appropriate for fragment screening. The 
structure of RAD51 in complex with a BRC repeat from BRCA2 shows a hotspot of the 
interaction in which a Phe side-chain points into a pocket on the surface of RAD51 (the ‘Phe 
pocket’, see figure 6.3). Initial screening of 1,249 fragments by DSF yielded a remarkably 
low hit rate of ~0.2%, where a hit was defined by a ΔTm > 1° (two standard deviations). The 
binding of the two hits that gave the largest thermal shifts were validated by ITC and soaked 
into crystals of humanised RadA; both were found to be buried in the Phe pocket in slightly 
different orientations. The authors report a subsequent screen using one of the initial hits 
(5-hydroxy indole) as a ‘reporter’ ligand for competitive STD NMR experiments, to identify 
more compounds that bound to the same site. Using this method, more hits were identified 
and several were subsequently validated and their binding affinity/mode characterised using 
ITC and X-ray crystallography, respectively (figure 6.3). The research provides a solid 
biophysical and structural foundation to guide efforts to increase the potency of the 
molecules, with the goal of producing a tool compound or therapeutic capable of disrupting 
the interaction inside cells. 
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Figure 6.3 Workflow of fragment screening against the BRCA2-RAD51 PPI from an academic laboratory, using a 
combination of thermal shift (differential scanning fluorimetry, DSF), saturation transfer difference (STD) NMR, 
ITC and X-ray crystallography to identify, validate and characterise hit fragments. 
 
6.1.2 Fragment screening against MTIP-myoA: some considerations 
A protocol from the Abell group was published recently suggesting a three-step triage of 
screens suitable for efficient fragment selection, i.e. (i) initial screening by DSF, (ii) validation 
by ligand-detected 1D NMR experiments and (iii) characterisation of interaction by ITC and 
X-ray crystallography.217 However, the selection of techniques will depend to a large extent 
on the system under study and on the resources and expertise available to the laboratory. 
The MTIP-myoA tail interaction is a highly challenging and unusual target for FBDD and its 
structural and dynamic features that were reported in chapter 3 give rise to a number of 
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considerations when designing a fragment screen against this PPI. These are summarised 
below. 
 
Figure 6.4 Structural features of the MTIP-myoA tail interaction. Shown is the crystal structure (PfMTIPΔ60 
shown as white cartoon and white surface, shaded by a white-red ramp according to chemical shift perturbations 
induced by binding to PfmyoA(799-818), which is shown as black cartoon and sticks). Thermodynamic 
parameters and notable features of the structure are indicated. 
 
Hotspots of the interaction with the myoA tail 
The NMR chemical shift perturbation (CSP)-based interaction hotspots for the interaction of 
PfMTIPΔ60 with the myoA tail peptide PfmyoA(799-818) were reported in chapter 3 and are 
reproduced in figure 6.4. Although spread across the myoA binding groove and present in 
both domains, there are several clear sites of elevated CSP that suggest important inter- and 
intra-molecular interactions. For instance, the hydrophobic groove created by the bundling of 
helices in the C-terminal domain and parts of the interdomain linker and connected helix α5 
are all particularly highlighted by the analysis. However, the most perturbed residues are 
those involved or proximal to the Ser108-Asp173 clamp; this structural feature was further 
validated as essential to the tight MTIP-myoA interaction by the data presented in chapter 4 
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on phospho-mimetic mutation of residues Ser107 and Ser108 to Glu. Fragments that bind to 
MTIP at any of these ‘hotspot’ sites or whose binding mode could compromise these various 
interactions may be of particular interest. 
Domain dynamics of MTIP 
From the detailed investigation into the dynamics of free and myoA-bound MTIP presented 
in chapter 3, it is clear that there is conformational flexibility on different timescales in the 
domains of the unbound state that is quenched in the presence of the myoA tail peptide. The 
change between free and bound state dynamics is likely associated with the coming together 
of the two domains to clamp around the helical myoA tail, with concomitant rigidification of 
the interdomain linker and adoption of the MTIP clamp via Ser108-Asp173 hydrogen 
bonding. In the free state, it appears from the relaxation parameters of backbone 15N nuclei 
that it is the C-terminal domain that is more flexible and therefore where the most drastic 
changes occur upon myoA tail recognition. Despite the modest differences in secondary 
structural elements between free and bound states according to chemical shift indexing, the 
combined biophysical data from chapter 3 point to a situation in which only the N-terminal 
MTIP domain has well-defined tertiary structure in the absence of the myoA tail.  
These features are important in the fragment screening strategy in several ways: 
(i) The fold and dynamics of the C-terminal domain may lead to complication of 
analysis, for example using DSF, since the hydrophobic residues that form a core 
via complexation with the myoA tail are solvent-exposed in free MTIP. 
(ii) 1D ligand-detected NMR screening methods are likely to be inappropriate for 
monitoring fragment binding to free MTIP, since the motions of the protein are not 
uniform across the entire sequence. Further, the small size and independent 
tumbling/dynamics of the individual domains may not give the requisite change of 
correlation time that these techniques rely upon. 
 
Inability to crystallise free MTIP 
As described in chapter 3, it has not been possible to crystallise MTIP in the absence of the 
myoA tail and as such fragment soaking experiments are not possible. Since the below data 
were acquired, a nanobody has been used as a crystallisation chaperone for the C-terminal 
domain of MTIP, which, as the authors of that study point out, opens up future possibilities 
for soaking experiments with small molecules.126 However, it is not yet clear whether the 
protein structure in complex with the nanobody (figure 6.5, pdb code 4GFT) is physiologically 
relevant and as such whether molecules that may be identified in this way would adopt the 
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same binding mode in the context of an isolated MTIP construct in solution. For instance, 
electron density is missing for key residues Gly172 and Asp173 in the loop connecting 
helices α6 and α7. 
 
 
Figure 6.5 1.6-Å crystal structure of the PfMTIP C-terminal domain (CTD, residues Asn140 to Gln204, shown as 
white cartoon and surface) bound to a nanobody crystallisation chaperone (yellow).
126
 
 
Clamping of the myoA tail is highly entropically disfavoured 
ITC data showed that the entropy change upon MTIP-myoA tail complexation is large and 
negative (-98 J/K.mol), as may be expected from comparing the backbone dynamics of the 
free and bound states. The buried protein-helix interaction is nevertheless tight (KD = 85 nM), 
particularly compared with many other surface-mediated PPIs, because the very large 
enthalpy change upon binding and clamping of the myoA tail more than compensates for the 
associated loss of entropy in the system. Since it is not feasible for a small molecule to 
occupy the large myoA binding groove with the same array of (enthalpically-favourable) 
interactions on all faces of the helix, allosteric modulation of the entropically-disfavoured 
MTIP clamp may represent an attractive strategy for disruption of the complex. 
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6.2 Identification of fragments that bind to MTIP 
6.2.1 Strategy for MTIP fragment screen 
Maybridge Ro3 fragment library 
The Maybridge Ro3-500 fragment library was selected, which contained 500 compounds 
representing a sub-set of the full library. Structural diversity and rule-of-three compliance 
was assured by the supplier i.e.: 
(i) MW ≤ 300 Da (mean value 178.3 Da) 
(ii) ClogP < 3.0 (mean value 1.5) 
(iii) ≤ 3 hydrogen bond donors acceptors (mean values 0.9 and 2.4, respectively) 
(iv) ≤ 3 rotatable bonds (mean value 0.9) 
Furthermore, the chemical purity (>95%) and solubility of all the fragments (200 mM in 
DMSO; 1 mM in neutral phosphate-buffered saline), were guaranteed. 
Triage of assays 
As described above, ligand-detected NMR methods were deemed to be unsuitable for the 
target protein PfMTIPΔ60. Furthermore, the resources required for screening by SPR were 
unavailable. Thermal shift by DSF was therefore selected as the initial screening method. 
This was to be followed by protein-detected NMR experiments to validate the initial hits and 
determine approximate binding sites, since expression of isotopically-enriched protein was 
sufficient (5-10 mg per litre of bacterial culture) and assignment of the HSQC spectrum of 
the free protein was essentially complete as reported in chapter 3 (figure 3.6). 
6.2.2 Initial screen by DSF 
Procedure and plate layout 
The method and workflow for handling of the fragment library is explained in table 6.3. The 
tracing of hit fragments to an original ‘coordinate’ in the storage plates was a convenient way 
of keeping track of compound identities, so care was taken in the first liquid handling step to 
manually transfer all 500 compounds into 96-well plates and keep a record of these 
coordinates. Thereafter, the fragments would remain in the same coordinate of the 96-well 
plate through each subsequent liquid handling step and experiment. The assay procedure 
was first validated using a ‘test’ (plate 1) of 60 compounds and then repeated for the 
remaining compounds (5 plates each containing 88 compounds; layout shown in figure 6.6) 
in duplicate. 
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Table 6.3 Workflow of fragment library handling for the initial DSF screening. [a] test plate, see main text. 
[b] Buffer contained 20 mM HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP. [c] 5 µM PfMTIPΔ60, 10 x SYPRO 
orange. 
 
 
Figure 6.6 Plate layout for DSF fragment screening experiments. Experiments were run between 15-80 °C in a 
Mastercycler ep realplex real-time PCR machine (Eppendorf). 
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Data analysis 
The melting curves were analysed using a customised MS Excel spreadsheet developed by 
Dr Frank Niesen (Structural Genomics Consortium, Oxford, U.K.), who kindly adapted the 
spreadsheet to tolerate raw data arising from the Eppendorf real-time PCR instrument used. 
Prof Robin Leatherbarrow (Institute of Chemical Biology, Imperial College) further adapted 
this spreadsheet to incorporate a plug-in for GraFit in order that the Tm curves may be 
quickly fitted in parallel (figure 6.7). 
 
Figure 6.7 Example screenshots from the adapted ‘DSF Analysis’ spreadsheet used to analyse the thermal shift 
data. 
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Results of initial screen 
The error associated with the DSF screen was estimated by taking the standard deviation of 
the control sample Tms i.e. the negative control (5 µM PfMTIPΔ60 + 1% DMSO) and the 
positive control (5 µM PfMTIPΔ60 + 200 µM PfmyoA(803-818)). Across the 48 
measurements of these samples (four wells in each of six plates, run in duplicate), the 
standard deviations for these measurements were 0.43 and 0.52 (to two decimal places). 
Using the two standard deviation cut-off reported for the screen against humanised RadA, 
the data for the screen against PfMTIPΔ60 gives a similar cut-off value of 0.8-1.0 °C, 
depending on which set of control data are used.  
The results for the fragment library are shown in table 6.4, using a cut-off of 1.0 °C to define 
a positive ΔTm. The initial screen of 500 compounds was run in duplicate and the results are 
shown for ‘Set A’ and ‘Set B’. 
 
Table 6.4 Overall results of initial fragment screen of the Maybridge Ro3 500 library using DSF, run in duplicate. 
 
It can be seen that the hit rate using this cut-off is remarkably high (~26%). It has been 
recognised elsewhere that entropy-driven hydrophobic interactions generally results in a 
large ΔTm.
153 Given the presence of exposed hydrophobic patches in the MTIP C-terminal 
domain, as discussed above, the high hit rate is perhaps less surprising than were the result 
obtained for a well-folded, globular protein. Nonetheless, it was decided in view of the 
primary data to increase the threshold to 2.0 °C in defining an initial hit. Furthermore, given 
that the screen had only been run in duplicate and there was some variability between the 
two datasets, the hits were retested using DSF to improve confidence in the measured 
values. From 500 compounds, 40 were selected (that showed ΔTm > 2.0 °C in both Set A 
and B) for retesting.  
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The following DSF experiments to measure fragment binding were done with the assistance 
of Zhang Wenlin (NTU Singapore).229 The selected 40 compounds were rerun four times 
using the same DSF assay protocol along with the same control sets (1% DMSO and 
200 µM PfmyoA(803-818)) and four additional ‘negative control’ fragments that had shown 
no binding (1.0 °C ≥ ΔTm ≥ -1.0 °C) in the initial screen. Of these 40 fragments, 15 were 
discounted upon retesting as they displayed a ΔTm < 2.0 °C or inconsistent results (standard 
deviation > 1.0 °C), 10 gave ΔTms between 2.0-4.0, and 15 gave ΔTms > 4.0 °C consistently. 
The latter 15 fragments (for which the data are summarised in table 6.5 and figure 6.8) were 
selected for further testing; future work could investigate further the binding properties of the 
10 other confirmed hits (table 6.6). The negative control fragments were all confirmed to 
bring about insignificant thermal shifts, as expected (table 6.7 and figure 6.9). 
Substituted aniline 1 (CC21914) and 4-phenoxyphenol 2 (BTB14064) caused the largest 
thermal shifts of the library with remarkable ΔTms of +10.3 °C and +9.0 °C – five and six 
degrees lower respectively than the positive control PfmyoA tail peptide despite its being an 
order of magnitude smaller in molecular weight. Notably, 1 induced a very slight sharpening 
of the melting transition. Of the other fragment hits, only di-substituted furan 8 (SB01748) 
obviously changed the slope of the melting transition; this molecule caused a drastic 
sharpening of the curve, suggesting a significant change in the dynamics of MTIP unfolding 
in its presence. Of the top 25 fragments, seven (1, 3, 9, 14, 17, 18 and 25) contained one 
amine that is predicted * to bear a positive charge at the assay buffer pH (7.5) with a further 
two compounds (8 and 24) containing two positively charged amines. By contrast, only one 
fragment hit (13) is predicted to bear negative charge, with the remaining 15 hits neutral or 
largely uncharged at this pH. PfMTIPΔ60 has a predicted isoelectric point of 4.4,† and the 
predominance of negative charge on its surface suggests the above over-representation of 
amines may be expected. Otherwise, it is difficult to pick out obvious trends or structure-
activity relationships (SARs) for the hit compounds, and excessive interpretation of the 
precise values of the ΔTms was deliberately avoided. 
 
 
                                                     
*
 Using the pKa tool in ChemAxon MarvinView version 6.1.6 
†
 Using http://web.expasy.org/compute_pi/ 
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Table 6.5 DSF data for 15 best fragment hits (named according to Maybridge Ro3 500 library codes), with their 
chemical structures and molecular weights. 
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Figure 6.8 Representative, normalised melting curves for PfMTIPΔ60 (5 µM) in the presence of 1% DMSO (grey) 
and 2 mM of various fragment hits.  
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Table 6.6 DSF data for 10 next best fragment hits (named according to Maybridge Ro3 500 library codes), with 
their chemical structures and molecular weights. 
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Table 6.7 DSF data for four negative control fragments (named according to Maybridge Ro3 500 library codes), 
with their chemical structures and molecular weights, and for the positive control PfmyoA tail peptide. 
 
 
 
 
Figure 6.9 Representative, normalised melting curves for PfMTIPΔ60 (5 µM) in the presence of 
1% DMSO (grey), 2 mM of various negative control fragments and 200 µM PfmyoA(803-818) (black). 
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6.2.3 Fragment ‘titrations’ by DSF 
It was of interest to investigate whether the stabilisation of PfMTIPΔ60 observed in the initial 
DSF screen (where the [fragment] was 2 mM) was dependent on the concentration of the 
fragment. Therefore, ‘titration’ experiments were performed (in collaboration with Zhang 
Wenlin), in which fragment concentrations were varied from 125-2000 µM. Interestingly, 
several types of behaviour were observed as illustrated in figure 6.10. For some fragment 
hits, the stabilising effect was saturable i.e. ΔTm increased with fragment concentration and 
reached a maximal value. Stabilisation by several other hits showed a linear variation and 
some showed a marked jump to a large ΔTm at high concentrations but were barely or not at 
all stabilising at lower concentrations. However, there were not obvious trends to draw from 
the identity or chemical functionality of the molecule to the type of behaviour seen. The last 
type of behaviour was random, and was evident in the DSF titration experiments with the 
negative control fragments. The data are summarised in table 6.8. 
 
 
Figure 6.10 Examples of four different types of behaviour in DSF ‘titration’ experiments. ΔTms shown are the 
mean value of triplicate experiments, with error bars illustrating ± one standard deviation. For each fragment 
concentration, the ΔTm was referenced to the Tm of a control in which the protein was incubated with the 
corresponding concentration of DMSO (0.0625% at 125 µM fragment, to 1% at 2000 µM). Experiments were 
performed in collaboration with Zhang Wenlin. 
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Table 6.8 DSF titration behaviour (see figure 6.10) for top 15 fragments (blue) and two negative control 
fragments (red), ranked top to bottom in order of mean ΔTm (given in parenthesis in degrees Celsius) from the 
DSF screen.  
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The effect of ligand concentration on protein stabilisation and its relationship with binding 
affinity is complex and has been studied theoretically and experimentally.230,231 It has been 
concluded broadly that for 1:1 protein-ligand binding and a simple two-state unfolding 
transition, ΔTm should correlate reasonably with both affinity and ligand concentration. 
Furthermore, while the change in Tm may increase sharply as the protein is saturated by the 
ligand (particularly for tight binding) the increase of protein Tm with ligand concentration 
should in principle continue after the protein (in its native state) is fully saturated.230 
However, limits on ligand solubility or increased binding of the ligand to the denatured state 
may result in ‘type 1’ behaviour i.e. a saturation point. The latter effect has been noted as a 
possible source of false negatives in DSF screens, since weak binding to the native state 
may be masked by association with the denatured protein.153,232 Another conclusion – 
working under the same two-state unfolding approximations – is that no significant increase 
in ΔTm should be observed for a ligand at a concentration well below its KD, which may lead 
to type 3 behaviour for weak-binding fragments. On this basis, the best hits should show not 
only give the largest ΔTm at a given concentration, but should display type 1 or 2 behaviour 
in the titration experiment.  
There are several caveats and points to note in relation to the above arguments. Firstly, as 
discussed previously, the ‘foldedness’ of PfMTIPΔ60 at room temperature is complex; the  
protein is highly flexible and the unfolding transition is shallow suggesting that the protein 
may sample a continuum of conformations. As a result, the existing equations modelling and 
predicting the effects of fragment binding to globular proteins in the thermal shift assays are 
likely to be insufficient, and ΔTm may correlate less well with affinity. For instance, it is highly 
unlikely that fragment 1 has an affinity approaching that of the positive control 
PfmyoA(803-818) (KD = 351 nM by ITC) despite comparable ΔTms (+10.1 and +15.3 °C 
respectively). In the case of the peptide binding, a sharpening of the melting curve is thought 
to be associated with a major change in the structure and dynamics of the protein i.e. the 
unfolding energy landscapes of the two protein-ligand complexes is likely to be totally 
different. Secondly, the reversibility of the MTIP unfolding transition is unknown, along with 
the character of the unfolded state of the protein. Thirdly, in relation to ranking the fragments 
on the basis of their behaviour in the titration experiments, the concentrations in the assays 
may be variable due to solubility* and/or inaccuracies in the small (2-6 mg) quantities 
provided in the library by the supplier. A combination of the above concerns underlines the 
particular importance of the validation stage of the screen, which is described in the next 
section.  
                                                     
*
 Some fragments were only partially soluble at 2 mM in the initial DSF screen; however, no solubility 
issues were detected in the follow-up experiments on the hit compounds.  
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6.2.4 Validation of binding by NMR 
‘Spike-in’ HSQC experiments 
Initially, binding of the 15 best fragments to PfMTIPΔ60 was monitored using a single-point 
1H, 15N-HSQC experiment for each compound. The spectra of 50 µM 15N-labelled 
PfMTIPΔ60 were recorded in the presence of 50 molar equivalents (2.5 mM) of the different 
fragments. These were compared to the spectrum of the protein in the presence of 1.25% 
DMSO, to ensure that any CSPs observed were not due to the presence of the solvent used 
to solubilise the fragment stocks. Despite slight changes of chemical shift in the presence of 
DMSO, these were mostly systematic and very minor such that the peak assignments made 
in chapter 3 for free PfMTIPΔ60 could be adjusted accordingly and used with confidence. A 
negative control fragment was also analysed in the same way. The protein concentration 
used was the minimum tolerable concentration for good signal to noise with a reasonable 
(~30 min) acquisition time, so that protein stocks were not wasted. The pH of each of the 17 
samples (15 compounds and 2 controls) was measured before the spectra were acquired, 
since variations in pH may also affect chemical shifts. The NMR samples were prepared 
identically as outlined in table 6.9. 
 
Table 6.9 Preparation of NMR samples for fragment screen validation by 
1
H, 
15
N-HSQC spectroscopy. NMR 
buffer contains 20 mM MOPS pH 7, 50 mM NaCl, 1 mM TCEP. 
 
The data are shown in figure 6.11. 
Figure 6.11 (see next four pages) Overlaid 
1
H, 
15
N-HSQC spectra of 
15
N-labelled PfMTIPΔ60 (50 µM in 20 mM 
MOPS pH 7, 50 mM NaCl, 1 mM TCEP) in the presence of 1.25% (v/v) DMSO (black) and 2.5 mM of various 
fragments (pink). Maybridge codes for the fragments are given and the spectra are presented in order of ranking 
from the initial DSF screen, followed by the negative control (CC50209).  
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Overall, the CSPs observed in most of the protein-fragment HSQCs were surprisingly small 
given the ΔTms obtained, suggesting either very weak interactions or no interactions with the 
fragments. The observations are summarised in table 6.10. Several residues appeared to be 
affected in nearly every sample, underlined by the small peak shifts observed in the 
CC50209 negative control sample (ΔTm = +0.1 °C) for Asp76, Ile133 and Ala149, which are 
presumed not to be caused by a direct interaction. Measuring the pHs of the samples was 
important because chemical shifts are very sensitive to pH in general – and residues lying 
close to the two histidine residues in PfMTIPΔ60 (His136 and His150) may be particularly 
affected. This is because the pKa of histidine’s imidazole side-chain is around 6, so small 
changes in pH will significantly alter the position of the equilibrium between protonated and 
non-protonated forms according to the Henderson-Hasselbalch equation; this in turn will 
affect the local chemical environment and the chemical shifts of nearby nuclei. Two of the 
negative control peak shifts (Ile133 and Ala149) are thus likely due to pH, since the sample 
pH was 7.02 compared to 7.19 for the DMSO control. It is unclear why Asp76, whose amide 
chemical shift is affected in nearly every sample, should be likewise perturbed. 
Unfortunately, the lack of a structure for free PfMTIPΔ60 prevents the mapping of the shifts 
in table 6.10 onto a model of the protein. It is conceivable that Asp76 is close in space to the 
poly(His) expression tag at the N-terminus of PfMTIPΔ60, but it is expected that other peaks 
nearby to Asp76 would also be affected if this were the case. Nonetheless, CSPs observed 
for these three amides were deemed to be non-specific if observed for other fragments.  
The other general point to consider when judging whether observed CSPs are significant 
(i.e. are caused by a direct interaction with the ligand) is whether or not the shifted peaks 
correspond to a contiguous stretch of amides, or amides spatially close to each other. On 
the latter point, it is again problematic that a structure of free MTIP is not available. However, 
proximity in primary sequence may be instructive when taken together with a prediction of 
the secondary structural elements (via chemical shift indexing, see figure 3.10). 
Taking the above points together, several fragments were deemed to have insignificant or 
non-specific direct interactions with MTIP on the basis of the NMR experiments: 1 (CC2914), 
4 (CC27209), 6 (CC20209), 7 (CC40909), 9 (MO00181), 11 (AC12704), 12 (SP00004), 14 
(CC47213) and 15 (SPB02288). Fragment 13 (CC46201), the only acid in the library, caused 
relatively substantial CSPs but these appeared to be associated with the largest pH change 
(6.94) relative to the control sample (7.19); indeed, the largest CSPs were in amides close in 
sequence to His136 and His150. It is not clear as to why so many of the fragments fail to 
interact with MTIP in the NMR experiment but stabilise the protein significantly. It is plausible 
that either the fragments are destabilising the unfolded state or, perhaps more likely, 
stabilise the protein by binding to a semi-folded intermediate conformation of MTIP that is 
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not present (or is present as a minor, invisible conformation in the NMR tube at 303 K). This 
point will be discussed further in the conclusions of the chapter. 
 
Table 6.10 Summary of NMR data for MTIP-fragment complexes. The pHs of the NMR samples and CSPs 
arising in each spectrum are listed according to the peak assignments reported in chapter 3. [a] According to the 
analysis shown in chapter 3. 
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Of the remaining fragments, the largest CSPs in MTIP were caused by 8 (SB01748), the 
compound which caused not only a positive ΔTm by DSF (+5.6 °C), but also a notable 
sharpening of the melting transition. The CSPs of 8 mainly localised to the C-terminal 
domain of MTIP and were of particular interest as the affected peaks included amides from 
several MTIP-myoA hotspot residues, of which a number were in a contiguous section of the 
protein (e.g. Leu168, Trp171, Gly172, Asp173, Ala 174, and Thr176). Therefore, another 
NMR experiment was carried out in which aliquots of 8 were added to a solution containing 
15N-labelled PfMTIPΔ60 in complex with three molar equivalents of PfmyoA(799-818). No 
CSPs were observed at 35 molar equivalents of fragment, supporting the notion that 8 binds 
to a part of MTIP that is engaged in interactions with the myoA tail (figure 6.12, left). At 100 
equivalents, minor CSPs were observed. The same experiment was performed with 3 
(CC40996), which was shown in the initial NMR experiments on ‘free’ MTIP to cause CSPs 
in several residues of the N-terminal domain far from the myoA binding site. At 35 molar 
equivalents, clear CSPs were observed suggesting that the interaction was not competitive 
with the myoA tail (figure 6.12, right).  
 
Figure 6.12 Testing fragment binding to a preformed MTIP-myoA complex. Overlaid 
1
H, 
15
N-HSQC spectra of 
100 µM 
15
N-labelled PfMTIPΔ60 in complex with 300 µM unlabelled PfmyoA(799-818) (black) with the addition of 
~35 molar equivalents of fragment SB01748 (red, left) or CC40996 (cyan, right). 
 
Interestingly, these localised both to a region in the N-terminal domain (including Leu68, 
Glu69, Glu74 and Asp76) and another region in the C-terminal domain (Ile181, Ala183, 
Asn185 and Ala186, also removed from the myoA binding groove) for which amide chemical 
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shifts in the free state had not been affected. This illustrates that there are new, well-defined 
pockets formed upon myoA complexation that are not presented in the more dynamic free 
state. Further, the observation supports the notion that the MTIP N-terminal domain largely 
preserves its tertiary structure upon binding (i.e. it is folded in the free state), while the highly 
flexible C-terminal domain does not exhibit well-defined tertiary structure until the myoA tail 
is present. 
Binding affinities of SB01748 and CC40996 to MTIP and initial crystallography experiments 
NMR titrations were carried out (with free MTIP) for two of the fragments that showed the 
largest CSPs: 8 (SB01748) and 3 (CC40996). As expected for weak interactions, the 
exchange regime was ‘fast’ in both cases, indicating that the frequency difference between 
the free and fragment-bound states of the protein was smaller than the rate of 
interconversion. CSPs were plotted on a per-residue basis against concentration of fragment 
and fit to an equilibrium binding model to estimate the KD for each compound (figure 6.13). 
  
Figure 6.13 NMR-derived binding curves for SB01748 (left) and CC40996 (right). The KDs shown below the data 
are the mean of the per-residue KDs, quoted ± standard deviation (n ≥ 3). 
1
H, 
15
N-HSQCs were recorded on 
PfMTIPΔ60 (80 µM, in 20 mM MOPS pH 7, 50 mM NaCl, 1 mM TCEP) after the addition of each aliquot of 
fragment up to ~120 molar equivalents. 
 
The affinities of both molecules are very low. However, given the large extent to which each 
fragment stabilised MTIP in the DSF assay, it was attempted to use them to crystallise the 
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protein in the absence of the myoA peptide. The NMR samples at the titration end-point (i.e. 
in the presence of ~120 molar equivalents of the fragment) were concentrated to 10 mg/mL 
(~600 µM) using a centrifugal concentrator (MWCO 2 kDa). The samples were then 
supplemented with a further 10 mM of the fragment to compensate for the small molecule 
leaching through the membrane of the concentrator, and sitting-drop crystallisation 
experiments set up with five 96-well sparse matrix screens.* However, no crystals were 
observed in any condition tested.  
6.2.5 Peptide-fragment ‘chimeras’ 
Design of chimeras based on hit 8 SB01748 
Although the affinity of 8 (SB01748) was low, the clear interaction with the myoA binding 
hotspot loop connecting helix α6 and α7 was in itself encouraging. It was desirable to obtain 
atomic resolution information on the mode of fragment binding to inform subsequent 
development of its affinity. Nina Vrielink synthesised a small library of SB01748 derivatives 
and assayed binding to MTIP by DSF, to investigate which parts of the molecule were 
important for the interaction.233 The results of this investigation are summarised in table 6.11. 
 
Table 6.11 DSF analysis to establish preliminary structure-activity relationships using derivatives of fragment hit 
8 (SB01748), performed in collaboration with Nina Vrielink. Values for ΔTms are quoted as mean ± standard 
deviation (n = 3).  
                                                     
*
 The components of the reservoir solutions for these screens (named ICL1-5 in the Centre for 
Structural Biology X-ray facility) are listed at www.imperial.ac.uk/xraycrystallography/crystn  
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The fragment hit itself is a precursor to histamine receptor antagonist ranitidine 
(commercially called Zantac). This compound (8a) gave a low ΔTm (+1.2 °C) relative to 8 
itself (+5.6 °C), suggesting that the primary free amine is important. Replacement of this end 
of the molecule altogether, by an alcohol (8b), severely reduced binding and actually led to 
destabilisation (-1.4 °C) of MTIP. However, removal of the dimethylamine moiety at the other 
end of the molecule was better tolerated (8c, ΔTm = +3.0 °C). Replacement of the thioether 
linker by an amide linker (8d) was destabilising. Taken together, these preliminary results 
suggest that the primary amine, linked to the furan via a thioether, is the essential feature of 
SB01748 (8).  
In order to crystallise MTIP, it has so far been necessary to include a myoA tail peptide in the 
crystallisation solution. It was therefore hypothesised that it might be possible to attach the 
fragment hit to the end of a peptide in order to grow crystals and thereby investigate the 
binding mode on the fragment in detail. Since one end of 8 was not necessary for interaction 
with MTIP, fragment peptide ‘chimeras’ were designed in which myoA peptides could be 
coupled to the fragment at that side of the molecule. Since the N-terminal end of 
PfmyoA(799-818) binds to the region of MTIP that binds to the fragment, the peptides were 
systematically truncated at the N-terminus and a library of chimeric molecules were 
synthesised by Nina Vrielink.233 
Synthesis and initial analysis of chimeras 
The general structure of the chimeras is shown in figure 6.14. They could be synthesised 
using Fmoc- solid phase chemistry, with a glycine spacer attached to the N-terminus of each 
myoA sequence. Final coupling of the key functionality of 8 using Boc-protected furan-2-
carboxylic acid 8e, followed by TFA-mediated cleavage and deprotection, yielded the 
desired product (figure 6.14). Three different myoA tail sequences were tested (terminating 
at Leu805, Leu804 and Ser803); by analysis of the CSPs caused by the fragment and the 
crystal structure of the WT PfMTIPΔ60-PfmyoA(799-818) complex it was rationalised that at 
least one of these should permit enough space for the fragment to adopt its binding 
conformation (figure 6.14). Controls, in which the fragment functionality was replaced by an 
acetyl cap, were also synthesised. The molecules were designed for crystallography 
experiments but were initially tested for MTIP binding by DSF (table 6.12). Two of the 
complexes of PfMTIPΔ60 with peptide-fragment chimeras (*803-816 and *805-816) showed 
greater thermal stability than with the corresponding acetylated controls, while one showed a 
lower Tm (*804-816). Overall, it could be seen via this analysis that truncation beyond 
Leu804 caused a major reduction in the stability of the protein-peptide complex, as expected 
in light of previous results from Thomas that showed a mutated myoA tail peptide 
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(PfmyoA(799-818)L804A) to have no activity in a fluorescence-based MTIP-myoA inhibition 
assay.110 
 
Figure 6.14 Top: design of peptide-fragment chimeras based on analysis of CSPs caused by SB01748 
(annotated red) and the crystal structure of the WT MTIP-myoA tail (pdb code: 4AOM). Bottom: schematic 
showing the synthesis and generalised structure of peptide-fragment chimera molecules designed in 
collaboration with, and synthesised by, Nina Vrielink. 
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Table 6.12 DSF analysis of peptide-fragment chimeras. Values for Tms of protein-peptide complexes are quoted 
as mean ± standard deviation (n = 6), and the difference between the chimera and the acetylated controls noted 
in each case. 
 
Crystallography of MTIP-chimera complex 
Complexes were formed between PfMTIPΔ60 and the three peptide-fragment chimeras. In 
each case, an aliquot of the protein (300 µL, 100 µM) was mixed with the chimeric molecule 
(five molar equivalents in the case of *804-816 and *803-816; ten molar equivalents in the 
case of *805-816) and the resulting complex concentrated to 50 µL (600 µM, ~10 mg/mL) 
using a centrifugal concentrator (MWCO 3 kDa). Sitting-drop crystallisation plates were set 
up using the screen ICL3 only,* since limited material was available and this screen 
contained a number of conditions that had yielded crystals in analogous trials for the WT 
                                                     
*
 The components of the reservoir solutions for ICL3 are listed at 
www.imperial.ac.uk/xraycrystallography/crystn 
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PfMTIPΔ60-PfmyoA(799-818) complex. Remarkably, single crystals appeared in a number 
of conditions for each complex within 48 hours (see figure 6.15 for examples). The crystals 
were mounted in loops and cryoprotected using reservoir solution supplemented with 30% 
(v/v) glycerol, flash frozen in liquid nitrogen and taken to Diamond Light Source synchrotron, 
Oxfordshire, U.K for data collection. 
 
Figure 6.15 Examples of co-crystals of PfMTIPΔ60 and peptide-fragment chimeras growing in sitting-drop 
crystallisation experiments, with approximate dimensions indicated. 
 
Datasets were collected for the complexes of MTIP with *803-816 and *804-816 chimeras; 
the crystals containing *805-816 diffracted to low (>3.5 Å) resolution and displayed unusual 
spot profiles (figure 6.16). All datasets were collected at 100 K and 1° oscillations. The initial 
indexing solution for one dataset collected at low resolution suggested one very long 
dimension in the unit cell, which was not seen for the other complexes; the dataset could not 
be further processed and the structure remains unsolved. This may suggest a substantial 
change in the protein structure and/or crystal packing in the presence of this shorter peptide, 
which was shown to have a much lower Tm than the other complexes. However, the datasets 
for complexes of MTIP with *803-816 and *804-816 were indexed in Mosflm,206 scaled in 
SCALA204 and initial models were generated via molecular replacement in Phaser,207 using 
the WT complex (pdb code: 4AOM) as a search model. 
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Figure 6.16 Examples of mounted crystals for complexes of PfMTIPΔ60 with chimeras *803-816 (top), *804-816 
(middle) and *805-816 (bottom) ready for data collection at Diamond Light Source, with example diffraction 
images illustrating the data obtained for each complex. 
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Although the crystals that produced the best datasets for the *803-816 and *804-816 
complexes appeared morphologically similar, the *803-818 complex crystallised with P212121 
symmetry (as for the WT complex) and diffracted to 1.98 Å resolution, while the *804-816 
complex crystallised in the P63 space group and diffracted to 2.90 Å resolution. The reduced 
number of crystal contacts in the latter led to a very high (~70%) solvent content*,234 likely 
explaining the diffraction to lower resolution. Both structures have been refined to 
reasonable Rwork/Rfree values (19.2/24.6% for the *803-816 complex and 17.5/22.3% for the 
*804-816 complex) using the same iterative process of model-building in Coot and restrained 
refinement in REFMAC (figures 6.17 and 6.18) as for the structures reported in chapter 5. 
The fragment functionality was modelled at the end of the peptide using JLigand to generate 
restraints. As was observed for the constrained myoA tail peptide-protein complexes 
reported in chapter 5, the conformation of the protein in both complexes is broadly the same 
as in the WT MTIP-myoA tail complex.  
In the *804-816 complex, for which the peptide-fragment chimera gave a lower Tm than the 
acetylated control, the fragment points towards solvent and does not appear to engage in 
interactions with the protein. Indeed, there is no electron density for the flexible thioether-
containing chain that terminates in the important free primary amine (figure 6.17). 
 
 
Figure 6.17 Crystal structure of the complex between PfMTIPΔ60 (white surface and cartoon) and peptide-
fragment chimera *804-816 (grey cartoon; glycine spacer shown as blue sticks and SB01748 functionality shown 
as red sticks): no electron density is observed for the end of the fragment functionality. 
                                                     
*
 By calculation of the Matthews coefficient. 
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Figure 6.18 Structural features of the complex between PfMTIPΔ60 and chimera *803-816. Top left: overview of 
the crystal structure. Top right: interactions of the SB01748-derived portion (red stick representation) of the 
chimera with MTIP residues (white sticks). Bottom: 1.98 Å electron density map (grey) shown as mesh around 
the fragment and glycine spacer (red and blue sticks). 
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By contrast, the SB01748-derived functionality in the peptide-fragment chimera *803-816 
makes a number of interactions with MTIP residues. Notably, the terminal free amine forms 
a salt bridge with the negatively charged side-chain of Asp173. This interaction does not 
appear to perturb the hydrogen bonding clamp of the latter with Ser108, which locks the 
stable protein conformation. The thioether moiety fits between Ile109 and Gly172 (as seen in 
the pGly[801,805] structure described in chapter 5), although the furan core does not make 
substantial interactions with MTIP. The glycine spacer affords some flexibility in the 
orientation of the fragment functionality, but the amide bond used to connect the two parts of 
the chimera restricts the motions of the furan and this is a limitation to the usefulness of such 
a crystal structure in understanding the possible binding mode(s) of SB01748 itself. 
 
Figure 6.19 Analysis of nearby peptide side-chain pockets to the fragment functionality that may be exploited in 
subsequent structure-guided development of peptidomimetics. 
 
Taking the data in combination with the above NMR analysis, it is evident that SB01748 is 
capable of binding to the loop connecting helices α6 and α7 when the protein is not bound 
by its myoA tail partner. However, whether or not the crystal structure of the MTIP-chimera 
complex reflects accurately the orientation of the fragment in this binding event remains an 
open question, since its orientation is governed to an unknown (conceivably, large) extent by 
its covalent attachment to the myoA tail peptide. Despite these concerns, the high resolution 
structure of *803-816 opens some interesting possibilities for development of SB01748. For 
example, rationally building the fragment molecule into the hotspot pockets occupied by 
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side-chains of nearby myoA residues (e.g. Leu804, Arg806 and Val807, see figure 6.19) 
may be an attractive approach to generate a small library of peptidomimetic-type inhibitors. 
Nevertheless, the inability to reconstruct the bound state conformation of MTIP without the 
myoA tail would likely remain problematic. This issue again returns to a central problem of 
fragment screening against protein-protein interaction targets like MTIP-myoA, in which one 
partner is highly dynamic in the absence of the other partner: without a structural model of 
the free protein, to what extent can any pockets or hotspots observed in the bound state be 
accurately targeted, or fragment binding modes be understood/resolved structurally?   
6.3 Conclusions and perspectives 
Since no biological insights have been provided by this chapter, the following conclusion will 
review the insights gained with respect to (i) development of fragment-based MTIP-myoA 
inhibitors in particular and (ii) fragment screening against PPIs in general. 
6.3.1 Insights for MTIP-myoA inhibitor development and FBDD against PPI targets 
 A 500-compound fragment library was screened for interaction with PfMTIPΔ60 using 
DSF. The hit rate was very high, likely reflecting the low thermal stability of the free 
protein and the presence of exposed hydrophobic regions, particularly in its C-
terminal domain, which is highly dynamic in the absence of the myoA tail and does 
not adopt a well-defined tertiary structure. One of the ways that this flexibility is 
manifested in the context of biophysical analyses is a large loss of entropy upon 
binding the myoA tail. Further evidence is in the shallow thermal unfolding transition, 
suggesting a complex pathway that may not be well-described by existing models of 
two-state unfolding. 
 As a result of the high hit rate, the cut off for hits was increased to +4 °C in the DSF 
experiment, leaving 15 fragments that were further tested. Surprisingly, despite the 
large (up to +10.3 °C) ΔTms given by these molecules, validation of binding by HSQC 
NMR experiments on MTIP in the presence of 50 molar equivalents of fragment 
suggested that the majority of fragments had negligible or very weak direct 
interactions with the protein. There are several possible explanations for this result. 
Firstly, it is possible that the hit fragments are false positives in the DSF experiment 
due to a specific destabilisation of unfolded MTIP by an undetermined mechanism. 
Alternatively, the fragments bind to one or more minor conformation(s) of MTIP that 
are hardly populated at the experimental temperature (303 K) and are thus invisible 
in the spectra. It is also possible that the affinity of the interactions with the ‘NMR-
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visible’ protein is so weak that (because such a small population of the bound protein 
would be present in the solution) chemical shift perturbations are undetectable.  
 Despite the above result, at least one genuine ‘hit’ fragment (SB01748, 8) was found 
that binds to the protein at myoA binding hotspots including the key loop connecting 
helices α6 and α7. Notably, this hit was the only molecule in the library that not only 
stabilised the protein to thermal unfolding significantly (ΔTm = + 5.6 °C) but also 
caused a sharpening of the shallow melting transition. This suggests that the 
molecule binds to the protein in such a way as to quench the dynamics of a specific 
part of the C-terminal domain and thus increase the cooperativity of unfolding. 
Another hit (CC40996, 3) bound with similar affinity (KD ~20 mM) at a site in the N-
terminal domain that was independent of the interaction with the myoA tail. 
 It is generally agreed across academic and industrial laboratories that use fragment-
based approaches that high resolution structural data on fragment binding modes are 
essential to rationally develop the affinity of the hit molecules. In the case of MTIP-
myoA, this has proven to be problematic since a crystal structure of the unbound 
MTIP has not been resolved, and the per-residue NMR data reported in chapter 3 
point to a highly flexible protein that samples a number of conformations, 
interconverting on different timescales. ‘Soakable’ crystals can be obtained for the 
complex with the WT myoA tail, which may enable resolution of the binding mode of 
hits such as CC40996 but not that of fragments like SB01748 that bind to PPI 
hotspots. In order to circumvent the latter issue, chimeric peptide-fragment molecules 
were synthesised with flexible linkers to probe the binding mode of the fragment 
functionality. However, this method has the disadvantage of biasing the orientation of 
the fragment due to its covalent attachment to the tight-binding myoA sequence. 
Increasing the flexibility of the linker between the peptide and the fragment could be 
beneficial in this case. 
 Overall, given the importance of high resolution structural data in FBDD, the work 
reported in this chapter highlights a significant challenge when the target is a protein-
protein interaction. The success stories discussed in section 6.1.1 are both illustrative 
examples of using such data in the validation and development of fragment hits 
against PPIs. However, in each of these PPIs, it was possible to screen compounds 
against unbound protein constructs that were reasonable models of the protein when 
bound to its partner. In the case of MTIP, so significant are the conformational 
changes upon binding to the myoA tail that the workflow used in the example 
systems may not be viable or appropriate. The initial DSF screening gave a number 
of hits that could not be validated by NMR experiments, presumably arising due to 
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the complexity of unfolding that is intimately related to the dynamics of the free 
protein. In cases such as this, it is likely that alternative screening strategies may be 
applied; for example, using protein-detected NMR in the initial screen or by 
developing screening against the complex itself. The problem with the latter 
approach is that a fragment is unlikely to displace a tight binding natural binding 
partner, so rational weakening of affinity may be a compromise. If this is not possible, 
attention must be paid to the generation of a crystal structure of the free protein; for 
example, by rationally reconstructing elements of the bound state conformation via 
mutagenesis, using appropriate crystallisation chaperones or by finding homologous 
proteins where the dynamics of the unbound state are not prohibitive to 
crystallographic studies. 
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7 Outlook 
Each chapter contained individual conclusions summarising the insights gained by the 
results reported in that chapter. Below, these are drawn together to provide an overall 
perspective on several areas and suggestions for future work are made. 
7.1 Dynamics of MTIP-myoA complex formation 
PfMTIP is a highly flexible protein on a range of timescales, and the dynamics of the protein 
are largely quenched upon interaction with the myoA tail. Residues 1-74 (the ‘N-terminal 
extension’) of the full-length protein are intrinsically disordered according to the analyses 
presented in chapter 3 and do not contribute to the myoA tail interaction, while 75-204 form 
eight α-helices in solution (four in each domain consisting of two pairs of non-calcium-
binding EF-hands) responsible for recognition of the binding partner. The helices of the N-
terminal domain may bundle in a stable tertiary fold; according to backbone NMR relaxation 
parameters there is evidence of millisecond, but not nanosecond-picosecond timescale 
dynamics. By contrast, parts of the C-terminal domain appear to move extensively on both 
timescales, as does the linker between the two domains. The millisecond timescale 
exchange processes in the free state of MTIP may include transient adoption of the 
hydrogen bond ‘clamp’ formed between Ser108 and Asp173, facilitated by the flexibility of 
the linker. The conformational continuum is further illustrated by a shallow thermal unfolding 
transition, suggesting low cooperativity therefore high flexibility. 
Together, the measurements points to a mode of myoA tail recognition as follows. Within the 
‘open’, un-clamped protein, the two pairs of helices in the C-terminal domain sample a 
number of conformations allowing recognition of the hydrophobic face of the myoA tail 
(Leu804, Val807 and Ile811); this enables formation of a compact hydrophobic core 
composed of non-polar side-chains from both molecules. Polar interactions are made 
between the myoA tail residues, namely Gln808 and Arg812, with the C-terminal domain; 
these contacts appear to contribute a large proportion of the binding energy since removal or 
perturbation of the functionality is not tolerated. An array of interactions made by the side-
chain of Arg806 templates the folded N-terminal domain to wrap around the myoA tail and 
adoption of a compact, clamped conformation, in which the Ser108-Asp173 interaction holds 
the clamp in place. This is stabilised further by an interaction between His810 and Asp139 in 
the interdomain linker. 
It is not surprising that binding of the myoA tail is strongly disfavoured entropically according 
to ITC experiments; despite the formation of the hydrophobic core in the C-terminal domain, 
which presumably gives a favourable entropy term, complexation is accompanied by 
significant rigidification of many parts of the protein and reduction in conformational degrees 
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of freedom. However, the interaction remains tight (KDs of PfmyoA tail peptides are 
~100 nM) because of the very large and favourable enthalpy term, presumably made up by 
the large number of intra- and inter-molecular polar and hydrophobic interactions.  
Once the myoA tail is bound, the crystal structures, solved at neutral pH, of PfMTIPΔ60 in 
complex with PymyoA and PfmyoA tails (pdb codes 2QAC and 4AOM, respectively) appear 
to be reasonable models of the solution-state structure. The unfolding of the complex is 
more cooperative than that of the free protein, suggesting that the stability of the protein 
structure is intimately associated with binding of the myoA tail.  
It would be interesting in the future to visualise the dynamic processes described above by 
using the experimental NMR data to restrain molecular dynamics simulations of MTIP-myoA 
complexation. 
7.2 Biological insights 
Although the N-terminal extension of PfMTIP appears to be intrinsically disordered in the 
context of a solution NMR experiment, its sequence is highly conserved, perhaps suggestive 
of a conserved function and/or interaction partner(s) in the glideosome. The partial chemical 
shift assignments of this portion of the protein, reported in chapter 3, will enable facile 
binding site determination if a binding partner is identified and can be purified in sufficient 
quantity. In addition, it might be of interest to monitor changes in the dynamics of this region 
upon interaction with other proteins and/or enzymatic modifications such as phosphorylation 
and palmitoylation. 
Upstream of residues 799-818 (the extreme C-terminus of PfmyoA), there are a number of 
conserved amino acids in the myoA tail whose function remains unannotated. Recently, it 
has been suggested that another light chain (called ‘essential light chain 1’ – or ELC1 – in 
T. gondii) may bind to this part of the myoA tail.67 The PfMTIPΔ60-PfmyoA(799-818) crystal 
structure extends the myoA tail at its N-terminus relative to previous structures and this 
understanding could aid a reconstruction of a ternary complex between both light chains and 
the entire myoA tail. It is plausible that Pro802, known to induce a break or a kink in an α-
helix, serves to mediate the orientation of the helical myoA tail in a defined manner. It could 
be that MTIP acts to direct the localisation of myoA to the inner membrane complex (via 
post-translational palmitoylation and/or interaction with other components) while the other 
light chain regulates myoA activity by rigidifying the remainder of its tail domain. NMR 
chemical shift assignments of MTIP in complex with myoA may be used to visualise any 
additional protein-protein surface contacts between the two myoA light chains in such a 
model. 
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The analysis presented in chapter 4 suggests that phosphorylation of MTIP may serve to 
modulate the interaction and dynamics of the MTIP-myoA complex in parasites. As 
emphasised in the conclusion of that chapter, the experiments resulted in a prediction of the 
structural effects of a specific phosphorylation event identified by phospho-proteomic 
analysis. However, it will require further work and investigation to identify the relevant kinase 
and/or cellular effect of such modification. Nonetheless, if MTIP is phosphorylated at Ser108 
at a given time point in development by a particular kinase, it is strongly implied by the in 
vitro data that this would disrupt the stable complex with the myoA tail. This could have a 
regulatory role in providing a temporal control to complex assembly or disassembly via 
kinase or phosphatase activity. Taken together with cellular data, the structural work could 
thus represent a starting point in the understanding of mode(s) of action of Plasmodium 
kinase inhibitors and associated phenotypes. 
Although PfmyoB tail peptides are able to bind to PfMTIPΔ60 in vitro, there is no evidence 
that this interaction occurs in parasites and the body of data suggests that MTIP is specific to 
myoA. Data reported in this thesis provides an interesting structural basis for the specificity 
of the light chain; while the MTIP C-terminal domain may be promiscuous in accommodating 
peptides with appropriate clustering of basic and hydrophobic residues (as evident from the 
clear and localised interaction with part of the myoB tail), the positionings of Arg806 and 
Gln808 in PfmyoA serve to template the adoption of the clamped interface and therefore a 
higher affinity, specific interaction. It would be interesting in the future to understand the 
specificity of the myoB light chain (identified recently according to a personal communication 
from J. Green and A. Holder, National Institute of Medical Research, London) for that myosin 
by a structural comparison of the two complexes. 
7.3 MTIP-myoA inhibitor design 
The hotspots of the MTIP-myoA interaction in solution have be established via mapping of 
NMR chemical shift perturbations onto the structure of the PfMTIPΔ60-PfmyoA(799-818) 
complex. More generally, the assignments have allowed rapid and reliable measurements of 
binding sites for designed ligands e.g. of small molecules, via direct titration into 15N-labelled, 
‘free’ MTIP, and of constrained peptides, via comparison of the spectra of different protein-
peptide complexes.  
Mimicry of the myoA tail peptide with constrained analogues employing mono-substituted 
pentenyl glycine staples or a hydrogen bond surrogate motif, as described in chapter 5, was 
shown to be a promising strategy. Since the myoA tail is completely buried by MTIP in the 
complex, published scaffolds based on oligoamides or terphenyls are unlikely to confer high 
potency to myoA helix ‘mimetics’ since in general only one face of the natural helix may be 
 221 
 
exploited. As described, for tight binding to both MTIP domains (as seen with the wild-type 
myoA tail), the enthalpy of interaction must be very favourable; the unliganded protein is 
highly flexible and ligand binding in this mode will likely pay an entropic penalty. It could be 
envisaged that a single domain might be targeted in an attempt to block the groove that is 
occupied by one face of the myoA tail. For example, helix mimetics presenting the 
functionality of Leu804, Val807 and Ile811 may be capable of sequestering the MTIP C-
terminal domain that forms a hydrophobic core upon binding to myoA. However, these 
molecules would likely have the substantial disadvantage of lower specificity, since the 
design does not exploit the particular features of MTIP-myoA recognition described above. 
Putting together these considerations, constrained peptides in which two or even all three 
helical faces may be mimicked are attractive as long as the constraint does not perturb any 
of the key native protein-helix interactions; this is clear from the analysis in chapter 5.  
Further, if the constraints confer cell-penetrating properties to the peptides (as has been 
shown in numerous other systems) whilst maintaining the high affinity and specificity of the 
wild-type sequence, then the molecules could realistically be used or developed as tools to 
disrupt myoA motor function or localisation, by replacing the native myosin from its complex 
with MTIP. This would be a powerful and complementary approach to discover basic 
parasite biology, especially given that contemporary genetic methods have reopened the 
debate regarding the molecular basis of processes such as gliding motility and host cell 
invasion by apicomplexan parasites, as described in chapter 1. Immediate future work 
should focus on the application of these molecules to parasite cultures and if necessary, 
iterative optimisation of the sequence to enhance cell penetration. This could be monitored 
by installation of fluorescent tags to the constrained peptides, and microscopy experiments. 
In the case of the stapled analogues, this should be facile since the N-terminus of the 
peptide is free to modify with e.g. a dansyl or fluorescein fluorophore; in the case of the 
hydrogen bond surrogate, a C-terminal modification would be required. 
The design of small molecule MTIP-myoA inhibitors is not only challenging in terms of the 
protein-protein interaction target, but also in terms of experimental methodologies. Since the 
target is not an enzyme, identification of hit molecules in a screening campaign must rely on 
accumulating biophysical evidence for interaction with one of the proteins. In the case of 
MTIP-myoA, the hit rate in the fragment screen (chapter 6) was very high, presumably 
reflecting the low stability and conformational heterogeneity of free PfMTIPΔ60. Many of 
these hits appeared to be false positives; despite inducing positive thermal shifts of up to ten 
degrees, little or no specific amide chemical shift perturbation was induced at 50 molar 
equivalents for many of the ‘hit’ ligands. One molecule, which notably induced a pronounced 
sharpening of the MTIP unfolding transition, was shown to bind weakly to a dynamic loop 
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containing myoA tail binding hotspot residues (e.g. Asp173). In order to promote co-
crystallisation of the small-molecule with the protein, a series of peptide-fragment hybrid 
molecules was developed. By tailoring the length of the peptidic portion of these molecules, 
it was possible to solve a high-resolution structure in which the binding mode of the fragment 
was resolved. This provides a starting point for further development of small molecule 
inhibitors targeting this MTIP-myoA hotspot. It would also be of interest to follow up some of 
the other hits from the screen; for example CC40996, which binds outside the myoA binding 
pocket. If a structure could be solved via soaking experiments on readily-obtained MTIP-
myoA tail crystals, it may be that these molecules could be further developed into specific 
binders of the complex, which could be useful tools – for example, via attachment of a 
proteasome-directing moiety according to the strategy published by the Crews group.235 
7.4 General insights for development of PPI inhibitors 
The research reported in chapters 5 and 6 has certain implications beyond the limit of MTIP-
myoA in terms of informing PPI inhibitor design. The detailed structural analysis of different 
constraining technologies in chapter 5 provides a number of novel insights, particularly if the 
PPI target involves a buried protein-helix interaction. It has been shown that careful, 
structure-guided design – with an appreciation for the atomic-level details of the particular 
complex – of peptide staples may enable their incorporation into sequences without 
concomitant perturbation of native interactions. Furthermore, it has been experimentally 
shown that incorporation of the hydrogen bond surrogate developed by Arora is an 
appropriate constraining strategy for buried interactions, by remote reinforcement of existing 
interactions via helix preorganisation at the N-terminus.  
In terms of fragment-based approaches towards PPI inhibitors, the work of chapter 6 
highlights some of the potential pitfalls in a case where the PPI partners are highly flexible in 
isolation. The screening and subsequent development of hits in such cases requires 
innovative strategies, and care must be taken in designing and interpreting the screening 
campaign and interpreting the biophysical data. The high hit rate resulting from a screen 
against a protein like MTIP requires some consideration: for example, in the DSF 
experiment, rather than judging a hit solely from shift in melting temperature, it may be more 
productive to search for molecules that appear to change the cooperativity or slope of the 
transition, with the view that such molecules may be able to trap a dynamic region of the 
protein and thus promote non-productive conformations. When it comes to structural 
characterisation of ligand binding in such systems, focusing on the development of suitable 
protein constructs may be worthwhile: ideally, the pockets which the natural ligand occupies 
would be presented in the free protein construct. In the case of MTIP-myoA, although the 
free protein was structurally characterised using NMR and shown to exhibit the same 
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secondary structure as the bound protein, the tertiary structure is less well-defined. 
Screening against engineered, individual MTIP domains, or a construct in which the protein 
is constrained in a stable tertiary fold that accurately reconstructs the bound-state 
conformation (using mutagenesis, homologues or crystallisation chaperones) might be 
fruitful in this regard, and enable co-crystallisation experiments without inclusion of the myoA 
tail peptide functionality. 
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Chapter 8 Materials and methods 
8.1 General 
All general chemicals, solvents, buffer components and biological components for cell 
culture were obtained from Sigma-Aldrich, Fisher, Merck, Invitrogen or VWR. Equipment for 
SDS-PAGE analysis was from the Mini-PROTEAN range (BioRad). Gases were from BOC. 
Ultra-pure water was used for the preparation of all solutions, buffers and growth media, 
obtained from a Millipore Elix Q-gard purification system.  
All materials for growing or manipulating cell cultures were sterilised before use. A 
refrigerated Eppendorf centrifuge 5810R was usually used to pellet cell cultures or lysates, 
or to concentrate large volumes of protein solutions in Vivaspin centrifugal concentrators 
(GE Healthcare). A Heraeus Fresco 17 centrifuge (Thermo Scientific) was used for smaller 
volumes. A Constant Systems cell disruptor was used for mechanical lysis of bacterial cells.  
Sample pH was either measured to the nearest 0.5 units with Whatman Panpeha indicator 
strips (Sigma-Aldrich) or accurately using a Mettler Toledo MP220 pH meter for small 
volumes (e.g. NMR samples) or a Hanna 8519 pH meter for larger volumes (e.g. buffers).  
UV-vis analysis (e.g. for the measurement of the A280 of a protein solution or the OD600 of a 
cell culture) was carried out on a Biowave II spectrophotometer for volumes greater than 
70 μL or a Fisher NanoDrop apparatus for very small (1-2 μL) volumes.  
Peptide synthesis was carried out using a ResPepSL synthesiser (Intavis), run using the 
supplied Multipep software. Precipitated peptides (following resin cleavage) were pelleted 
with a Jouan BR4 centrifuge. Microwave-assisted reactions were performed using an 
Initiator Classic microwave (Biotage). 
Analytical size exclusion chromatography used a 25-mL Superdex-75 10/30 column (GE 
Healthcare). Preparative size exclusion chromatography used a 120-mL Superdex-75 16/60 
column. In both cases, buffers were filtered (0.2 µm) and degassed before use; elution of the 
protein was followed by A280 with the ÄKTA purification platform running UNICORN software 
(GE Healthcare).  
Analytical and semi-preparative LC-MS used various gradients of MeOH:H2O over 18 min; 
the solvents were degassed and supplemented with 0.1% formic acid prior to use. The LC-
MS platform consisted of a Waters RP-HPLC system (Waters 2767 autosampler for sample 
injection and collection; Waters 515 HPLC pump to deliver the mobile phase to the source; 
XBridge C18 columns with dimensions 4.6 mm x 100 mm for analytical runs and 19 mm x 
 225 
 
100 mm for preparative runs) coupled to a Waters 3100 mass spectrometer (with ESI in 
positive and negative modes) and a Waters 2998 Photodiode Array (with detection between 
200-600 nm).  
Following LC-MS purifications, solvent was removed with a centrifugal evaporator (Genevac) 
and lyophilisation of molecules was done with an Alpha 2-4 LD Plus freeze-dryer (Christ). 
Commercially available sitting-drop crystallisation screens provided by the Centre for 
Structural Biology at Imperial College were set up using a Mosquito-LCP high-throughput 
liquid-handling robot (TTP Labtech), stored in temperature and vibration-controlled 
incubators (Molecular Dimensions) and inspected using a Leica microscope. Crystals were 
mounted in nylon loops of different sizes depending on their dimensions (Hampton 
Research) and X-ray crystallography experiments either carried out in house with a Rigaku 
Micromax 007HF-M high flux generator coupled with a Rigaku Saturn 944+ CCD detector, or 
using the apparatus at Diamond Light Source beamlines. Model building and refinement 
were carried out in Coot and REFMAC or Phenix, respectively. Analysis of protein structures 
was done in PyMOL (DeLano Scientific). 
1D, 2D and 3D NMR experiments were either carried out on a Bruker Avance III 600 MHz or 
a Bruker Avance II 800 MHz spectrometer, both equipped with triple resonance cryoprobes 
and running Topspin software. All spectra were recorded at 303 K. Spectra were either 
processed within the Topspin interface or using NMRPipe,129 in which case they were 
analysed in a locally-modified version of NMRView (One Moon Scientific).130,131 NMR spectra 
were plotted in NMRView and figures prepared using GIMP. Chemical shift perturbation 
analysis was done in MS Excel, and CPMG relaxation dispersion analysis was performed 
with NESSY.145 
ITC experiments were performed using a VP-ITC calorimeter (MicroCal) and analysed in 
Origin (OriginLab corps). 
CD spectra were obtained on a Chirascan spectropolarimeter (Applied Photophysics). 
Fluorescence measurements were made with a SpectraMax M2E Microplate reader 
(Molecular Devices) and analysed in the supplied SoftMax Pro package. 
DSF experiments were performed out in 96-well real-time PCR plates (Eppendorf) using 
either a Mastercycler ep realplex machine (Eppendorf) running realplex software, or a 
Stratagene MX3005P machine (Agilent Technologies) running MxPro qPCR software. Data 
were analysed with customised MS Excel spreadsheets and unfolding curves fitted using a 
GraFit plug in (Erithacus software).  
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8.2 Buffers 
The range of buffers used in the experiments reported are summarised in table 8.1. 
 
Table 8.1 Compositions of buffers used in experiments reported in this thesis. 
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8.3 DNA manipulations 
The plasmids used for expression of MTIP constructs are shown in table 8.2. 
 
Table 8.2 Plasmids used for protein expression in this thesis. 
 
8.3.1 Plasmid purifications 
Transformation 
50 μL E. coli XL1 blue competent cells were removed from storage at -80 °C and thawed on 
ice for 5 min in a sterile 1.5-mL microcentrifuge tube. 1 μL (~100-200 ng) of the plasmid was 
added to the cells and mixed by gentle pipetting. The cells were left on ice for 20 min before 
being heat-shocked for 45 s at 42 °C. They were returned to ice for another 2 min after 
which 500 μL of prewarmed SOC medium was added and the tube was incubated for 30 min 
at 37 °C with vigorous shaking. 200 μL of the cells were plated onto an LB agar plate 
containing 50 μg mL carbenicillin (carb50) for pQE30 and pRSETA vectors, or 30 μg/mL 
kanamycin (kan30) for the pREP4 vector. The plates were incubated overnight at 37 °C. 
DNA amplification and purification 
DNA was amplified and purified by inoculating 5-mL LB(carb50) or LB(kan30) cultures as 
appropriate, growing the cultures overnight (37 °C, 220 rpm) before following the QIAprep 
Miniprep protocol (Qiagen).  
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8.3.2 Site-directed mutagenesis 
PCR 
To introduce phospho-mimetic mutations S107E and S108E, a QuikChange site-directed 
mutagenesis kit was used (Stratagene). Table 8.3 shows the template DNA and primers 
used to introduce the mutations. 
 
Table 8.3 Primers used for site-directed mutagenesis (underlined are mutated codons) to generate phospho-
mimetic mutant MTIP genes. 
 
Components for the PCR (shown in table 8.4) were mixed in a thin walled 0.2-mL PCR tube. 
 
Table 8.4 PCR components for amplification of phospho-mimetic mutant MTIP genes. 
 
The following cycle was used for the PCR, which was carried out in a Techne instrument: 
(i) 95 °C for 30 s; (ii) 95 °C for 30 s; (iii) 55 °C for 60 s; (iv) 68 °C for 6 min. Steps (ii)-(iv) 
were repeated 18 times, after which the tube was held at 10 °C. Each reaction was digested 
with 1 µL (20 U) Dpn1 (New England BioLabs) to remove template DNA.  
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Transformation, purification and sequencing 
5 µL of the reaction was then transformed into E. coli XL1 blue supercompetent cells, 
essentially as described in section 8.3.1, and two of the resultant colonies (for each mutant 
gene) were used to amplify the DNA, which was purified following the QIAprep Miniprep 
protocol (Qiagen). DNA samples were sent for recombinant gene sequencing by Source 
BioSciences and confirmed as bearing the designed mutations.  
8.4 Protein expression and purification 
8.4.1 Expression of PfMTIP constructs 
PfMTIP constructs were expressed in E. coli BL21 (DE3) cells; the DE3 labelling refers to 
the phage inserted into the bacterial genome encoding T7 RNA polymerase, essential when 
using the pRSETA expression vector which incorporates a T7 promoter. The pQE30 
expression vector contains a T5 promoter, the high transcription rate of which may lead to 
leaky expression of the gene of interest (i.e. before induction with IPTG). Therefore, the 
pREP4 plasmid, which expresses high levels of the lac repressor protein, was co-
transformed with pQE30 (containing the PfMTIP gene). 
Transformation and starter culture 
50 μL E. coli BL21 (DE3) cells were removed from storage at -80 °C and thawed on ice for 
5 min in a sterile 1.5-mL microcentrifuge tube. 1 μL (~100-200 ng) of the relevant plasmid(s) 
– either pRSETA in isolation or pQE30 in combination with pREP4 – was then added to the 
cells and mixed by gentle pipetting. The cells were left on ice for 20 min before being heat-
shocked for 45 s at 42 °C. They were returned to ice for another 2 min after which 500 μL of 
prewarmed SOC medium was added and the tube was incubated for 30 min at 37 °C with 
vigorous shaking. 200 μL of the cells were plated onto an LB agar plate containing 
50 μg mL carbenicillin (pRSETA) or both 50 μg mL carbenicillin and 30 μg mL kanamycin 
(pQE30/pREP4). The plates were incubated overnight at 37 °C. 
A starter culture consisting of 100 mL LB medium supplemented with the appropriate 
antibiotic(s) (at the same concentrations as on the LB plates above) was inoculated with a 
fresh colony and incubated overnight with shaking (37 °C, 220 rpm). 
Day culture – unlabelled PfMTIPΔ60 (WT and mutants) 
The OD600 of the starter culture was measured and the culture diluted in a fresh, sterile 2-L 
flask containing 800 mL LB medium supplemented with the appropriate antibiotic(s) to give a 
‘starting’ OD600 of 0.05. The culture was incubated with shaking (37 °C, 200 rpm) until the 
 230 
 
OD600 reached 0.5-0.8 (this typically took 3-5 h), at which point 0.1 mM IPTG was added to 
induce protein expression via allosteric release of the lac repressor protein. Expression was 
allowed to continue for 3 h further incubation with shaking (37 °C, 200 rpm). 
Day culture – 15N-labelled PfMTIPΔ60 (WT and mutants) or 13C, 15N-labelled PfMTIPΔ60 
The OD600 of the starter culture was measured, and the culture was pelleted by 
centrifugation (room temperature, 4,000 rpm, 10 min). The supernatant was carefully 
discarded and the pellet resuspended gently with the desired isotope-labelled minimal 
media, following which the resuspension was diluted in a fresh, sterile 2-L flask containing 
800 mL of minimal media supplemented with the appropriate antibiotic(s) to give a ‘starting’ 
OD600 of 0.1. The culture was incubated with shaking (37 °C, 200 rpm) until the OD600 
reached 0.5-0.8 (this typically took 4-7 h), at which point 0.1 mM IPTG was added to induce 
protein expression. Expression was allowed to continue for 3 h further incubation with 
shaking (37 °C, 200 rpm).  
Minimal media components were as follows (per litre, for 13C, 15N labelling): 6 g Na2HPO4; 
3 g KH2PO4; 0.5 g NaCl; 0.7 g 
15NH4Cl. This solution was autoclaved, then the following 
supplements filter-sterilised (0.2 µm) and added: 2 mM MgSO4; 100 μM CaCl2; 0.2% (v/v) 
13C D-glucose; 1 x vitamins solution; 1 x trace elements solution.  
Trace elements (1000 x) components were: 3 μM ammonium molybdate; 400 μM H3BO3; 
30 μM CoCl2; 10 μM CuSO4; 80 μM MnCl2; 10 μM ZnSO4.  
Vitamins (1000 x) contained: 0.4 g Choline chloride; 0.5 g Folic acid; 0.5 g Pantothenic acid; 
0.5 g Nicotinamide; 1.0 g Myo-inositol; 0.5 g Pyridoxal.HCl; 0.5 g Thiamine.HCl; 0.05 g 
Riboflavin; 1.0 g Biotin. 
Cell harvest 
The day culture was pelleted (in batches if necessary) by centrifugation (4 °C, 4,000 rpm, 
15 min) and the supernatant discarded. The resulting cell pellet was either frozen at -20 °C 
until required, or used immediately. The final protein yield was found to be superior when the 
purification was carried out immediately. 
Cell lysis 
The pellet was defrosted on ice and 10 mL of lysis buffer added (scaled up if necessary, 
depending on the number of 800-mL cultures used for protein expression). The cells and the 
lysis buffer were mixed by gentle agitation over the course of 10 min on ice, to ensure 
resuspension of the cell material, and then on a rotary mixer for a further 10 min (40 rpm, 
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room temperature). The cells were lysed using a cell disrupter at a pressure of 10 kpsi, and 
the suspension was recycled once through the system to achieve maximum lysis. The lysate 
was placed on ice for a further 10 min and then centrifuged at high speed to remove cell 
debris (4 °C, 12,000 rpm, 45 min). The supernatant, containing the desired protein, was 
retained and filtered (0.2 µm) ready for purification. 
8.4.2 Protein purification 
The following procedures were carried out either on ice or in a cold room (4 °C), where 
possible. 
Protein concentration was determined throughout using UV spectrophotometry (the 
estimated ε280 for PfMTIPΔ60 is 17,545 M
-1cm-1). The calculated mass of PfMTIPΔ60 is 
16,425 Da. 
Purification employed two steps: (i) Ni-NTA affinity chromatography and (ii) size exclusion 
chromatography, to ensure highly homogeneous samples required for the biophysical and 
structural experiments carried out. 
Ni-NTA affinity chromatography 
Initial protein purification was achieved by Ni-NTA affinity chromatography, exploiting the N-
terminal His tag of all the constructs. 4 mL of Ni-NTA resin (Qiagen, supplied as a 50 % (v/v) 
suspension in EtOH) was washed several times in wash buffer and combined with the 
cleared lysate containing the desired protein. The mixture was incubated on a rotary mixer 
for 2 h and then poured into a 15-mL polypropylene column (Qiagen). The supernatant was 
retained for SDS-PAGE analysis. The Ni-NTA resin was washed a further 3 times with 5mL 
wash buffer and these washes were also retained for analysis. The His-tagged protein was 
eluted in a stepwise manner by adding 3 x 5 mL of elution buffers containing increasing 
concentrations of imidazole (200, 300 and 500 mM). 1 mM TCEP was immediately added to 
the protein, before overnight dialysis in 2.5 L of the desired buffer, depending on the next 
step of the purification, using Snakeskin dialysis tubing (Thermo Scientific, MWCO 3.5 kDa). 
The dialysis was repeated twice the following day with 1 L of fresh buffer for 1-2 h.  
Where His-tag cleavage was required (for protein expressed with the pRSETA construct), 
the protein was dialysed into thrombin cleavage buffer. Cleavage of the tag was achieved by 
incubating the dialysed protein on ice for 2 h in the presence of 1 U of restriction-grade 
thrombin (Novagen) per mg of protein. Where the protein was expressed with the pQE30 
construct, the protein was dialysed into GF buffer. 
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Size exclusion chromatography 
Following dialysis (and His-tag cleavage, if applicable), the protein sample was concentrated 
to a volume between 1-5 mL depending on the individual purification and yield and purified 
further by size exclusion chromatography, eluted with GF buffer at a flow rate of 1 mL/min. 
Subsequent buffer exchange for biophysical and/or structural analysis was either achieved 
by dialysis or by repeated concentration/dilution of the pure fractions in the desired buffer 
using a centrifugal concentrator (MWCO 3 kDa). Finally, aliquots of the purified protein 
required for different experiments were made at appropriate volumes and concentrations, 
flash frozen in liquid N2 and stored at -80 °C.  
8.4.3 SDS-PAGE 
Bis-Tris gels were used to separate proteins on gels by SDS-PAGE; the gel compositions 
are shown in table 8.5. Samples were prepared by mixing with 4× NUPAGE LDS sample 
loading buffer (containing 10% v v β-mercapto-ethanol) and boiling for 5 min. Gels were run 
using NUPAGE MES buffer, typically for 40 min at 200 V, after which they were fixed by 
soaking in a solution comprising 50% (v/v) H2O, 40% (v/v) MeOH and 10% (v/v) AcOH for at 
least 5 min, washed in H2O and stained with Bio-safe Coomassie blue (BioRad) to enable 
visualisation of proteins. Representative gels following MTIP purifications are shown in figure 
8.1. 
 
Figure 8.1 (Left) SDS-PAGE gels following Ni-NTA chromatographic purification of WT PfMTIPΔ60 and mutants. 
(Right) WT protein (with and without His tag) following secondary purification by size exclusion chromatography, 
as used for biophysical and structural assays. The calculated mass of PfMTIPΔ60 is 16,425 Da. 
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Table 8.5 Composition of gels for SDS-PAGE. 
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8.5 Solid-phase peptide synthesis 
The amino acid sequences of the peptides used in this thesis are shown in table 8.6. All the 
peptides were capped with an acetyl group on the N-terminus to remove unnatural charge 
(except HBS myoA, HBS myoA R806A and dGmyoA). All the peptides have C-terminal 
amide groups for the same reason (except PfmyoA peptides which extend to the natural C-
terminus of myoA and were therefore left as free acids). For peptides terminating in C-
terminal acids, preloaded Fmoc-Gln(Trt) Wang resin was used. For peptides terminating in 
C-terminal amides, Rink Amide AM resin was used.  
 
 
Table 8.6 Peptides synthesised and used in the results chapters of this thesis. The pGly series were synthesised 
and purified in collaboration with Sabrina Maas. X = (4)-pentenoic acid; † = N-allyl glycine; * = (S)-pentenyl 
alanine; ω = (R)-octenyl alanine; γ = (S)-pentenyl glycine. Where relevant, the sequences represent the 
structures prior to ring-closing metathesis. 
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8.5.1 General method for synthesising natural sequences 
All of the following reactions and manipulations were carried out at room temperature unless 
otherwise stated. The protocols are given for a 20 µmol scale (i.e. one column in the 
automated synthesiser), but were scaled up as necessary. 
The chosen resin (20 µmol) was swelled in DMF and transferred to fritted reaction columns 
in the automated synthesiser. The following steps were handled automatically.  Deprotection 
of the N-terminal Fmoc group was achieved using 20% (v/v) piperidine in DMF (400 µL, 
3 x 10 min), followed by washing with copious amounts of DMF. The incoming Fmoc-
protected amino acid (87.5 µmol, 4.4 eq.; 175 µL of a 0.5 M stock in NMP) was preactivated 
with HBTU (85 µmol, 4.25 eq.; 170 µL from a 0.5 M stock in NMP) and NMM (200 µmol, 
10 eq.; 50 µL from a 4 M stock in NMP) before addition to the resin, and coupling was 
allowed to take place over 30-45 min. The resin was washed and the coupling repeated (i.e. 
the amino acid was ‘double-coupled’). Any unreacted N-terminal amines were acetylated by 
addition of ‘capping mixture’ (5% (v v) Ac2O in DMF, 400 µL, 10 min) to prevent deletion 
sequences, followed by washing with copious amounts of DMF. The process of 
deprotection-coupling-capping was repeated for each amino acid in sequence; after the final 
(N-terminal) amino acid coupling, Fmoc deprotection and washing gave the crude, resin-
bound, fully side-chain-protected peptide. The peptide was then acetylated or dansylated. 
N-terminal acetylation 
The crude peptide was transferred to a fritted 5-mL syringe and the resin swelled in 1 mL 
DMF for 30 min with shaking. 1 mL of ‘acetylation mixture’ was added (10% (v v) Ac2O and 
20% (v/v) DIEA in DMF) and the reaction allowed to proceed for 1 h with shaking. The 
mixture was then removed by filtration. 
N-terminal dansylation 
The crude peptide was transferred to a fritted 5-mL syringe and the resin swelled in 1 mL 
DMF for 30 min with shaking. The syringe was wrapped in foil. 1 mL of ‘dansylation mixture’ 
was added, containing dansyl chloride (54 mg, 200 µmol, 10 eq.) and DIEA (70 µL, 
400 µmol, 20 eq.) in DMF and the reaction allowed to proceed for 1 h with shaking. The 
mixture was then removed by filtration. 
8.5.2 Synthesis of constrained peptides 
HBS myoA and HBS myoA R806A 
Rink Amide AM resin (20 µmol) was swelled in DMF and transferred to fritted reaction 
columns in the automated ResPepSL synthesiser (Intavis). Couplings of natural amino acids 
were achieved using the protocol described above for WT sequences. Incorporation of the 
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HBS functionality, and subsequent microwave-assisted ring-closing metathesis using 
Hoveyda-Grubbs II, followed ‘method B’ in the protocol published by Patgiri et al. (i.e. myoA 
residues Pro802 and Lys799 were replaced by N-allyl glycine (†) and 4-pentenoic acid (X) 
respectively).173 For the incorporation of N-allyl glycine, the free peptide N-terminus was 
coupled to bromoacetic acid (56 mg, 400 µmol, 20 eq.) in the presence of DIC (62 µL, 
400 µmol, 20 eq.) and HOAt (34 mg, 200 µmol, 10 eq.) in 0.5 mL DMF for 2 h with shaking. 
The reactant mixture was drained and the resin was thoroughly washed (3 x 2 mL DMF, 
3 x 2 mL DCM, 3 x 2 mL DMF) before addition of allylamine (30 µL, 400 µmol, 20 eq.) in 
0.5 mL DMF and shaking for 20 min. The reactant mixture was then drained and the resin 
washed again with copious amounts of DMF and DCM.  Coupling of the next amino acids 
were achieved as described for WT sequences, but scaled up i.e. 10 eq. of the incoming 
Fmoc-protected amino acid, 9.8 eq. of HBTU and 15 eq. of base (DIEA) were used. 
Otherwise, the same deprotection-coupling-capping protocol was used. Finally, coupling of 
4-pentenoic acid was achieved by addition of 4-pentenoic acid (10.2 µL, 100 µmol, 5 eq.), 
HBTU (37 mg, 99 µmol, 4.95 eq.) and DIEA (35 µL, 200 µmol, 10 eq.) in 0.5 mL DMF to 
generate the bis-olefin HBS precursor. The resin was washed thoroughly with DMF, DCM, 
MeOH and Et2O (5 x 3 mL each), then dried under vacuum. 
Ring-closing metathesis of the resin-bound, fully side-chain-protected bis-olefin was 
achieved by addition of a solution of Hoveyda-Grubbs second generation catalyst (2.5 mg, 
4 µmol, 0.2 eq.) in 500 µL dry 1,2 dichloroethane. The reaction was transferred to a 2-mL 
microwave vessel (Biotage) containing a magnetic stirrer. The microwave-assisted 
metathesis reaction employed a protocol of 2 min pre-stirring followed by 10 min at 120 °C, 
after which the resin was washed in 1,2 dichloroethane. 
i, i+4 pGly ‘stapled’ peptides 
Rink Amide AM resin (20 µmol) was swelled in DMF and transferred to fritted reaction 
columns in the automated ResPepSL synthesiser (Intavis). Couplings of natural amino acids 
and final acetylation were achieved using the protocol described above for the WT 
sequence. Elongation with (S)-N-Fmoc pentenyl glycine (pGly (γ), synthesised by Sabrina 
Maas),200 was identical except that 3 eq. of amino acid were used, HATU (2.95 eq.) was 
used to preactivate, and the double coupling was allowed to proceed for 2 x 2 h. Ring-
closing metathesis was achieved as described in the protocol published by Kim et al.201 
Briefly, a fresh solution of Grubbs first-generation catalyst (6 mM in dry 1,2 dichloroethane; 
4 µmol, 0.2 eq.) was prepared and added to the resin-bound, N-terminally acetylated, fully 
side-chain-protected peptide. The reaction was allowed to proceed for 2 h with shaking, after 
which the catalyst was drained and the reaction repeated once with fresh catalyst. 
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i, i+4 and i, i+7 pAla/oAla ‘stapled’ peptides 
Rink Amide AM resin (20 µmol) was swelled in DMF and transferred to fritted reaction 
columns in the automated ResPepSL synthesiser (Intavis). Couplings of natural amino acids 
and final acetylation were achieved using the protocol described above for the WT 
sequence. Elongation with (R)-N-Fmoc (4’-octenyl) alanine (oAla (ω), a kind gift from Pfizer 
plc.), or (S)-N-Fmoc (4’-pentenyl) alanine (pAla (*), purchased from Novabiochem) was 
identical except that 3 eq. of amino acid were used, HATU (2.95 eq.) was used to 
preactivate, and the double coupling was allowed to proceed for 2 x 2 h with shaking. 
Addition of the amino acid after either pAla or oAla was identical except that the double 
coupling was allowed to proceed for 2 x 2 h. Ring-closing metathesis was achieved using 
Grubbs first generation catalyst as described in the protocol published by Kim et al. and 
above for the pGly series.201 
Washing of resin treated with ruthenium-based catalysts 
To wash the resin of residual ruthenium-containing impurities following metathesis reactions, 
the following method was applied, which was adapted from those used by Galan et al. and 
Hossain et al.236,237 Potassium isocyanoacetate (4.4 eq., in a 1:1 mixture of DCM/MeOH) 
was added to the protected resin-bound peptides and gently agitated for 1 h. The reagent 
mixture was removed by filtration and further extensive washing of the resin was carried out 
using DMF/DMSO (1:1, 5 x 3 mL). 
8.5.3 Deprotection, cleavage and purification of all peptides 
The resin was washed with DMF (5 x 3 mL), DCM (5 x 3 mL), MeOH (5 x 3 mL) and Et2O 
(5 x 3 mL), before desiccation under vacuum. Cleavage from the resin and deprotection of 
side-chains was achieved by adding 1.5 mL of deprotection mix (94% (v/v) TFA, 2.5% (v/v) 
H2O, 2.5% (w/v) DTT, 1% (v/v) TIS) to the resin and shaking vigorously for 3 h. The liquid 
containing the desired product was then filtered into a 15-mL centrifuge tube and 5 mL ice-
cold TBME added to precipitate the crude peptide. A pellet was formed by centrifugation 
(4 °C, 4,500 rpm, 15 min) and washed several times with cold TBME by 
resuspension/centrifugation, before being desiccated under vacuum overnight. Once dry, the 
crude peptide was dissolved in H2O and purified by semi-preparative LC-MS, using a 
focused gradient of H2O (0.1% HCOOH): MeOH (0.1% HCOOH) over 18 min which was 
dependent on the retention time of the crude product as measured by analytical LC-MS runs.  
After purification, the solvent was removed using a centrifugal evaporator before 
lyophilisation. 
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8.5.4 Characterisation of peptides 
 
Table 8.7 Characterisation data for purified peptides used in this thesis. Analysis of the peptides was performed 
with a Waters LC-MS system using an isocratic gradient of 5-98% H2O/MeOH (0.1% HCOOH) over 18 min. 
* cis/trans- isomers could be isolated. 
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8.6 Biophysical assays 
8.6.1 Isothermal Titration Calorimetry (ITC) 
ITC experiments were performed at 303 K and all solutions were degassed prior to use. The 
cell contained 1.4 mL of 20 µM PfMTIPΔ60 (WT or mutants), and PfmyoA peptides were 
added in 5- or 10-µL injections (from a 200-400 µM solution in crystallisation buffer). The 
measurements were carried out in duplicate, and control titrations of the peptides into buffer 
confirmed no significant heat of dilution for either sequence. 
8.6.2 Differential Scanning Fluorimetry (DSF) 
Peptide binding 
20 µL samples were arrayed in at least triplicate and contained 5 µM PfMTIPΔ60 (WT or 
mutants) with or without 200 µM peptide in DSF buffer. Fluorescence of the SYPRO Orange 
dye was monitored in each well over 15-80 °C (when the Eppendorf machine was used) or 
25-95 °C (when the Agilent machine was used). 
Fragment screening 
The DSF experiments and liquid handling workflows pertaining to the fragment screen are 
detailed in chapter 6. 
8.6.3 Fluorescence Resonance Energy Transfer (FRET) assay 
The experiments followed a protocol adapted from the work of Thomas.110 Assays were 
carried out in triplicate in a 96-well plate, such that four separate inhibitors were tested 
simultaneously. 150 µL FRET buffer was added to wells B–G in rows 12, 9, 6 and 3. 225 µL 
of inhibitor 1 was added to well A12, 225 µL of inhibitor 2 to A9, 225 µL of inhibitor 3 to A6 
and 225 µL of inhibitor 4 to A3.  Tripling dilutions using 75 µL of each of these inhibitors were 
carried out between wells A-G to give a concentration range between 100-0.14 µM. 50 µL 
was transferred from row 12 into rows 11 and 10, 50 µL from row 9 into rows 8 and 7, 50 µL 
from row 6 into rows 5 and 4, and 50 µL from row 3 into rows 2 and 1 to set up triplicate 
experiments. 50 µL of buffer was added to wells 1–12 of column H which were to be used for 
controls.  
7.5 mL dGmyoA (1.3 µM) was mixed with 7.5 mL PfMTIPΔ60 (1.6 µM); 350 µL dGmyoA 
(1.3 µM) was mixed with 350 µL FRET buffer, and 350 µL PfMTIP Δ60 (1.6 µM) was mixed 
with 350 µL FRET buffer. Each of these solutions was incubated at 37 °C for 10 min along 
with the plate containing the various concentrations of inhibitor. 150 µL of the 
PfMTIPΔ60-dGMyoA complex was then added to wells A–G of rows 1–12 to give wells 
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containing the complex (final concentrations: 0.6 µM PfMTIPΔ60; 0.5 µM dGmyoA) with 
various concentrations of inhibitor. 150 µL was also added to wells H1–H3 to be used as 
controls. 150 µL of PfMTIPΔ60 (0.8 µM) mixed with plate assay buffer was added to wells 
H4–H6, and 150 µL dGmyoA (0.65 µM) mixed with FRET buffer was added to wells H7–H9. 
150 µL plate assay buffer was added to H10–H12 to complete the control lane. The plate 
was incubated at 37 °C for 30 min before fluorescence was scanned between 320–600 nm 
(excitation 280 nm, cutoff 325 nm) and single point readings were taken at emission 320 nm 
(excitation 280nm, no cutoff) and 525 nm (excitation 280 nm, cutoff 325 nm). Measurements 
were taken at 37 °C. The readings at 525 nm (corresponding to the FRET signal) were 
normalised and plotted against inhibitor concentration to generate IC50 curves. 
8.7 Structural studies 
8.7.1 Circular Dichroism (CD) spectroscopy 
200 μL of peptide solution (200 μM in H2O) was placed in a 1-mm quartz cuvette and the CD 
spectrum recorded between 190-260 nm at 25 °C at a band width of 1 nm, step size of 1 nm 
and 1 s per step. The spectra presented represent an average of five scans. 
8.7.2 X-ray crystallography 
Details of the experiments are given in chapters 5 and 6. In general, crystals of PfMTIPΔ60 
(expressed from the pRSETA vector, with His tag cleaved) were screened by recording of 
two or four diffraction images at 90° oscillations in order to assess the diffracting power of 
different crystals and approximate resolution limits. Initial indexing solutions in Mosflm were 
used to dictate the strategy of full dataset collection, or if this was ambiguous, a complete 
360° dataset was recorded. Datasets were generally collected at 1° oscillations unless 
otherwise stated. Processing was either done automatically using the in-built Diamond Light 
Source software pipeline i.e. the xia2 bundle202 (running XDS,203 XSCALE, Pointless and 
Aimless),204,205 or indexed in Mosflm206 and scaled in Scala.204 In all cases, generation of an 
initial model i.e. data phasing was achieved by molecular replacement in Phaser207 using the 
structure of PfMTIPΔ60-PfmyoA(799-818) as a search model. The inspection of electron 
density maps and model building was done using Coot122 and refinement steps were carried 
out in REFMAC208 or Phenix123 as described in the main text. Restraints for non-natural 
ligands, amino acids or linkages were generated in JLigand.209 
8.7.3 NMR spectroscopy 
Samples for NMR consisted of either 500 µL of protein or peptide solution in a standard 
5-mm tube (Norell) or 350 µL in a microscale tube (Shigemi) and contained 10% (v/v) D2O to 
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provide a lock signal. The length of the 1H 90° RF pulse and the water offset frequency were 
calibrated prior to running each experiment. 
 
Table 8.8 Acquisition parameters for NMR assignment experiments reported in this thesis. 
Protein backbone assignment experiments 
Details of experiments used for assignments are given in table 8.8 and are further explained 
in chapter 3. Samples contained 400-500 µM 13C, 15N-labelled PfMTIPΔ60 expressed from 
the pQE30 vector, in NMR buffer and in the absence or presence of three molar equivalents 
of PfmyoA(799-818). The same samples were used for relaxation and RDC measurements. 
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The chemical shifts of 1HN, 
15N, 13Cα, 13Cβ, and 13C’ were obtained from the 
HNCACB/CBCA(CO)NH and HNCO/HN(CA)CO experiment pairs; the spectra were 
processed in NMRPipe129 and analysed in NMRView,130 and assignments were made using 
a combination of the MARS automated assignment program127 and an in-house assignment 
module.131 The experiments and pulse programs were set up with the kind assistance of Dr 
Pete Simpson.  
Peptide assignment experiments 
Details of experiments used for assignments are given in table 8.8 and are further explained 
in chapter 3. The chemical shifts of 1HN, 
1Hα, 1Hβ, 15N, 13Cα and 13Cβ were obtained by 
analysis of natural abundance 15N SOFAST-HMQC and 1H, 13C-HSQC spectra together with 
a 1H, 1H TOCSY spectrum (mixing time 100 ms) and a 1H, 1H ROESY spectrum (mixing time 
300 ms) on a solution of ~3 mM PfmyoA(799-816) in H2O. The spectra were processed in 
NMRPipe and analysed in NMRView. The experiments and pulse programs were set up with 
the kind assistance of Dr Jan Marchant.  
Relaxation data 
Details of other experiments not pertaining to chemical shift assignments are given in table 
8.9. 
Backbone amide 15N longitudinal (T1) and transverse (T2) relaxation times and steady state 
heteronuclear [1H]-15N nuclear Overhauser enhancements (NOEs) were measured at 14.1 T 
(~600 MHz 1H frequency). For the T1 experiment, 
1H, 15N correlation spectra were recorded 
at longitudinal relaxation delays of 50, 2500, 350, 1800, 650, 1400, 950, and 1200 ms (with 
duplicate measurements for 350 and 1800 ms); for the T2 experiment a Carr-Purcell-
Meiboom-Gill (CPMG) refocusing pulse train was applied during transverse relaxation delays 
of 15.33, 245.35, 30.66, 168.61, 45.98, 107.30, and 76.64 ms (with duplicate measurements 
for 30.66 and 168.61 ms), and the NOE spectrum used a 1H presaturation period of 5 s. T1 
and T2 relaxation curves were fit to simple exponential functions using the rate analysis 
module in NMRView, and NOEs are reported as the ratio of intensities of the backbone 
amide peaks with and without 1H presaturation. 
CPMG relaxation dispersion NMR experiments were performed at 14.1 and 18.8 T (~600 
and 800 MHz 1H frequency, respectively) using the pulse sequences reported by Kay and 
co-workers.238 Spectra were recorded with refocusing CPMG pulse frequencies (νCPMG) 
ranging from 40 to 1600 Hz with 2 repeat measurements at a constant relaxation delay 
(Trelax) of 50 ms together with two control experiments recorded with no relaxation delay to 
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give reference intensities I(0) for each measurable amide resonance. Effective transverse 
relaxation rates R2
eff were then plotted against νCPMG to generate relaxation dispersion 
trajectories for each field strength. These plots were fitted simultaneously on a per-residue 
basis to a model for two-site exchange to determine Rex, i.e. the exchange contribution to R2 
using the program NESSY.145 
 
Table 8.9 Acquisition parameters for other NMR experiments reported in this thesis. 
 
Residual dipolar couplings 
2D 1H, 15N-IPAP HSQC and 3D 1H, 13C, 15N-IPAP HNCO spectra were recorded on the 
complex of 13C, 15N-labelled PfMTIPΔ60 with (unlabelled) PfmyoA(799-818) in the absence 
and presence of ~15 mg/mL filamentous Pf1 bacteriophage (ASLA Biotech), that was added 
to the NMR buffer.  
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IPAP spectra were split in the Topspin interface, processed in NMRPipe and RDCs 
measured in a module developed in-house for NMRView by Dr Jan Marchant.133 The 
program MODULE was used to fit RDCs as described in the main text. 
Interaction studies 
Generally, NMR titrations were monitored by 1H, 15N-HSQC spectra on 100 µM 15N-labelled 
PfMTIPΔ60 in NMR buffer at each point. The resonance corresponding to the backbone 
amide of Gly157 (at a 1H chemical shift of ~10.3 ppm) in the spectrum of free PfMTIPΔ60 
was used as a read-out for an appropriate number of scans to ensure reasonable signal to 
noise for these experiments. For single-point experiments where the protein solution was 
spiked with a set molar excess of ligand (e.g. the fragment screen), a lower protein 
concentration (40-60 µM) was used and the number of scans increased accordingly. 
8.8 PfmyoA precipitation experiment 
The following experiments were conducted in collaboration with Dr Judith Green. 
8.8.1 Parasite cultures 
P. falciparum 3D7 parasites were maintained in human O+ erythrocytes provided by the 
National Blood Transfusion service. 3D7 is a cloned line derived from NF54 obtained from 
David Walliker at Edinburgh University. Parasites were cultured in RPMI 1640 medium 
supplemented with 1% Albumax at 3% hematocrit in gassed (90% nitrogen, 5% oxygen, 5% 
carbon dioxide) flasks at 37 °C. For tight synchronisation of parasite stages, a combination 
of sorbitol treatment239 and stage-specific separation using a magnetic separator was 
performed.240 
8.8.2 Precipitation of parasite-derived PfmyoA with recombinant MTIP 
1 mL of purified 3D7 schizonts was lysed in 10 volumes of hypotonic lysis buffer (10 mM Tris 
HCl (pH 8.0), 1 x Complete protease inhibitors (Roche)) and incubated on ice for 10 min. 
Lysates were centrifuged at 3500 x g for 15 min at 4 °C. The insoluble fraction was washed 
in hypotonic lysis buffer and centrifuged as described a further two times or until there was 
no hemoglobin visible in the supernatant. The pellet, a membrane protein fraction, was 
solubilised in lysis buffer (0.5% Nonidet P-40, 125 mM NaCl, 25 mM Tris (pH 8.0), 
1 x protease inhibitors) and incubated on ice for 20 min. Detergent-soluble proteins were 
present in the supernatant after centrifugation at 16,000 x g at 4 °C for 20 min. 1 mL of a 
50% slurry of Ni-NTA resin (Qiagen) was added to the lysate followed by incubation at 4 °C 
for 1 h to remove proteins that interacted non-specifically with the resin. 300 µg of schizont 
lysate was added to the appropriate amount of recombinant PfMTIPΔ60 or mutants thereof 
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(1, 2, 5, 10, or 20 µg) in a final volume of 630 µL. The samples were mixed by rotation for 
15 h at 4 °C. 100 µL of 50% Ni-NTA was added to each sample, and incubation continued 
for a further 3 h. The beads were washed with 5 x 0.5 mL of lysis buffer using empty 0.8-ml 
centrifuge columns (Pierce), with centrifugation for 30 s at 1200 x g. Proteins bound to the 
resin were eluted by the addition of 100 µL of 2 x reducing LDS sample buffer, samples were 
heated to 95 °C for 5 min and recovered from the column by centrifugation at 16,000 x g for 
10 s. For Western blot analysis, 20 µL of the samples were run on a 10% NuPAGE Bis-Tris 
gel in MOPS running buffer, transferred to nitrocellulose, and probed with a rabbit anti-
myosin A antibody (a gift from Dr. J. Fordham). Horseradish peroxidase-conjugated 
secondary antibodies (Bio-Rad) were used, and signal was detected using an enhanced 
chemiluminescence kit (Amersham Biosciences) and Biomax MR film (Eastman Kodak Co.). 
For verification of MTIP loading quantities, 20 µL of the samples were run on a 12% 
NuPAGE Bis-Tris gel in MES running buffer, and proteins were visualised by staining with 
Instant Blue reagent (Expedeon). 
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